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1 Introduction 
1.1 Nutrition and Cancer 
 
Nutrition and health are closely connected. Numerous plant foods or physiologically 
active ingredients derived from plants have been investigated for their role in disease 
prevention and health [Gwyn et al., 2002]. The main reason for nutrition–dependent 
diseases in our society, however, is over nutrition and malnutrition characterized by 
high energy uptake and an unbalanced diet (“western style diet”). Imbalanced 
nutrition results in a higher risk for developing diseases such as arteriosclerosis, 
cancer, obesity and diabetes. Within this list, cancer is of special importance, because 
not only does it account for one quarter to one third of deaths in countries with 
western style diet but also has dramatic consequences for the affected individuals 
[Berlau et al., 2004]. The most frequent type of cancer in this context is colorectal 
cancer with more than 100,0000 new patients and 500,000 deaths annually 
worldwide [Dirk Schrijvers, 2008]. 
1.2 Colorectal cancer: Incidence and prevalence 
 
Cancers of colon and rectum are the third most common type of cancers worldwide. 
Around 1 million cases were recorded in 2002, accounting for around 9 percent of all 
types of cancer [WCRF/AICR, 2007]. There is no clear trend in global age-adjusted 
rates of colorectal cancer. In general, the age standardized incidence rate of colorectal 
carcinoma is very high in Western Europe, Australia and New Zealand, whereas it is 
very low in India and Africa [Parkin and Muir, 1992;Tamakoshi et al., 2001]. There 
has however been a rapid increase in rates in high income countries that have 
recently made the transition from a relatively low income economy such as Japan, 
Singapore and Eastern European countries [WCRF/AICR, 2007]. Rates have at least 
Introduction 
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doubled in many of these countries since the mid 1970s [Parkin and Muir, 1992]. 
Studies have also shown that risk of colorectal cancer changes in migrants after a 
period of 20-30 years in a high risk country, and that the risk of developing colorectal 
cancer may decrease after migration from a high to a lower risk country [Schottenfeld 
and Beebe-Dimmer, 2005]. For example, the incidence increased for Japanese 
migrants after moving to Hawaii or from Southern Europe to Australia [McMichael et 
al., 1980; Schottenfeld and Beebe-Dimmer, 2005]. In Europe, colorectal cancer is the 
most common form of cancer, too, with more than 300,000 cases a year even more 
than lung cancer. It is the second-leading cause of cancer deaths in European men and 
women (www.oncolink.com). 
The lifetime colorectal cancer risk in general population is reported to be 
approximately 5 %, with individual risk increasing significantly with age [Pisani et 
al., 1990]. Additionally, family history of colorectal cancer increases the risk and 
there are several rare genetic syndromes which account for about 5 % of all cases of 
colorectal cancer [Potter, 1999]. 
1.2.1 Molecular mechanisms of colorectal carcinogenesis 
 
The intestinal tract consists of the small intestine (duodenum, jejunum and ileum) 
and the large intestine (caecum, colon and rectum). The absorptive surface of the 
small intestine is covered with villi (finger like outgrowths) which increase the 
amount of surface area available for absorption of digested food. The colonic 
epithelium in the large intestine has larger crypts. Crypts are anatomical structures 
that are narrow and deep invaginations which secrete various enzymes. Proliferative 
stem and precursor cells occupy the bottom two-thirds of the crypts, whereas 
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Putative stem cells (dark blue) populate the 
bottom of the crypt. Proliferating progenitor 
cells (light blue) occupy two thirds of the 
crypt. Differentiated cells make up the rest 
one third and surface of the epithelium, which 
in contrast to the small intestine is a flat 





Colorectal cancer (CRC) is usually observed in one of two specific patterns; sporadic 
and inherited. The two most common inherited syndromes associated with an 
increased risk of CRC are familial adenomatous polyposis coli (FAP) and hereditary 
non polyposis colorectal cancer (HNPCC) also called Lynch Syndrome. FAP is a rare 
autosomal dominant syndrome and least understood pattern of colon cancer 
development [de and Fernando, 1998]. A germline mutation in the tumour suppressor 
gene for adenomatous polyposis coli (APC) results in FAP [Kinzler and Vogelstein, 
1996]. Almost 20 % of cases occur in people who have a family history of colorectal 
cancer [Lynch and de la, 2003]. HNPCC is an inherited autosomal dominant 
syndrome [Jass et al., 1994]. Specific genetic mutations have been identified as the 
cause of HNPCC, these mutations are estimated to account for only 5-10 % of 
colorectal cancer cases overall. HNPCC is characterised by inactivated DNA mismatch 
repair (by inherited or acquired mutation or methylation) that results in 
microsatellite instability in the tumours [Lynch and Lynch, 2000]. People with FAP 
develop a large number of adenomas at a relatively young age; if left untreated, nearly 
Figure 1 Tissue anatomy of human large intestine 
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all will develop colorectal cancer by the time they reach the 40s whereas, people 
develop HNPCC in their mid 40s and HNPCC further increases the risk of other 
gastrointestinal cancers [Weitz et al., 2005]. Other colon tumours associated with 
predisposing factors are related to inflammatory bowel diseases. However, the 
greatest numbers of colorectal cancers develop either sporadically or are caused by 
external factors [Berlau et al., 2004] (Figure 2). The external factors can cause genetic 
alterations or modulate the processes for the development of cancer namely initiation, 












Figure 2 Causes of Colorectal Cancer 
 
(www.images1.clinicaltools.com/images/gene/crcpiechart) 
The pathogenic pathway leading to the so-called adenoma-carcinoma sequence was 
first described by Hill and colleagues [Hill et al., 1978]. According to them mutations 
in at least four or five genes are required for formation of a malignant tumour (Figure 
3). The first events are mutations in the gene APC (adenomatous polyposis coli) in 
both chromosomes. APC is a human gene that is classified as tumour suppressor gene 
Figure 2 Causes of Colorectal Cancer 
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and prevents the uncontrolled growth of cells that may result in cancerous tumours 
[Fodde et al., 2001]. When a mutation eliminates the function of APC gene, the cells 
are immediately launched on the pathway towards malignancy. Loss or mutation of 
APC thus induces polyp formation as a result of loss of orderly cell replication, 
adhesion and migration. This is followed by mutation in the oncogene K-ras and 
further mutation of the tumour suppressor genes SMAD4 and TP53. Other genetic 
events also play a role, for example modulation of DNA methylation in CpG 
sequences of the promoter regions of tumour-suppressor and DNA repair genes, 
leading to inactivation, or DNA amplification as a mechanism of oncogene activation 
[Kinzler and Vogelstein, 1996]. These genetic alterations are associated with the 
development of preneoplastic lesions (aberrant crypt foci, polyps, adenomas) which 
can develop into carcinomas [Vogelstein et al., 1989]. It has now become clear that in 
HNPCC, in addition to the above mentioned genes some other genes e.g. 
Transforming growth factor ß (TGF ß) or Bax (involved into apoptosis) are also 
damaged [Rampino et al., 1997]. Furthermore, ulcerative colitis also predisposes to the 
risk of colorectal cancer. Although this disease is a minor contributor to the overall 
population burden of colorectal cancer, individuals with ulcerative colitis have about 










Figure 3 Molecular Mechanisms of Colorectal Carcinogenesis 
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APC, Adenomatous polyposis coli, K ras, Kirsten rat sarcoma; SMAD4, mothers against 
decapentaplegic, drosophila, homolog of 4; TGFBR2, transforming growth factor-β receptor, 
type 2; TP53, tumour protein p53; B-RAF, v-raf murine sarcoma viral oncogene homolog B1 
[Tejpar and Van, 2003] 
 
1.2.2 Risk factors for colorectal cancer 
 
Epidemiological studies have suggested that the incidence of colon cancer could be 
increased by composition of diet [Keown-Eyssen and Bright-See, 1984; Hill, 1997]. 
However, the mechanisms which increase the risk are not clear. It has been suggested 
that DNA damage in the human colonic cells can be caused by specific food 
ingredients or their metabolic products for e.g. red meat, processed meat and 
substantial consumption of alcoholic drinks [WCRF/AICR, 2007]. High meat 
consumption for instance leads to higher levels of amino compounds, nitrosamines, an 
altered gut flora and changed enzyme patterns. These compounds may be either 
cytotoxic or genotoxic themselves or increase the formation of genotoxic compounds 
in the gut lumen. Furthermore, low folate uptake, combined with high alcohol 
uptake, might pose another risk to colorectal cancer as lack of folate leads indirectly 
to physiologically disturbed DNA methylation, which might inhibit transcription of 
tumour suppressor genes or increase transcription of proto-oncogenes [Berlau et al., 
2004]. Moreover, it has been shown that physically active persons with a lower body 
mass index are at less risk of cancer [Kinzler and Vogelstein, 1996].  
Nutritional factors not only affect colorectal carcinogenesis as a result of the direct 
activity of individual compounds, but also act indirectly by enhancing the lipid 
peroxidation. Dietary intake of polyunsaturated fats represents a major source of lipid 
hydroperoxides in the intestinal lumen [Bartoli et al., 1993]. In addition to nutritional 
factors, radical structures such as superoxide anions (O2-) and hydroxyl radicals (OH-) 
are generated in biological systems not only by extrinsic factors as, for example, 
Introduction 
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visible light or ionising radiation, but also by intrinsic factors like by-products 
emerging during oxygen metabolism or cellular redox reactions [Oberreuther-
Moschner et al., 2005]. These radicals can react directly with DNA resulting in 
oxidized bases and, ultimately, mutations after replication [Berlau et al., 2004] which 
in turn increases the risk of degenerative diseases such as colorectal cancer. 
Unfortunately, our knowledge of the specific substances which are actually 
responsible for molecular alterations in cell transformation is still fragmentary, and 
adequate toxicological assessment of relevant endogenous risk factors is usually still 
missing. 
1.3 Chemoprevention of colorectal cancer 
1.3.1 Overview of chemoprevention  
 
Cancer chemoprevention, i.e. the use of chemicals or dietary components to block, 
inhibit or reverse the development of cancer in normal or preneoplastic tissue, is 
considered one of the most promising areas in current cancer research. There are 
currently three strategies for cancer prevention [Kanduc et al., 2003]: 
I. Primary chemoprevention: removal or neutralization of etiological agents, 
II. Secondary chemoprevention: interference with either the tumour promoting 
metabolic mechanisms associated with particular etiologic agents or with the 
responses of the target cells or tissue to an activated form of an etiological 
agent, 
III. Tertiary chemoprevention: interrupting the sequence of events during the 
cellular evolution from precancer to cancer. 
Much of the work on the anticarcinogenic properties of naturally occurring 
compounds has been carried out by Wattenberg and his coworkers [Wattenberg, 
1992]. According to them, anticarcinogens are subdivided into two major classes 
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defined as “blocking agents” and “suppressing agents” (Figure 4). Blocking agents are 
typically compounds which have been thought to prevent initiation, either by 
inhibiting the formation of carcinogens from precursor compounds, or by preventing 
the active carcinogenic species from acting upon its cellular target. In contrast, 
suppressing agents are thought to act by preventing the progression of initiated cells 
to fully transformed tumour cells, e.g. by inhibition of cellular proliferation or 














1.3.2 Diet and chemoprevention 
 
The elucidation of molecular sites of action for dietary components is fundamental for 
the development of effective prevention strategies. Studies indicate that dietary 
constituents can influence various genetic and epigenetic events that determine 
cellular metabolism, differentiation and apoptosis [Bradlow et al., 1999; Knowles and 
Figure 4 Mechanisms whereby protective factors may inhibit Carcinogenic process.  
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Milner, 2000]. Compounds encompassing such diverse categories as carotenoids, 
flavonoids, glucosinolates, isothiocynates and fermentable dietary fibres have been 
found to reduce experimentally induced cancers. Numerous reviews highlighting the 
benefits (and possible risks) of these and other bioactive food components have been 
published [Abdulla and Gruber, 2000; Pool-Zobel, 2005]. These chemopreventive 
compounds induce biological responses by serving as an antioxidant, promoting the 
activity of detoxification enzymes, blocking carcinogen formation, shifting hormonal 
homeostasis, retarding cell division and inducing apoptosis [Milner, 2002].  
Among various chemopreventive compounds studied so far, vitamin A has been 
linked to differentiation [Milner, 2002], whereas vitamin D inhibits the accumulation 
of ß-catenin by facilitating its degradation [Murillo and Mehta, 2005]. The reduced ß-
catenin causes a decrease in its transcriptional activity that stimulates the expression 
of oncogenes such as c-myc. Moreover, vitamin E and C and the mineral selenium can 
act as antioxidants [Bingham, 1996]. Furthermore, literature involving the inhibition 
of inflammatory processes by compounds such as butyrate [Hamer et al., 2008], n-3 
fatty acids [Brink et al., 2004] and dietary fibres [Roberfroid, 1993] is increasing.  
1.4 Dietary fibres as potential chemoprotective 
substances 
1.4.1 Dietary fibres 
 
Since the original description of dietary fibres as remnants of edible plant cell 
polysaccharides and associated substances resistant to hydrolysis by human 
alimentary enzymes [Trowell, 1976], the definition has been extensively debated. The 
American association of cereal chemists defined dietary fibres as the remnants of 
edible parts of plant and analogous carbohydrates that are resistant to digestion and 
absorption in the human small intestine with complete or partial fermentation in the 
human large intestine [Jonathan, 2003]. Furthermore, it also defines oligosaccharides 
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as being dietary fibres. Therefore, “dietary fibres” consist of a great variety of food 
components mainly cell wall fractions as well as some storage carbohydrates.  
During their passage through the upper intestine, dietary fibres influence the 
digestion process through several mechanisms. It stimulates bacterial growth, and 
together with water binding to residual unfermented fibre, it leads to an increase in 
stool weight, dilution of colonic contents and faster transit time through the large gut 
[Cummings, 1981; Phillips et al., 1995]. Faecal bulking as well as reduced transit times 
has been associated with the protection against colorectal cancer by decreasing the 
probability of colonic carcinogen exposure [Ferguson et al., 2000]. 
Additionally, dietary fibres entering the large bowel stimulate anaerobic 
fermentation, leading to the production of short chain fatty acids (SCFA), acetate, 
propionate, and butyrate and an increase in microbial cell mass [Bingham, 1996]. Of 
these SCFA, butyrate is physiologically relevant to the colonic epithelium by serving 
as a principle energy source. Interest in its role as possible chemoprotective agent has 
arisen from its properties to inhibit proliferation and induce apoptosis of cancer cells 
in vitro [Kruh, 1982]. Next to SCFA there are still other fermentation products that 
arise mainly from a wide variety of plant ingredients for example phytic acid, 
hydrocinnamic acid and in particular ferulic acid from wheat bran. These compounds 
have also been shown to have diverse biological activities such as scavenging of 
radicals [Ogiwara et al., 2002] or acting anti inflammatory and anti carcinogenic in rat 
colon [Ozaki, 1992]. 
1.4.2 Epidemiological and clinical data for relationship 
between dietary fibres and colorectal cancer 
 
The potential importance of dietary fibre intake for prevention of colorectal cancer 
was suggested more than three decades ago by Burkitt, who related the low incidence 
of colon cancer in parts of Africa to the local diets, which were high in plant foods 
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and dietary fibres [Burkitt, 1969]. Burkitt hypothesized that high fibre intake results 
in high stool bulk, which reduces stool transit time and thus lowers exposure of 
colonic epithelium to potential carcinogens. A combined analysis of 13 [Howe et al., 
1992] case control studies as well as a meta analysis of 16 case control studies [Trock 
et al., 1990] indicated an inverse association between fibre intake and colorectal 
cancer. In contrast, 10 prospective studies including initial analysis from the Nurses 
Health Study (NHS) [Fuchs et al., 1999] and Health Professional’s Follow up study 
(HPFS) [Giovannucci et al., 1994] have largely failed to support this association. Most 
recently the European Prospective Investigation into Cancer and Nutrition (EPIC) 
including 1065 incident cases of colorectal cancer among 519,978 individuals 
followed for an average of 4.5 years described an inverse link between fibre intake 
and colorectal cancer incidence [Bingham et al., 2003].  
1.4.3 Short chain fatty acids as products of gut fermentation of 
dietary fibres 
 
The physiology of the fermentation process of dietary fibre has been reviewed in 
depth [Scheppach et al., 1995]. The major products of fermentation of dietary fibre 
metabolism are SCFAs, the gases H2 and CO2 and bacterial cell mass [Cummings and 
Macfarlane, 2002]. SCFA are produced in the proximal colon in an average molar 
ratio of acetate: propionate: butyrate 60:20:20 mmol/l [Wong et al., 2006]. This ratio, 
however, is fairly constant, although alterations in production and absorption may 
occur with the kind of substrate fermented [Cummings et al., 1987]. Much has been 
written about SCFA production in the hind gut and the differing metabolic 
significance of the individual SCFA [Cummings and Macfarlane, 2002].  
Among SCFA, butyrate serves as an energy yielding substrate in colonocytes and 
additionally affects several cellular functions like induction of apoptosis, suppression 
of cell proliferation, anti-inflammatory actions, up regulation of immunosurveillance 
Introduction 
 20    
and down regulation of angiogenesis [Williams et al., 2003]. Butyrate seems to be of 
essential importance for the metabolic welfare of normal intestinal epithelia where it 
prevents mucosal atrophy [Wachtershauser and Stein, 2000]. Interest in its role as a 
possible protective agent has arisen from its anti-proliferative and pro-apoptotic 
effects on colon cells [Hague and Paraskeva, 1995]. Moreover, literature depicts that 
butyrate also induces Glutathione S Transferases (GSTs) detoxifying enzymes that 
provide defence against carcinogens [Pool-Zobel et al., 2005]. Butyrate was also found 
to modulate c-myc expression by post translational degradation of the mRNA 
[Souleimani and Asselin, 1993]. C-myc belongs to the family of proto-oncogenes and 
their gene products are involved in cell growth [Rochlitz et al., 1996]. Propionate and 
acetate are metabolized less than butyrate and are transported to liver [Cook and 
Sellin, 1998]. Propionate is substrate for hepatic gluconeogenesis and has been 
reported to inhibit cholesterol synthesis in hepatic tissue whereas acetate is utilized in 
the synthesis of long chain fatty acids, glutamine and betahydroxybutyrate [Rombeau 
and Kripke, 1990].  
1.5 Inulin type fructans as potential dietary fibres 
 
Among various dietary fibres inulin and oligofructose have been subjected to 
extensive research [Pool-Zobel, 2005; Roberfroid, 2005]. Inulin type fructans are the 
natural constituents of a wide range of common vegetables and fruits such as onion 
and garlic. The estimated average daily intake per capita of inulin-type fructans from 
natural sources is 3-11 g in Western Europe and 1-4 g in North America [Moshfegh et 
al., 1999]. Typically, inulin has a degree of polymerization (DP) between 3 and 60 
(average DP is approximately 12) and is produced industrially from chicory roots by 
hot water extraction, followed by refining and spray drying. Structurally, inulin type 
fructans are polydisperse carbohydrates consisting mainly of ß (2-1) fructosyl fructose 
links. This linkage cannot be hydrolysed by pancreatic or brush border digestive 
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enzymes. Therefore these fructans reach the colon undigested, where they are 
fermented by Bifidobacterium spp. and other lactic acid-producing bacteria to yield 
SCFA and gases. Therefore, they are classified as “dietary fibres” (oligo and 
polysaccharides) that resist both hydrolysis by mammalian digestive enzymes and 
absorption in the small intestine but are, at least partly, hydrolyzed and fermented by 
the colonic flora [Roberfroid, 2005]. 
Synergy1, a commercially available mixture of inulin enriched with oligofructose 
(Orafti Belgium) is a prebiotic dietary fibre that has been specifically formulated to 
improve digestive health (Figure 5). In vitro fermentation experiments revealed that 
molecules with a DP >10 like inulin are fermented, on an average, half as quickly as 
molecules with a DP of < 10 like oligofructose [Ten Bruggencate et al., 2004]. Rapid 
fermentation of oligofructose by the intestinal microflora may lead to high luminal 
concentrations of organic acids which in turn may induce damage to the mucosal 
barrier [Ten Bruggencate et al., 2004]. Therefore in order to decrease the rapid 
fermentation of oligofructoses, Synergy1 is enriched with inulin. Thus, the longer 
chain fructan is fermented at a slower and more selective rate which maintains the 








The inulin is extracted from chicory roots using hot water. Oligofructose is then obtained 
through partial enzymatic hydrolysis. Synergy1 is a composition of oligofructose and inulin. 
Figure 5 Preparation of Synergy1 (modified according to www.orafti.com) 
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1.5.1 Biological activities of Synergy1 
 
In experimental animals a large number of publications demonstrate that inulin type 
fructans significantly increase mineral absorption, essentially Ca and Mg [Weaver and 
Liebman, 2002]. In a study aimed at comparing oligofructose, inulin and Synergy1, 
Coudray et al. have shown that the latter product was more active than oligofructose 
or inulin alone in enhancing Ca and Mg absorption [Coudray et al., 2003].  
Modulation of either the digestion/absorption or the metabolism of lipids is another 
physiological effect of inulin-type fructans that influence triglyceridaemia and 
cholestrolaemia as well as the distribution of lipids between the different lipoproteins 
in favour of a more beneficial health pattern [Delzenne et al., 2002]. 
Moreover, inulin type fructans beneficially affect the intestinal immune system by 
targeting gut-associated lymphoid tissues and especially Payer’s patches, and 
consequently have been shown to decrease the risk of diseases related to dysfunction 
of gastrointestinal defense functions [Roberfroid, 1993].  
1.5.2 In vitro and in vivo studies of inulin type fructans in 
relation to colon cancer 
 
A number of different experimental studies have shown that the fermentation 
products of inulin contribute to colon cancer-preventing properties, as has been 
summarized in two recent reviews [Pool-Zobel, 2005; Roberfroid, 2007]. Regarding 
the risk of colon cancer it has been shown that gut fermentation products of inulin-
type fructans beneficially modulate markers of tumour progression in human colon 
tumour cells [Beyer-Sehlmeyer et al., 2003; Klinder et al., 2004a]. In vivo studies by 
Buddington et al evaluated chicory fructans for their potential inhibitory properties 
against total ACF formation in the colon of rats and mice [Buddington et al., 2002]. 
These studies were further supported by Poulsen et al. who also observed a significant 
inhibition in the number of ACF in rats after feeding inulin [Poulsen et al., 2002]. Not 
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only do these fermentation products reduce the number and the size of lesions but 
also they reduce the risk of progression of these lesions towards malignancy. An in 
vitro study by Klinder et al. also reports distinct functions of inulin in inhibiting the 
growth and metastasis in colon tumour cells [Klinder et al., 2004a]. All of these 
findings suggest potential colon tumour inhibitory properties of these fructans. The 
mechanisms proposed to explain these beneficial effects include changes in the 
composition and/or activity of colonic microflora (prebiotic effect), and in the 
composition of the SCFA pool and especially an increased relative proportion of 
butyrate as a result of anaerobic fermentation. Therefore, these studies indicate that 
fermentation supernatants derived from Synergy1 impair growth, survival, and 
progression of human tumour cell lines, all mechanisms that are associated with 
suppressing activity and secondary cancer prevention. Moreover, these fructans 
strengthen and stimulate gastrointestinal defense functions and especially intestinal 
immunity, two effects that certainly improve resistance to cancer development [Van 
Loo et al., 2005]. 
In a human intervention study, the synbiotic treatment [(oligofructose-enriched 
inulin (Synergy1) + Lactobacillus rhamnosus GG (LGG) and Bifidobacterium lactis 
Bb12 (BB12)] resulted in a reduction of DNA damaging capacity of faecal water in 
polyp patients [Rafter et al., 2007]. The modulation of DNA damage reflects 
reasonably well the modulated exposure to genotoxic compounds that cause the 
damage and hints towards the “blocking agent” activity of these fructans. Another 
human study detected a decline of toxic bile acids in faecal samples after a 3 months 
intervention with oligofructoses [Boutron-Ruault et al., 2005].  
Thus, inulin type fructans exert several effects on the gastrointestinal tract, but the 
precise mechanisms for its probable protective role are still not clearly understood. 
Therefore, it was of interest to explore the biological effects of inulin type fructans 
and their metabolites in terms of colon cancer prevention. In the present study the 
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fermentation sample from Synergy1 was tested in vitro using human adenoma and 
carcinoma cells (representing an early and a late stage of carcinogenesis). This study 
presents an experimental approach to analyze the biological activities of dietary fibres 
and their resulting complex fermentation products. The results were expected to 
enhance our understanding of the chemo-preventive properties of dietary fibres in 
terms of reducing colorectal cancer risk. 
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2 Objectives of the study 
 
To elucidate chemopreventive mechanisms of dietary fibres investigation strategies 
are needed to characterise not only the fibre itself, but rather the metabolites 
produced after fermentation by the gut flora. The formed products have the potential 
to interact with cells of the gut mucosa and elicit a number of different biological 
activities. Therefore, the aim of this study was to find possible chemo-preventive 
effects of Synergy1, a prebiotic dietary fibre and its metabolic products in vitro in 
human colon cancer cell lines. Since chemoprevention means preventing non 
transformed cells from being initiated (primary chemoprevention) or preventing 
further growth of already transformed cells (secondary chemoprevention), a series of 
experiments were performed in human colon tumour cells to elucidate possible 
chemoprotective mechanisms [growth inhibition, anti genotoxic and apoptosis 
inducing mechanisms of Synergy1 fermentation supernatant (SFS)]. 
Therefore, two different colon cancer cell lines were used namely LT97 (preneoplastic 
adenoma cells) and HT29 (highly transformed adenocarcinoma cells) to address the 
following questions: 
 
• Does fermentation of Synergy1 result in increased production of metabolites 
mainly SCFA and reduction of toxic secondary bile acids? (Published) 
• Does incubation with SFS modulate the growth of both cell lines, if yes; 
whether the modulation of cell growth is due to the concentration of 
metabolites? (Published) 
• Does incubation with SFS protect the DNA from oxidative stress which in turn 
could be a reflection of inhibitory activities related to inhibition of tumour 
initiation? 
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• Is the modulation of oxidative stress by SFS due to the ability to modulate 
mRNA expression of phase II genes and corresponding enzymes of 
biotransformation?  
• Does incubation with SFS induce PARP cleavage; a marker of apoptosis 
(Published) and modulate the activity of apoptotic enzymes mainly caspases? 
• Are chemo-preventive mechanisms of SFS also involved in modulation of 
genes relevant to apoptosis (secondary chemoprevention)? 
• Are apoptosis inducing activities of fermentation supernatant similar to a 
synthetic fermentation mixture (SFM) mimicking the SFS in the amount of 
SCFA and desoxycholic acid (DCA), a secondary bile acid or due to presence of 
other substances? 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Cell models 
 
LT97 cells 
The human colon adenoma cell line LT97 was a kind gift from Professor Brigitte 
Marian (Institute for Cancer Research, University of Vienna, Austria) who established 
it from colon microadenomas of a patient with familial adenomatous polyposis 
[Richter et al., 2002]. These cells represent an early stage of colorectal cancer. 
 
HT29 cells 
The HT29 cell line that had been established by Fogh and Trempe from a colon 
adenocarcinoma of a Caucasian female [Fogh, 1986] was originally purchased from 
the American tissue culture collection (Rockville, MD). When these cells are grown 
under standard conditions, they display an undifferentiated phenotype [Cohen et al., 
1999]. HT29 cells are highly transformed and represent a late stage of colorectal 
cancer. 
3.1.2 Test substances 
 
The carbohydrate source used in the fermentation experiments was the fructan 
Synergy1, a commercially available 1:1 mixture of inulin [Femia et al., 2002] and 
oligofructose and was obtained from ORAFTI, Tienen, Belgium.  
A synthetic fermentation mixture (SFM) mimicking Synergy1 fermentation 
supernatant (SFS) in the amount of SCFA and DCA (desoxycholic acid) was prepared 
by mixing required concentrations of SCFA (Na-acetate, Na-butyrate from Merck, 
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Darmstadt; Germany, Na-propionate from Fisher Scientific, Schwerte, Germany) and 
DCA (Sigma-Aldrich; Steinheim; Germany) to identify to which proportion the SCFA 
and DCA might be responsible for the apoptosis inducing activities of the SFS. 
Additionally, to identify whether bile acids could modify the apoptosis inducing 
effects of SCFA we investigated SCFA and DCA individually. All synthetic mixtures 
were prepared by dissolving in respective cell culture medium before use in 
experiments. 
3.1.3 Solutions, reagents and kits 
 
All the solutions, reagents and primers used in the present study are listed in 
Appendix A and B. 
3.1.4 Equipments and instruments 
 
All the equipment and instruments used in the present study are listed in Appendix C. 
3.1.5 Softwares 
 
All calculations, statistical analyses and diagrams were made with Graph pad Prism 
Version 4.0 (Graph Pad, USA) or MS Excel 2002 (Microsoft, USA). The list of 
softwares is mentioned in Appendix D 
3.2 Methods 
3.2.1 In vitro fermentation of Synergy1 
 
The in vitro fermentation of Synergy1 was conducted under anaerobic conditions (80 
% Nitrogen, 10 % Carbon dioxide, and 10 % Hydrogen at 37°C) in a batch-culture 
system with faecal inocula of three different adult healthy donors according to a 
described procedure [Barry et al., 1995]. All the donors consumed their normal diet 
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without any restrictions. The use of nutritional supplements and antibiotics were 
forbidden for the last six months. The samples were weighed and filled in a 
homogenizing bag. Potassium phosphate buffer (0.1 M, pH 7.0) was added (5:1 v/w) 
and the mixture was homogenized thoroughly in a Stomacher 400 (Seward U.K). 
From the faecal homogenate 40 ml aliquots were filled into 500 ml glass bottles. 
Synergy1 samples were solubilised with anaerobic potassium phosphate buffer to 
provide 20 g/l fermentable substances (fiber, carbohydrate and protein). 40ml of 
Synergy1 solution was added to bottles to obtain a final fibre content of 10 g/l and a 
faecal suspension of 10 % as recommended [Barry et al., 1995]. Each tube was shaken 
to mix the contents. Anaerobic conditions in the glass bottles were achieved by 
removing the air with an injected canula and subsequently filled with fermentation 
gas mixture and incubated at 37 °C for 24 h in a shaking water bath. After placing the 
suspensions on ice to stop the fermentation, the samples were centrifuged at 6000 g at 
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A negative control containing only the faecal samples was prepared as faecal blank 
(FB) (figure 6). The SFS and FB were divided into aliquots and stored at -80°C. 
Samples were sterilised two times by filtration (pore size 0.45 µm and 0.22 µm) before 
use.  
3.2.2 Analysis of Short chain fatty acids and Desoxycholic acid 
 
Concentrations of SCFA, namely acetate, propionate and butyrate and secondary bile 
acid DCA were determined by gas chromatography in Department of Nutritional 
Physiology [Keller and Jahreis, 2004]. Briefly, the samples were mixed with an 
isocapronate standard (1:11 v/v), shaken, and centrifuged at 6400 g for 10 min. at 4 °C. 
Thereafter, the gas chromatographic measurements (GC 17A, Shimadzu, Duisburg, 
Germany) were performed using a 15 m FFAP column (Phenomenex, Aschaffenburg, 
Germany) and a specific temperature program (start temperature 130 °C; increase 
35°C/minute; and a final temperature of 170 °C) [Glei et al., 2006]. 
To analyse faecal bile acids, aliquots of the samples were hydrolyzed under alkaline 
conditions with ethanolic NaOH (10 M) at 120 °C for 2 h. The samples were then 
acidified to pH 1.0 with HCl and extracted with cyclohexane in a tube containing 
internal bile acid standard (hyodeoxycholic acid). The solvent of the combined 
extracts were evaporated, and the residues were methylated and silylated. After 
evaporation, the residual content was resolved in decane, shaken, and centrifuged. 
The clear solution was injected into a gas chromatograph-mass spectrometer (GC 17-
QP 5000, Schimadzu). 
3.2.3 Cell culture 
 
Cultivation of cells 
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Both HT29 and LT97 cells were maintained as adhesion cultures in cell culture flasks 
(75 cm2 and 25 cm2, respectively). For HT29 cells DMEM (Dulbecco’s Modified eagle 
Medium, Invitrogen, Germany) supplemented with 10 % fetal calf serum (FCS) was 
used. Subconfluent cells were subcultured twice per week by trypsinisation. For this, 
the old medium was fully removed with a Pasteur pipette and the cells were 
incubated with 1:10 v/v Trypsin / Versene (5 ml for 75 cm2 and 2.5 ml for 25 cm2) for 
4 min. Thereafter, Trypsin / Versene was removed and cells were resuspended 
properly (to avoid cluster formation) in 5 ml of pre-warmed medium. For routine 
passaging cells were subcultivated at a dilution of 1:5 to 1:10 in cell culture flasks with 
DMEM supplemented with 10 % FCS.  
LT97 cells were maintained in a LT97 culture medium (MCDB 302 containing 20 % 
L15 Leibovitz medium, 2 % FCS, 0.2 nM Triiodo-L-thyronine, 1 µg / ml 
Hydrocortisone supplemented with 10 µg / ml Insulin, 2 µg / ml Transferrin, 5 nM 
Sodium selenite, 30 ng / ml Epidermal growth factor and 50 µg / ml Gentamicin. The 
medium was changed at regular intervals of 2-3 days (5 ml for 25 cm2 and 15 ml for 75 
cm2). Therefore, the old medium was fully removed and replaced with pre-warmed 
medium. The cells were harvested with PBS+Na2EDTA. For this the cells were first 
rinsed with PBS+Na2EDTA followed by incubation with 6 ml PBS+Na2EDTA for 6-8 
min. The PBS+Na2EDTA solution was then completely removed and the cells were 
resuspended in 5 ml of pre warmed medium. LT97 cells were subcultured in clusters 
as they require cell to cell contact for growth. The cells were cultivated in humidified 
incubator (95 % O2 and 5 % CO2) at 37 °C. 
 
Cell counting and determination of vitality 
 
For each experiment the cell number and vitality was measured using CASY TT 
(Schärfe System GmbH, Germany) cell counter. The principle of this electronic cell 
counter is based on the measurement of electrical resistance. For this, the cells were 
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suspended in an isotonic electrolyte solution which is then aspirated by a capillary to 
which an electric current is applied and the resistance is measured. The increase of 
resistance is proportional to cell volume. Cell viability can be assessed based on the 
integrity of plasma membrane as the living cells have intact plasma membranes 
whereas membranes of dead cells are broken. Therefore, in dead cells only the nuclei 
account for increase in resistance and vital or dead cells respectively can thus be 
differentiated. To count cells and determine viability 20 µl of cell suspension were 
mixed with 10 ml of isotonic CASYton solution which in turn was aspirated by the 
capillary. The relative cell number is measured as 1x106 cells per ml, whereas the 
vitality is measured in percent. The absolute cell number was calculated by 
multiplying relative cell number with the total volume of the cell suspension. 
3.2.4 Determination of metabolic activity 
 
To determine metabolic activity in HT29 cells; 8000 cells per well were seeded in 96 
well plates. LT 97 cells were however seeded in clusters corresponding to 30-40 % 
confluency. HT29 cells were incubated with SFS, FB and SFM after 24 h of seeding, 
whereas LT97 cells were incubated after 5-6 days (according to confluency) in a 
concentration range of 1.25-20 % v/v. The cells were incubated for 24, 48, and 72 h in 
a humidified incubator. Metabolic activity (measure of cell viability) was determined 
by Cell titer blue assay [Klenow et al., 2008]. Two hours before the end of the 
incubation time 20 µl of cell titer blue (CTB) reagent (Promega, Mannheim, 
Germany) was added to each well. Metabolic activity was determined by 
fluorimetrical analysis with Ex/Em 520/595 nm (Spectrafluor Plus, Tecan Germany 
GmbH, Crailsheim). Results were normalised with cell number determined on the 
basis of cell growth. 
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3.2.5 Cell growth assay (DAPI Assay) 
 
The DAPI assay measures effects on growth of cells [Glei et al., 2006] which is based 
on the amount of DNA present after a definite incubation time. Therefore, this assay 
measures the relative amount of cells at the end of the incubation. Results were 
calculated on the basis of medium control set to 100 %. 
Effects on cell growth were also determined in 96-well microtiter plates after removal 
of CTB reagent followed by fixing and permeabilising the cells with 100 µl of 
methanol for 5 min, and addition of 100µl of 20 µM fluorescent DNA stain, 4’, 6-
diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma-Aldrich, Germany). After 
30 min, DNA content, as a reflection of the number of remaining cells, was detected 
by fluorimetrical analysis with Ex/Em 360/465 nm in a microplate reader (Spectra 
Fluor Plus, Tecan, Austria). Results were calculated on the basis of medium control 
set to 100 %. Mean values (3 determinations per experiment, 3 experiments) were 
recorded for final evaluation. 
3.2.6 Single cell gel electrophoresis assay (Comet assay) 
 
The comet assay has a unique potential for monitoring genetic damage [Tice et al., 
2000]. It is the only technique to monitor DNA damage and repair at the level of 
single cells [Knoll et al., 2005]. The principle behind this assay is that the negatively-
charged broken DNA molecules are free to migrate in an electric field towards the 
anode, with the shorter fragments moving faster (figure 7). The pattern of migration 
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For long term incubations 2x106 cells HT29 cells were seeded in 6 well plates. The 
LT97 cells were however, seeded in clusters. The medium was replaced with medium 
containing 5 % of SFS or FB after 24h of seeding in HT29 cells whereas in LT97 cells 
the medium was replaced after reaching 50-70 % confluency. The cells were then 
incubated for 24 h at 37°C in a humidified incubator (5 % CO2 / 95 % O2). At the end 
of incubation the cells were trypsinised and centrifuged (380 x g, 5 min) and washed 
with PBS. The cell number and vitality was measured using the CASY TT cell 
counter. The pretreated cells were subsequently incubated with either 75 µM H2O2 
(diluted in PBS) for 5 min at 4 °C or 300 µM 4-hydroxy-nonenal (HNE) (64 mM stock 
solution of HNE in 95 % ethanol was diluted with respective media) for 30 min at 37 
°C under shaking conditions (380 x g). H2O2 and HNE were used as potential model 
genotoxic substances. H2O2 was used as a model substance for free radical 
intermediates of oxidative stress [Raschke et al., 2006] whereas, HNE is the main lipid 
Figure 7 Important steps for performing Comet assay 
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peroxidation product [Knoll et al., 2005]. After incubation genotoxic substances were 
removed by centrifugation and washing the cells with PBS and subsequently cell 
viabilities were determined using CASY TT cell counter. The remaining cells were 
mixed with low-melting agarose and distributed on frosted microscopical slides 
precoated with normal-melting agarose followed by distribution one more layer of 
agarose. Further steps were carried out as described elsewhere [Glei et al., 2006]. In 
short the cells were lysed for 60 min at 4 °C and subjected to alkaline conditions using 
electrophoresis buffer for 20 min. The electrophoresis was carried out at 25 V and 300 
mA and subsequently the slides were neutralized using PBS and stained with SyBr 
Green (Sigma- Aldrich GmbH, Steinheim, Germany). The slides were analyzed with a 
fluorescence microscope equipped with a CCD camera as well as a software from 
Perceptive Instruments namely Comet assay 2.0 (Halstead, United Kingdom). From 
each slide 150 cells were analyzed and mean values of tail intensities (the percentage 
of fluorescence in the comet tail) were determined. At least three independently 
reproduced experiments were performed for statistical analyses. 
3.2.7 Enzyme activity assays 
 
Cell seeding and incubation 
To determine enzyme activity the cells were seeded in 6 well plates as described 
above for Comet assay. After 24 h the medium was replaced with 5 % SFS and FB and 
the cells were incubated for 24 h at 37°C.  
 
Cytosol preparation 
The cells were harvested by trypsinisation and cytosols were prepared by 
resuspending the cells in cold homogenization buffer (250 mM sucrose, 20 mM Tris 
HCl, 1 mM DTT, and 1 mM Pefabloc; pH 7.4) and homogenized for 1 min using 
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ultrasound (Bandelin Electronics, Berlin, Germany). Following centrifugation (16000 
x g, 60 min, 4°C), the supernatant was aliquoted and stored at -80°C until use. 
 
Glutathione S Transferase (GST activity) 
The GST activity was measured spectrophotometrically at 340 nm using 1 mM 1-
chloro-2.4-dinitrobenzene (CDNB) and 1 mM glutathione as substrates [Habig et al., 
1974]. Therefore 1 mM of glutathione and CDNB were added to a quartz cuvette in a 
final volume of 1 ml potassium phosphate buffer (pH 6.5; 100 mM). The cuvette was 
placed in spectrophotometer and the reaction was initiated by addition of cytosol. 
The increase in absorbance at 340 nm over a 4 min period was measured at 30°C. An 
extinction coefficient of 9.6 cm/mM was used to determine activity from the initial 
slope of the reaction. The activity was calculated by ‘Lambert-Beer’ law (equation 1). 
The values were expressed as nmol / 106 cells / min since this was considered to be 
more accurate than nmol / µg protein, because environmental factors can enhance 
general protein content in parallel to induction of GSTs [Treptow-van et al., 1999] 
and thereby falsify the results 
Equation 1 Calculation of total GST enzyme activity 
 
Aktivity   =   ∆ E / min * V   * 1000   
(nmol x min-1 x ml-1)   ε * d * v   
 
delta E = change in Extinktion slope (Abs/min)  
V = total volume in cuvette 1 ml 
ε  = molar Extinktions coefficient 9.6 mM -1 cm -1 (Habig et al.) 
d = thickness of cuvette 1 cm 
v = cytosol volume 50-100 µl 
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Catalase activity 
 
Catalase activity was measured by the method of Aebi [Aebi, 1984]. The principle of 
this method is based on the hydrolyzation of H2O2 and decreasing absorbance at 240 
nm since water and oxygen do not absorb at this wavelength. The assay principle is 









One catalase unit is the amount of enzyme decomposing 1 mM of H2O2 per minute at 
pH 7.0 and 25°C, with an initial H2O2 concentration of 10 mM. The activity assay is 
typically carried out with 10-50 mM H2O2 at 25°C. 
The assay mixtures used in the experiments contained 10 mM H2O2 and 100 µl of 
cytosols in 50 mM potassium phosphate buffer, pH 7.0. Enzyme activities were 
calculated using 0.0394 mM -1 x cm-1 as absorption coefficient of H2O2 at 240 nm. 
3.2.8 Determination of Poly (ADP-ribose) polymerase cleavage 
by Western blot  
 
To analyse effects of SFS and FB on apoptosis, PARP cleavage [Germain et al., 1999] 
was examined by Western blot. Therefore 2 x 106 cells per well were seeded in 6 well 
plates. After 24 h the medium was replaced with 10 % of SFS, FB and equal 
concentrations of corresponding SFM, SCFA, DCA and FB. At the end of incubation 
the cells were lysed using lysis buffer (described below). The chosen concentration of 
the test substance for apoptosis experiments had a growth inhibiting effect on the 
cells and was chosen on the basis of EC50 from cell growth studies. 
Figure 8 Hydrolysation of H2O2 by Catalase 
2H2O2 2H2O + O2
Catalase
Absorbance at 240 nM No absorbance at 240 nM
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Preparation of Cell lysates  
 
Cell lysates were prepared by using cell lysis buffer (20 mM Tris HCl, pH 8.0, 150 mM 
NaCl, 10 % Glycerol, 2 mM EDTA, 1 mM DTT, 1 % Nonidet P40, 0.5 mM Pefabloc 
SC, 1 mM PMSF, 1 µg / ml Pepstatin A, 1 µg / ml Leupeptin, 1 mM Sodium 
orthovanadate). The lysates were then incubated on ice for 20 min and centrifuged at 
16000 x g for further 20 min. The pellet containing the debris was discarded and the 
cell lysates were transferred to new eppendorf tube and analysed for total protein 
content using the method of Bradford (see below) with bovine serum albumin (BSA) 
as standard protein. The cell lysates were stored at -20 °C until use. 
 
Determination of protein concentration by Bradford  
 
The Bradford protein assay is a photometric analytical procedure used to measure the 
concentration of protein in a solution. It is a colorimetric protein assay based on the 
absorbance shift in the dye Coomasie brilliant blue G when the previously red 
reagent changes and stabilizes into coomassie blue by the binding of protein 
(Bradford, 1976). The trimethylmethan dye reacts with basic and aromatic amino 
acids and forms a complex, which is stable for 30 min and its absorption can be 
measured at 592 nm. Bovine serum albumin (BSA) in different defined concentrations 
(5-80 μg/ml) was used to generate a standard curve and allow calculation of unknown 
protein concentrations in the samples.  
 
Western Blot  
 
Sodiumdodecylsulfate (SDS) was used for separation of proteins. SDS is an anionic 
detergent which denatures secondary and non-disulfide-linked tertiary structures of 
proteins and applies a negative charge to each protein in proportion to its mass so that 
all the proteins move towards the cathode when a current is applied. The cell lysates 
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were diluted with loading buffer (125 mM Tris, 2 % SDS, 10 % Glycerol, 6 M Urea, 
324 mM DTT, and 0.1 % Bromphenolblue) and denatured for 5 min at 99 °C in a 
thermomixer. 40 µg of total protein was loaded and subjected to SDS gel 
electrophoresis (stacking gel 4 % w/v; separating gel 10 % w/v acrylamide) for 34-45 
min at a constant voltage of 200 V. After separation, the proteins were then blotted 
by semi dry blotting to a nitrocellulose membrane (Schleicher & Schuell, Germany) 
for 35-45 min at 80 mA. Thereafter, unspecific binding sites on the nitrocellulose 
membrane were blocked with blocking solution (1 % milk powder in TBS for at least 
1 h. The membrane was incubated overnight with the polyclonal rabbit-anti-PARP 
antibody (Cell Signalling Technology, Frankfurt, Germany) diluted 1:1000 in blocking 
solution. PARP is a 116 kDa nuclear protein which is involved in surveillance and 
maintenance of genome integrity and functions as a key molecule in repair of DNA 
single strand breaks [Rottenberg et al., 2008]. PARP cleavage is considered to be one 
of the classical characteristics of apoptosis. During apoptosis, caspases such as caspase-
3 and -7, cleave PARP in two fragments of 89 kDa and a 31 kDa [Tewari et al., 1995]. 
As a loading control a monoclonal mouse-anti-ß-actin antibody (Sigma-Aldrich, 
Taufkirchen, Germany) in 1:40,000 dilution in blocking solution was used. Following 
the incubation with the primary antibodies, the membrane was washed two times 
with TBST (Tris-buffered saline with Tween 20) and one time with TBS (Tris-
buffered saline). The blots were probed with corresponding secondary HRP-goat anti-
rabbit or HRP-rabbit anti-mouse antibodies (1:800 dilution) for PARP and ß-actin, 
respectively for 1 h at room temperature. After rinsing the membrane specific bands 
were visualized by enhanced chemiluminisence using ECL (enhanced 
chemiluminiscence) Reagent (Amersham, Buckinghamshire, UK). The enzyme horse 
radish peroxidase (HRP) converts the luminol contained in the ECL reagent into its 
oxidized form thereby emitting flashes of light. Luminescence can be visualized using 
photographic films. The densitometric quantification of band intensities was done 
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using Quantity One 4.1 Software (Bio Rad Munich, Germany). Data was presented as 
the means ± SD of three independently reproduced experiments. 
3.2.9 Caspase activity assay 
 
Caspases are a group of aspartic acid-specific cysteine proteases which are activated 
during apoptosis. These unique proteases, which are synthesized as zymogens, are 
involved in the initiation and execution of apoptosis once activated by proteolytic 
cleavage. In the present study the activity of caspase-8 and -9 (as markers of extrinsic 
and intrinsic induced apoptosis, respectively) was measured after incubation with SFS 
and FB. Additionally, activity of caspase-3 was measured as a general marker of 












AMC, 7-amino-4- methyl coumarin; Capital letters stand for codes of amino acids 
 
Figure 9 Fluorometric detection of caspase activity during apoptosis 
(www.clontech.com) 
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The caspase assay detects the shift in fluorescence of specific substrates. After protease 
activation, the caspases recognize their respective substrates which are covalently 
linked to the fluorogenic dye, 7-amino-4- methyl coumarin (AMC). Upon cleavage by 
the respective caspase, the free dye can be detected using a plate reader (380 nm 
excitation and 460 nm emission).  
To determine the effects on caspase activity cells were seeded in 6 well plates as 
mentioned above for comet assay. After 24 h the medium was replaced with medium 
containing 10 % of SFS, FB or SFM respectively. The experiments were performed 
according to the manufacturer’s protocol (ALEXIS Biochemicals, Switzerland). In 
brief, the cells were harvested after 24 h incubation and cell number and vitality was 
measured with CASY cell counter. Afterwards the cells were centrifuged at 380 x g 
for 5 min. The cell pellets were resuspended in chilled lysis buffer (1M HEPES, 100 
mM CHAPS, 1 M DTT, 1 mg / ml Leupeptin, 1 mg / ml Pepstatin, 100 mg /ml 
Pefablock, 100mm Sodium orthovanadate. 100 mM PMSF in Methanol). The cell 
lysates were kept on ice for 20 min followed by centrifugation at 16000 x g for 15 min 
at 4°C. Afterwards 50 μl cell lysates were incubated with 2 μl of 50 nM caspase 
inhibitor (caspase 9: Ac-LEHD-CHO, caspase 3: Ac-DEVD-CHO, caspase 8: Ac-IETD-
CHO) for 10 min on ice in 96 well microtitre plates. This step verifies that the signal 
detected by the kit is due to the specific caspase activity. Next, 100 μl of 37.5 μM of 
respective substrates (caspase-9-substrate: Ac-LEHD-AMC, caspase-3-substrate: Ac-
DEVD-AMC, caspase-8-substrate: Ac-IETD-AMC) were added. The cells were then 
incubated for 2 h at 37° C at 5 % CO2 in an incubator. The fluorescence was measured 
by fluorimetrical analysis with Ex/Em 380/465 nm in a microplate reader (Spectra 
Fluor Plus, Tecan, Austria). For calculations the fluorescence value of wells 
containing the inhibitor was subtracted from the fluorescence values of wells 
containing the substrate. Mean values (3 determinations per experiment, 3 
independent experiments) were recorded for the final evaluation. 
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3.2.10 Real-time RT-PCR 
 
cDNA-Synthesis  
2x 106 cells per well were seeded in 6 well plates. After 24 h the medium was replaced 
with medium containing 10 % of SFS or FB. The cells were harvested, centrifuged 
(2000 rpm / min, 5 min) and washed with PBS. Afterwards RNA was isolated and 




2 x 106 cells per well were seeded in 6 well plates. After 24 h the medium was 
replaced with 10 % of SFS or FB. The cells were harvested, centrifuged (380 x g, 5 
min) and washed with PBS. The RNA was isolated with RNeasy Plus Mini Kits 
(Qiagen) [Sauer et al., 2007a], according to manufacturer’s instructions. The RNAeasy 
Plus procedure integrates patented technology for selective removal of double 
stranded DNA with well established RNAeasy technology. 
In brief, cells were first lysed and homogenised in a highly denaturing guanidine-
isothiocyanate containing buffer, which immediately inactivates RNases to ensure 
isolation of intact RNA. The lysates were then passed through a gDNA eliminator spin 
column. This column, in combination with the optimized high salt buffer, allows 
efficient removal of genomic DNA. Ethanol was then added to the flow through to 
provide appropriate binding conditions for RNA. The sample was then applied to an 
RNeasy spin column, where total RNA binds to the membrane and contaminants are 
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RNA quantification and quality control  
The quantity of isolated RNA was measured using NanoDrop (ND-1000) (Peqlab 
Biotechnology Erlangen, Germany). Typically nucleic acids are quantified by UV 
absorption using a spectrophotometer. In its simplest form the absorbance is measured 
at 260 and 280 nm. The concentration of nucleic acid can be determined using the 
Beer-Lambert law, which predicts a linear change in absorbance with concentration.  
RNA has its absorption maximum at 260 nm and the ratio of the absorbance at 260 
and 280 nm was used to assess the RNA purity of RNA preparations. Typically, pure 
RNA has an A260/A280 of 2.1. A value of 1.8-2.0 was used for further experiments.  
The integrity of RNA was measured using Agilent RNA 6000 nano kit (Agilent 
technologies Waldbronn, Germany) according to manufacturer’s instructions. Here, 
total RNA sample was deposited into a RNA Nano Lab Chip. The RNA integrity 
number (RIN) algorithm was then determined. The RIN is determined to estimate the 
integrity of total RNA samples. This algorithm assigns a value of 1 to 10 RIN score, 
where a level of 10 RNA means completely intact RNA. Values between 8 and 10 are 
optimum [Fleige and Pfaffl, 2006]. Because interpretation of the electropherogram is 
automatic and not subject to individual interpretation, universal and unbiased 
comparison of samples is enabled and repeatability of experiments is improved. 
 
First strand synthesis 
First-strand cDNA was synthesized by reverse transcription using 2 µg of total RNA, 
100 pmol / µl Oligo (dT)12-18 primer (Invitrogen, Germany), 5 x First strand buffer 
(Invitrogen, Germany), 0.1 M DTT, 10 mM dNTPs, 200 U / µl Superscript II RT 
(Invitrogen, Germany). The reaction was carried out at a programme 65°C for 5 min, 
42°C for 60 min, 70°C for 15 min and 4°C forever using a temperature controlled PCR 
machine (Biometra). Afterwards 1 µl of RNase H (New England Biolabs, Frankfurt, 
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Germany) was added and the reaction mixture was incubated at 37°C for 20 min to 
degrade the RNA. 
 
Control PCR 
A control PCR was done to check the success of cDNA synthesis. Therefore, the 
GAPDH (Glycerinaldehyde-3-phosphate dehydrogenase), a house keeping gene was 
amplified. The control PCR was done by adding 1 μl of cDNA (1:10 diluted with aqua 
bidest) in a 24 μl of master mix containing 200 μM dNTPs (Invitrogen. Germany), 5 μl 
of 5 x green buffer (Invitrogen, Germany) 0.2 μM each of reverse and forward primer, 
5 U / µl GoTaq DNA (Promega, Germany). The following conditions for the PCR 
were used: 94°C initial denaturation for 2 min followed by 20 cycles each of 94°C 
denaturation for 30 sec, 60°C annealing for 30 sec, 72°C extension for 45 sec and a 
final extension step of 72°C for 5 min. Afterwards 5 µl PCR products were run on a 
2 % agarose gel (120 V for 30 min). Additionally 4 μl of 100 bp DNA-Ladder (Peqlab 
Biotechnology, Erlangen, Germany) was also loaded. Ethidium bromide was added to 
the agarose gel to visualize the bands. The bands were detected by BioRad System 
Program Quantity OneTM (Bio-Rad Laboratories, München, Germany). 
 
Real-time qRT-PCR using iQ SYBR Green I 
Real time PCR monitors the progress of the PCR as it occurs in “real time” by reading 
fluorescence intensities after each cycle. It is based on the detection and quantitation 
of a fluorescent reporter. Intensities are proportional to the amount of PCR product 
generated. Real Time PCR is a kinetic approach in which we can look at the reaction 
in the early stages while it is still linear. The relative differences in expression levels 
of selected apoptosis relevant (Bax, DR4, DR5, and Bid), and biotransformation 
(GSTA4, Catalase ) genes were evaluated by real time PCR using the iCycler IQ ® 
(Bio-Rad GmbH München, Germany) system. GAPDH was used as a reference 
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control for normalization of the expression levels of all genes of interest. The primer 
sequences used to amplify genes of interest are shown in Appendix C. 
SyBr Green I technique was used to detect the fluorescence. SyBr Green I is cyanin 
dye which intercalates with double stranded DNA and fluorescence is enormously 
increased upon binding to double stranded DNA. During the extension phase more 
and more SyBr Green I will bind to the PCR product, resulting in an increased 
fluorescence which is measured after each PCR cycle. 
The experiments were done using the iCycler iQ real time PCR (Bio-Rad 
Techonologies München, Germany) according to available instructions. The cycler 
contains a sensitive camera that monitors the fluorescence in each well of a 96-well 
plate at frequent intervals during the PCR reaction. Therefore, the cDNA samples 
were diluted to 1:2.5 and mixed with iQ SYBR Green Supermix (2 x) and 10 pmol 
each of respective forward and reverse primers. The temperature profile for the 
iCycler is shown in table1.  




Denaturation Annealing Extension Terminal 
Extension 
Temperature 95°C 94°C 56°/60°C 72°C 72°C 
Time 2 min 30 s 30 s 40 s 10 min 
Cycle Number 1 40 1 
 
 
For apoptosis relevant genes we used an annealing temperature of 56°C whereas, for 
biotransformation genes a temperature of 60°C was used. 
 
Calculation of relative gene expression levels 
For the gene expression analysis of the selected genes a method from Pfaffl was used 
to calculate relative gene expression levels [Pfaffl, 2001]. Product specific 
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amplification was confirmed by melting curve analysis. All experiments were 
performed in triplicates. The fluorescence threshold value (CT) was calculated by the 
iCycler iQ® v.3 optical system software. The relative quantification of the target-
mRNA expression was calculated with the comparative ∆∆ CT method (∆∆CT= ∆ CT 
control - ∆CT experiment). The fold change was calculated according to the efficiency method 
where it is assumed that the PCR efficiency is 100 % (E=2; fold change=E difference) 
(equation 2). 
 









The ratio shows how much the expression of a gene in a treated sample differs from 
that of the control sample. The gene expression of the medium-treated cells was set to 
1. 
3.2.11 Determination of Bid cleavage  
 
Bid relays an apoptotic signal from the cell surface to mitochondria. However, the 
precise molecular mechanism for the translocation of the cleaved Bid is still unclear. 
Therefore, the Western blot analysis of cell lysates from both cell lines incubated 
with SFS & FB for modulation of this marker protein was done in order to get a 
overview of the cleavage of this apoptosis marker protein. 
(E target )∆CT target (control-treated)
Ratio =
(E reference )∆CT reference (control-treated)
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The cell lysates were prepared as described above for PARP (3.2.13) and proteins 
were run by SDS polyacrylamide gel electrophoresis (stacking gel 4 % w/v; separating 
gel 15 % w/v acrylamide). The proteins were blotted on a nitrocellulose membrane 
which was blocked with blocking solution (5 % milk powder in TBS) for at least 1 h. 
The membrane was incubated overnight with the polyclonal rabbit-anti-Bid antibody 
(Cell signalling technology, Frankfurt, Germany) diluted 1:250 in blocking solution. 
As a loading control a monoclonal mouse-anti-ß-actin antibody diluted to 1:5000 in 
blocking solution (Sigma-Aldrich, Taufkirchen, Germany) was used. Bid antibody 
detects endogenous levels of both the full length (22 kDa) and cleaved large fragments 
(15 kDa) of human Bid [Mandic et al., 2001]. 
The blots were probed with corresponding secondary HRP-goat anti-rabbit or HRP-
rabbit anti-mouse antibodies (1:800 dilution) for Bid and ß-actin, respectively for 1 h 
at room temperature. After rinsing the membrane specific bands were visualised by 
enhanced chemiluminisence. 
3.2.12 DNA microarray (Custom array) 
 
It was of interest to analyse which genes involved in mechanisms of carcinogenesis or 
chemoprevention could be modulated by fermentation samples of Synergy1. This was 
done using a customised cDNA-array system (Miltenyi Biotech, Bergisch Gladbach, 
Germany) spotted with 300 genes belonging to nine functional categories 1) phase I 
metabolism, 2) phase II metabolism, 3) phase III metabolism, 4) phase II gene 
regulation pathway 5) stress and signal transduction pathway, 6) apoptosis signaling 
pathway 7) tumour suppressor genes, 8) cell cycle arrest / regulation of cell cycle and 
9) miscellaneous. 
 
Custom array procedure (PIQOR Microarray, antisense) 
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A microarray experiment for gene expression profiling consists of RNA preparation 
and labeling, followed by hybridization of the labeled sample to the microarray. If a 
limited amount of sample is available, a sample amplification step is included. Here 
we used PIQOR Microarray, antisense Microarray kit (Miltenyi Biotech, Bergisch 
Gladbach, Germany) for multiple gene expression. Figure 10 shows the different steps 














First and second strand cDNA synthesis 
First strand cDNA was synthesized by reverse transcription using 2 µg of total RNA, 
100 pmol / µl T7-(T) 24 primer, 5 x First strand buffer, 0.1 M DTT, 10 mM dNTPs, 40 
U /µl RNAaseOUT, 200 U / µl Superscript II RT. The reaction was carried out at 70°C 
Figure 10 Flowchart for microarray procedure 
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for 10 min, 42°C for 60 min, 70°C for 10 min and 4°C forever using a temperature 
controlled PCR machine (Biometra, Göttingen, Germany) 
Second strand cDNA was then synthesized using RNAse free water, 5x Second strand 
buffer, 10 U / µl DNA Polymerase I, 10 mM dNTPs, 10 U / µl E. coli ligase, 2 U / µl 
RNase and 20 µl of first strand cDNA and incubating them at 16° C for 2 h using the 
controlled PCR machine. The cDNA was isolated and purified using Nucleospin® 
Extract kit, (Macherey & Nagel, Düren, Germany) according to manufacturer’s 
instructions. 
 
cRNA synthesis and clean up 
cRNA was then synthesized by in vitro transcription (using MEGA script TM T7 Kit 
Ambion) according to manufacturer’s instructions. In brief 8 µl ds cDNA was added to 
75 mM dNTP solution along with T7 RNA polymerase and the mixture was incubated 
at 37°C for 10 h using controlled PCR machine followed by TURBO DNAase 
treatment. This DNase treatment removes the template DNA present at a very low 
concentration relative to RNA. The resulting cRNA was cleaned using NucleoSpin® 
RNAII kit (Macherey & Nagel, Düren, Germany). 
 
Synthesis of labeled cDNA  
The synthesis of fluorescently labeled cDNA was performed using CyScribe GFX, 
(Amersham Pharmacia) kit according to the manufacturer’s instructions. For the 
labeling reaction 5x first strand buffer, 2 µl Primer mix (PIQOR), 10 mM Low 
CdNTPs, 25 nmol Cy3-dCTP, 25 nmol Cy5-dCTP and 0.1 M DTT were mixed with 2 
µg cRNA and spiked with control RNA 1 and control RNA 2. The reaction was 
performed using the PCR program PIQOR-cRT (65°C for 5 min cool to 42° C, 60 min) 
paused at 42°C. 1 µl of SS-RT (200U /µl) was added, mixed and the reaction was 
Materials and Methods 
 50    
continued at 42°C for 30 min. After 30 min. an additional 1 µl SS-RT was added. After 
the reaction, remaining cRNA was hydrolysed by addition of 0.5 µl RNase H and 
incubating the reaction mixture at 37°C for 20 min. The purification of fluorescently 
labeled cDNA samples was done using CyScribe GFX PCR purification kit (Amersham 
Pharmacia Biotech, München, Germany) according to manufacturer’s instructions. 
 
Hybridisation and analysis of microarray slides 
Microarray slides were heated in distilled water using a water bath at 95°C for 2 min 
followed by treatment with 96 % Ethanol for 30 sec and drying them completely by 
centrifugation for 3 min at 500 x g. Prehybridisation was done by applying 
prehybridisation solution to the microarray slides and incubating the slides in 
humidified hybridisation cassette “PIQOR HybChamb” in a water bath at 65°C for at 
least 40 min. Afterwards, hybridisation was done by mixing equal amounts of 
hybridisation solution to cDNA samples and incubating the slides in a humidified 
hybridisation cassette in a water bath at 65°C overnight. The arrays were then washed 
with 40 ml wash Buffer I and wash Buffer II (2 times each) for 5 min at 50°C to 
remove excess of hybridisation solution. 
Slides were then sent to Miltenyi Biotech for scanning. Basically, fluorescence signals 
of the hybridised PIQOR microarrays were detected using a laser scanner from 
Agilent (Agilent Technologies, Waldbronn, Germany). The mean signal and mean 
local background intensities were obtained for each spot of the microarray images 
using the Imagena software (Biodiscovery, California, USA). Low quality spots were 
flagged and excluded from data analysis. The unflagged spots were analysed with the 
PIQORTM analyser software (Milltenyi Biotech). This analyser includes background 
substraction to obtain the net signal intensity, data normalisation and calculation of 
the Cy5/cy3 ratios. PIQORTM analyser calculates all normalized mean Cy5/Cy3 ratios 
of the four replicates per gene. Further processing of custom array data was carried 
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out using Gene Spotter® microarray scanner and Gene spotter v2 6.0 and the mean 
intensity of all four replicates was calculated. Experiments were reproduced three 
times and average intensity of each set of probes was used for normalisation based on 
the GAPDH gene. The differential gene expression was analysed by using the cut off 
value (≥ 1.5 or ≤0.7 fold change) and changes in genes of interest were confirmed by 
real time PCR. For defining the significant modulation of gene expression the 
normalised data of the treatment was compared with that of the control with 
unpaired t-Tests. The differential expressions of genes were calculated on the basis of 
significance (p< 0.05). 
3.2.13 Statistical analysis and graphical presentation 
 
The results were statistically analysed using Sofware GraphPad Prism Version 4.0 
(San Diego USA). Means and standard deviations were calculated from at least three 
independently reproduced experiments. For all the experiments the respective 
parametric tests were done. Differences between the dataset for proliferation studies 
were calculated by two way ANOVA and Bonferroni’s post hoc test. Here two 
different groups (control and treatment) were compared with each other on the basis 
of different concentrations. Other data sets were compared with one way ANOVA 
and Bonferroni post hoc test. In these cases two groups were tested based on the 
difference of one factor between them. The Bonferonni post hoc test allows the 
comparison of each group with a defined group (medium control). For the entire tests 
a significant difference of p<0.05 was taken. For proliferation assays EC50 was 
calculated. EC50 is the inhibitory concentration leading to 50 % reduction in cell 
number and was calculated by non linear regression curve fit. However, custom array 
results were analysed with two side unpaired t-Test. The significance is shown in 
respective tables and figures. 
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4 Results 
4.1 Analysis of Short chain fatty acids and secondary 
bile acids 
 
Dietary fibres escaping enzymatic digestion in the small intestine are delivered to 
the colon where they are fermented by the anaerobic microflora. It has been shown 
that dietary fibres modify the intestinal microflora, altering carcinogen metabolism, 
lower colonic pH and increase faecal SCFA concentration [Pool-Zobel et al., 2005]. 
Furthermore, they are able to modify faecal bile acid excretion [Owen, 1997]. 
Therefore, we investigated in vitro fermentation samples of Synergy1 for their 
properties to increase the concentration of SCFA and to decrease toxic secondary 
bile acids.  
Table 2 shows that fermentation of Synergy1 increased the yields of total SCFA in 
SFS in comparison to FB. In the SFS, the total amount of SCFA was 127.6 mmol/l 
whereas only 48.1 mmol/l were detected in feces blank (FB) as control. The major 
products were acetate, propionate and butyrate which were increased after 
fermentation of Synergy1. Noteworthy, the proportion of butyrate increased four 
times in SFS compared to FB. The relative molar concentrations, with molar ratios 
for acetate: propionate: butyrate in FB was 62:22:16 and in SFS was 65:14:21. In 
addition SFS contained much lower amounts of the potentially toxic secondary bile 
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Table 2 Concentration of SCFA (mmol/l) and DCA (mmol/l) in faeces blank (FB) 
and Synergy1 fermentation supernatant (SFS) 
 

































4.2 Effect on cell growth 
 
Cell growth experiments were performed to find out the appropriate subtoxic 
concentration of test substances (SFS and FB) which can be used for further 
experiments. Additionally, to investigate, to which proportion SCFA and DCA 
contribute to the growth inhibitory properties of SFS, we compared these results 
with a synthetic fermentation mixture (SFM) mimicking the SFS in the amount of 
SCFA and DCA. The effects of the SFS and FB on growth of LT97 and HT29 cells 
are shown in Figure 11 and 12. The growth of both cell lines was efficiently reduced 
in a concentration and time dependant manner. Calculated EC50 values (inhibitory 
concentrations leading to 50 % reduction in cell number) after 48 h and 72 h 
incubation with SFS were 4.9 % and 4.3 % for LT97 and 10.4 % and 8.7 % for HT29 
cells (Table 3). However, no EC50 was detectable after 24 h in both cell lines. 
Anyhow, in LT97 cells a significant decrease in cell growth was already observed 
after 24 h of treatment (Figure 11). 
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Displayed are means ± SEM (n=4). Statistical variance was analysed with two-way ANOVA 
and Bonferroni’s post hoc test of each concentration compared to medium control (*p<0.05, 
**p<0.01, ***p<0.001). 
 
The growth inhibition in HT29 cells was observed later, reaching significance at ≥ 
10 % SFS after 48 h of incubation (Figure 12). The treatment of cells with FB also 
inhibited growth of both cell lines, but the growth inhibiting effect was weaker and 
not comparable to SFS in the above mentioned manner and EC50 could only be 
observed after 72 h of incubation with FB (Table 2). Additionally, incubation of 
HT29 cells with low concentrations (2.5 and 10 %) of SFS and FB resulted in 
moderate increase in cell growth (>100 %). 
Figure 11 Effect of Synergy1 fermentation supernatant (SFS) (a) and fermentation blank (FB) 
(b) on growth of LT97 cells 
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Displayed are means ± SEM (n=4). Statistical variance was analysed with two-way ANOVA 
and Bonferroni’s post hoc test of each concentration compared to medium control (*p<0.05, 
**p<0.01, ***p<0.001).  
 
Comparison of the EC50 values for both cell lines shown in Table 3 indicates that 
growth inhibitory effects of SFS and SFM were much stronger in LT97 cells than in 
HT29 cells. The SFM however found to be almost equally effective as SFS in 
inhibiting the growth in both cell lines when EC50 was compared. 
Table 3 EC50 (inhibitory concentrations leading to 50 % reduction of cell number) 
after treatment of LT97 and HT29 cells for 24-72h with Synergy1 fermentation 





SFS SFM FB 
 LT97 HT29 LT97 HT29 LT97 HT29 
24 h - - - - - - 
48 h 4.9 % 10.4 % 3.2 % 12.0 % 10.7 % - 
72 h 4.3 % 8.7 % 3.1 % 7.3 % 10.0 % 17.6 % 
 
 
Figure 12 Effect of Synergy 1 fermentation supernatant (SFS) (a) and fermentation blank (FB) 
(b) on growth of HT29 cells. 
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4.3 Effect on metabolic activity 
 
Figure 13 compares the effects of SFS (1.25-20 %) on metabolic activity of both cell 
lines incubated for 24-72 h. The results show that metabolic activity of the 
remaining cells (HT29 & LT97) was not significantly affected by incubation up to 48 
h with SFS. Only the incubation for 72 h with 15 and 20 % SFS resulted in a 
significant increase in metabolic activity in LT97 cells, whereas only the highest 












Displayed are means ± SEM (n=4). Statistical variance was analysed with two-way ANOVA 
and Bonferroni’s post hoc test of each concentration compared to medium control (*p<0.05, 
**p<0.01, ***p<0.001).  
 
In contrast, treatment of both the cell lines with FB (20 %) after 72 h resulted in 
only a minor (3 %) in metabolic activity (data not shown). The results underline 
that the lower concentration of SFS tested (5 and 10 %) inhibited cell growth but 
Figure 13 Effect Synergy 1 fermentation supernatant (SFS) on the metabolic activity of 
LT97 cells (a) and HT29 (b) cells. 
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did not impair the metabolic activity of the remaining viable cells. Therefore, the 
metabolic status of the remaining cells was not influenced by the concentrations of 
SFS used in the further experiments. 
4.4 Modulation of DNA damage (Comet assay) 
 
The Comet assay detects DNA strand breaks in single cells and was used here in 
order to test genotoxic / anti-genotoxic activities of fermentation products of 
Synergy1. This assay does not give any information about the mutagenicity of the 
test substances, but it provides important information about the possible damage to 
DNA integrity [Collins, 2004].  
4.4.1 Analysis of genotoxic effects of Synergy1 fermentation 
supernatant 
To measure the genotoxic potential of the test compounds, SFS and FB were 
investigated at a concentration of 5 % for 24 h. In this amount the effective 
concentrations of acetate, propionate and butyrate in SFS and FB were 16.2 mM, 3.4 
mM, 5.2 mM and 5.4 mM, 1.8 mM and 1.3 mM respectively. Additionally, the 










Figure 14 Effect of preincubation with Synergy1 fermentation supernatant (SFS) and 
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Displayed are the means and SD of 3 independently reproduced experiments One way 
ANOVA, Bonferroni post-tests (SFS 5 %: Synergy fermentation supernatant 5 %, FB 5 %: 
Fermentation Blank 5 %.  
 
Figure 14 shows clearly that incubation of LT97 and HT29 cells with SFS and FB did 
not result in any genotoxic effect. The moderate decrease in tail intensity did not 
result in significance in both cell lines. 
4.4.2 Analysis of anti-genotoxic effects Synergy fermentation 
supernatant 
 
A challenge assay was done in order to determine the possible protective effects of 
SFS against induced DNA damage. Therefore, two genotoxic agents namely H2O2 
and HNE were chosen. Both HT29 and LT97 cells were pre-incubated with 5 % SFS 
or 5 % FB for 24 h to test the influence on the toxicological defence of the cells. The 
cells pre-incubated with medium were used as untreated controls. Subsequent to 
this pre-incubation, the cells were exposed to 75 µM H2O2 for 5 min or 300 µM HNE 
for 30 min. Figure 15 & Figure 16 show that both H2O2 and HNE were clearly 
genotoxic without any indication of concomitant cytotoxicity. Cell viability 
determined by CASY cell counter was always > 80 %. 
Pre-incubation with SFS resulted in significantly reduced levels of H2O2-induced 
DNA strand breaks (39 % in medium control to 22 % in SFS) in HT29 cells (p ≤0.01) 















Displayed are the means and SD of 3 independently reproduced experiments. One way 
ANOVA, Bonferroni post-tests **p<0.01; (SFS 5 % Synergy fermentation supernatant 5 %, 









Displayed are the means and SD of 3 independently reproduced experiments One way 
ANOVA, Bonferroni post-tests (SFS 5 % Synergy fermentation supernatant 5 %, FB 5 % 
Fermentation Blank 5 %.  
Figure 15 H2O2-induced DNA damage (75 µM) after pretreatment of LT97 (A) and HT29 cells 
(B) with Synergy1 fermentation supernatant (SFS) and fermentation blank (FB) for 24 h. 
Figure 16 HNE-induced DNA damage (75 µM) after pretreatment of LT97 (A) and HT29 cells 
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In contrast to the results with H2O2, the SFS was unable to modulate the genotoxic 
effects of HNE (figure. 16).  
4.5 Effects on mRNA expression of Glutathione-S-
Transferase and Catalase 
 
To investigate the possible mechanisms of detoxification involving modulation of 
mRNA levels; both cell lines were incubated with 5 % SFS and FB to determine the 
effects on gene expression of GSTA4 and CAT using real-time RT-PCR. Both 
GSTA4 and CAT have very high substrate specificity towards genotoxins namely 
HNE [Knoll et al., 2005] and H2O2 [Sauer et al., 2007a] and thus help in 
detoxification in the body. These genotoxins react with large biomolecules such as 
DNA and lipids in the body which in turn can lead to mutations. Therefore, the up-
regulation of the analysed genes at the mRNA level may be an important step in the 
prevention of cellular damage by free radicals. Here, both the cell lines were 
incubated with 5 % SFS and FB for 24 h to determine the effects on gene expression 
of GSTA4 and CAT using real-time RT-PCR. The effects on gene expression are 
shown in figure.17 and figure 18. In general, incubation with SFS resulted in a 
significant up-regulation of GSTA4 (fold change 2.4) in HT29 tumour cells. The 
expression of CAT however increased ony non-significantly in both cell lines (fold 
change of 1.85 and 1.33 in HT29 and LT97 cells respectively. Noteworthy, the 
faeces blank (FB) also tended to significantly increase GSTA4 gene expression in 














Displayed are the means and SD of 3 independently reproduced experiments. One way 
ANOVA, Bonferroni post-tests. **p<0.01;***p<0.001 (SFS 5 % Synergy fermentation 








Displayed are the means and SD of 3 independently reproduced experiments. One way 
ANOVA, Bonferroni post-tests. (SFS 5 % Synergy fermentation supernatant 5 %, FB 5 % 
Fermentation Blank 5 %) 
 
Figure 17 mRNA expression of GSTA4 (A) and CAT (B) in HT29 cells after incubation with 
Synergy1 fermentation supernatant (SFS) and fermentation blank (FB)  
Figure 18 mRNA expression of GSTA4 (A) and CAT (B) genes in LT97 cells after incubation 
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4.6 Phase II enzyme activity 
4.6.1 Effect on Glutathione-S-Transferase activity 
 
One possible mechanism by which SFS could decrease the genotoxicity of potential 
carcinogens is the enhancement of GST activity. Therefore, the effect of 5 % SFS on 
total GST enzyme activity was measured. The GSTs constitute one major family of 
phase II detoxification enzymes involved in the cellular protection against 
electrophilic intermediates. Although the basal activity (in medium control) of GSTs 
in LT97 cells was much lower than in HT29 cells, there was a small trend for a 
increased GST activity resulting from incubation of both cells lines for 24 h (figure 









Displayed are the means and SD of 3 independently reproduced experiments. One way 
ANOVA, Bonferroni post-tests. (SFS 5 % Synergy fermentation supernatant 5 %; FB 
5 % Fermentation Blank 5 %) 
Figure 19 GST activity / 106 cells for LT 97 (A) and HT 29 (B) cells after incubation 
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4.6.2 Effect on Catalase activity 
 
Another possible mechanism by which SFS could decrease genotoxicity of oxidative 
stressors could be an enhancement of catalase activity. Catalase is a common 
enzyme found in nearly all living organisms and is a hydrogenperoxide 
oxidoreductase [Patlolla et al., 2008]. Its function includes catalysing the 
decomposition of H2O2 to water and oxygen. Compared to medium control and FB, 
SFS treatment resulted in a significant induction of catalase activity (p<0.5) in HT29 
cells (figure 20). Although there was an increasing trend of catalase activity in 
LT97cells but this was not significant. The incubation with FB control however had 








Displayed are the means and SD of 3 independently reproduced experiments. One way 
ANOVA, Bonferroni post-tests. *p<0.5 (SFS 5 % Synergy fermentation supernatant 5 %, FB 
5 % Fermentation Blank 5 %) 
4.7 Effect on PARP cleavage 
 
Resistance to death by apoptosis is one of the hallmarks of cancer cells [Hanahan 
and Weinberg, 2000] and this factor, together with maintained or enhanced rates of 
Figure 20 Catalase activity / 106 cells for LT 97 (A) and HT 29 (B) cells after incubation 
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cell proliferation, contributes to expansion of the tumour mass [Hague et al., 1993]. 
Studies show that incubation with butyrate results in tumour cell apoptosis by up-
regulating the expression of the pro-apoptotic protein BCL-2 homologous 
antagonist/killer (BaK) and induces caspase-3 mediated cleavage of target proteins 
including PARP [Chai et al., 2000]. The latter is cleaved after Asp777 to yield a 
characteristic and stable 89 kDa fragment [Browne et al., 1998]. In order to get 
general overview about the SFS induced apoptosis, PARP cleavage was measured by 
incubating the cells with both 5 and 10 % of SFS and FB. The Western blot analysis 
revealed specific, cleavage of PARP upon incubation of LT97 cells with SFS 
demonstrating induction of apoptosis. The results in figure 21 show that treatment 
of LT97 cells for 24 h with SFS significantly increased cleavage of PARP when 
compared to medium control. However, in HT29 cells, 24 h treatment did not lead to 
increase of PARP cleavage indicating that HT29 cells were not sensitive towards SFS-
induced apoptosis. Additionally, 10 % of FB was also able to induce a significant 












Figure 21 PARP-cleavage induced by Synergy1 fermentation supernatant (SFS) and 












































































 65    
Displayed are means ± SD (n=3). Statistical variance was analysed by one-way ANOVA and 
Bonferroni’s post hoc comparison test of each concentration compared to medium control 
(*p<0.05). Differences between SFS and FB were analysed by two way ANOVA (§p<0.05). 
(SFS 5  % Synergy fermentation supernatant 5 %, SFS 10 % Synergy fermentation 
supernatant 10 %, FB 5 % Fermentation Blank 5 %, FB 10 % Fermentation Blank 10 %) 
 
Additionally, in order to find out whether PARP cleavage induced by SFS is due to 
the modulation of metabolite composition (increase in SCFA and decrease in DCA); 
both cell lines were incubated with SFM mimicking SFS in the concentration of 
SCFA and DCA. Incubation of LT97 cells for 24 h (figure 22) with synthetic SCFA 
mixture resulted in a significant increase in PARP cleavage. However, the levels of 
cleaved PARP with SFM were lower in comparison to SFS which points to the role 












Displayed are means ± SD (n=3). Statistical variance was analysed by one-way ANOVA and 
Bonferroni’s post hoc test of each concentration compared to medium control (*p<0.05, 
**p<0.01). (SCFA5 % Short chain fatty acid mixture 5 %, SCFA 10 % Short chain fatty acid 
Figure 22 PARP-cleavage induced by Synthetic fermentation mixture (SFM) in LT97 
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mixture 10 %, DCA 5 % Desoxycholic acid 5 %, DCA 10 % Desoxycholic acid 10 %, SFM5 
% Synthetic fermentation mixture 5 %, SFM10 % Synthetic fermentation mixture 10 %) 
 
4.8 Effect on Caspase activity 
In order to get more information about the possible mechanisms of apoptosis 
induction (extrinsic or intrinsic) we determined the caspase activity. Therefore, in 
relation to apoptosis we measured the activity of 3 different caspases namely 
caspase-3, caspase-8 and caspase-9 after incubation of both cell lines with 10 % of 
SFS and FB for 24 h because this concentration had a significant impact on cell 
growth. In LT97 cells, in general the activity of all the investigated caspases were 












Figure 23 Effect of incubation with Synergy1 fermentation supernatant (SFS 10 %) and 
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Displayed are the means and SD of 3 independently reproduced experiments. One way 
ANOVA, Bonferroni post-tests. *p<0.05 (SFS 10 % Synergy fermentation supernatant 10 %, 
FB 10 %: fermentation Blank 10 %) 
However, only the activity of caspase-3 was increased significantly after 24 h of 
incubation (p<0.05). Among caspase-8 and -9 a trend of increased activity was 
visible. In addition to SFS, incubation of LT97 cells with FB also resulted in an up 














Displayed are the means and SD of 3 independently reproduced experiments. One way 
ANOVA, Bonferroni post-tests. *p<0.05 (SFS 10 % Synergy fermentation supernatant 10 %, 
FB 10 %: Fermentation Blank 10 %) 
 
Figure 24 Effect of incubation with Synergy1 fermentation supernatant (SFS 10 %) and 
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In HT29 cells, a significant increase in activity of caspase-3 was visible after 
incubation with SFS for 24 h. However, there was no change in the activity of 
caspase-8 and-9 (figure 24). Additionally, there was no change in the activity of all 
the three investigated caspases in HT29 cells after incubation with FB 10 % for 24 h. 
Thus, the activity of caspase-3 was most clearly modulated after incubation of both 
cell lines with SFS pointing towards the role of some common apoptosis inducing 
mechanisms which converge at caspase-3. 
Further, incubation of both cell lines with SFM also lead to a significant increase in 
the activity of caspase-3 (figure 25) pointing towards the role of change in the 








Displayed are the means and SD of 3 independently reproduced experiments. One way 
ANOVA, Bonferroni post-tests. *p<0.05 (SFS 10 % Synergy fermentation supernatant 




Figure 25 Effect of incubation with SFM on caspase-3 activity in LT97 cells (A) and 
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4.9 Effect on apoptosis relevant genes 
 
In order to get detailed information on the apoptosis inducing mechanisms of SFS at 
the mRNA level, both cell lines were incubated with 10 % SFS and FB for 24 h and 
the modulation in the apoptosis relevant genes namely DR4, DR5, Bid and Bax were 
investigated. DR4 and DR5 are members of the tumour necrosis factor receptor 
family [Thorburn, 2004]. Bid is the BH3 domain-only protein and is a death agonist 
member of the Bcl-2 family [Wang et al., 1996] whereas Bax is a key component for 
cellular induced apoptosis [Wei et al., 2001]. All these genes play an important role 

















Figure 26 Expression of apoptosis relevant genes DR4 (A), DR5 (B) Bid (C) and Bax (D) 
genes in LT97 after incubation with Synergy1 fermentation supernatant (SFS 10 %) and 
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Displayed are the means and SD of 3 independently reproduced experiments. One way 
ANOVA, Bonferroni post-tests. *p<0.05 (SFS 10 % Synergy fermentation supernatant 10 %, 
FB 10 %: Fermentation Blank 10 %) 
 
According to our data analysis of RT-PCR, DR4 and Bax were down-regulated 
significantly (0.13 fold and 0.2 fold respectively) after incubation of LT97 cells with 
SFS (figure 26). The incubation of cells with FB resulted in a significant up-
regulation of Bid (2.19 fold). In contrast to LT97 cells, we observed a significant up-
regulation of mRNA expression of DR5 and Bax (fold change 2.15 and 1.68 
respectively) in HT29 cells when compared to medium control (figure 27). There 
was, however, a significant down-regulation of DR4 (fold change 0.33) after 













Figure 27 Expression of apoptosis relevant genes DR4 (A), DR5 (B) Bid (C) and Bax (D) 
genes in HT29 cells after incubation with Synergy1 fermentation supernatant (SFS) and 
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Displayed are the means and SD of 3 independently reproduced experiments. One way 
ANOVA, Bonferroni post-tests. **p<0.01 (SFS 10 % Synergy fermentation supernatant 10 %, 
FB 10 %: Fermentation Blank 10 %) 
4.10 Effect on Bid Cleavage 
In addition to real time analysis the expression of Bid was also analysed at the 
protein level by Western blot. Bid antibody (human specific) detects endogenous 
levels of both the full length (22 kDa) and cleaved fragment (15 kDa) of human Bid. 
Here, we measured the levels of full length Bid after incubation of both the cell 











Displayed are the means and SD of 3 independently reproduced experiments. One way 
ANOVA, Bonferroni post-tests. (SFS 10 % Synergy fermentation supernatant 10 %, FB 10 
%: Fermentation Blank 10 %) 
Figure 28 Effect of incubation with Synergy1 fermentation supernatant (SFS) and 
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In general, there was no significant change in the level of full length Bid (22 kDa) 
after incubating both the cell lines with 10 % SFS and FB after 24 h. These results 
correspond to the effects observed in the real time analysis. However, in HT29 cells 
a trend of decreased full length Bid was visible. This non-significant decrease in the 
amount of full length Bid from 1.34 to 1.12, HT29 cells could hint towards a weak 
signal of Bid induced apoptosis in HT29 cells. 
4.11 Analysis of gene expression using custom array 
Further, it was of interest to also analyse a broader range of genes involved in 
additional mechanisms of carcinogenesis or chemoprevention. This was done using 
a customised cDNA array system spotted with more than 300 genes of which 
apoptosis signaling pathway, tumour suppressor genes and cell cycle 














Figure 29 Representative of array image LT97 cells (A) and HT29 cells (B) after 
incubation with Synergy fermentation supernatant (SFS) 
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In LT97 cells; custom array results indicated that mRNA expression of 37 genes 
were up-regulated whereas 53 genes were down-regulated on the basis of the 
evaluation criteria (≥1.5 or ≤ 0.6) after incubation with SFS for 24 h. Among 37 
genes found to be up-regulted; only 6 namely, Metallothionein 2A; MT2A (fold 
change 6.11), c-Fos proto-oncogene; FOS_2 (fold change 7.92), Heat shock 70 kDa 
protein 5; HSPA5 (fold change 3.80), DNA-damage-inducible transcript 3; DDIT3 
(fold change 2.21) and two genes with miscellaneous functions; namely Aryl 
hydrocarbon receptor nuclear translocator;  ARNT (fold change 1.77) and 
Baculoviral IAP Repeat-Containing Protein 4; BIRC4 (fold change 3.15) were found 
to be significantly up-regulated (p≤0.05, t test). 
Among 53 genes found to be down-regulated after incubating LT97 cells for 24 h 
with SFS 10 %; 36 genes were significantly down-regulated on the basis of t-test. 
These include Acetyl-Coenzyme A acetyltransferase 2; ACAT2 (fold change 0.16), 
Epoxide hydrolase 2, cytoplasmic; EPHX2 (fold change 0.25), three genes of 
Glutathione S transferase family, GSTO1, MGST1, MGST2 (fold change 0.42, 0.27, 
0.15 respectively), Catechol-Omethyltransferase; COMT (fold change 0.22), 
Sulfotransferase family, cytosolic, 1A; SULT1A1 (fold change 0.50), two UDP 
glucosyltransferase, UGT1A7, UGT2B17 (fold change 0.49, 0.57 respectively), two 
NRF1 mediated regulators KEAP1 and NRF2 (fold change 0.50 and 0.39 
respectively), all seven genes related to oxidative and metabolic stress e.g. GPX1, 
GPX2, FMO5, HMOX1, HSPA1A, PRDX2, DIA4; two DNA damage repair genes 
namely XRCC2, XRCC5 (fold change 0.43, 0.47 respectively), two genes related to 
growth arrest CCND1, PCNA (fold change 0.45 and 0.32), Apoptosis signaling genes 
namely CASP3 and 6 (fold change 0.59 and 0.34), tumour necrosis factor receptor 
TNFSF6 and TNFSF10 (fold change 0.44 and 0.58), Bid (fold change 0.50), two cell 
cycle arrest genes; CCNB1, CCNB2 (fold change 0.40 and 0.53), tumour protein; 
PIG3 (fold change 0.35), two metal storage genes; FTL and SLC11A2 (fold change 
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0.60 and 0.31) and four genes with miscellaneous functions e.g. GSS, MCM7, 
NFKB1, TYMS (fold change 0.41, 0.23 and 0.31, 0.28) were down-regulated 
significantly (Table 4). 
Table 4 Gene expression analysis of Synergy1 fermentation supernatant (SFS) 
treated LT97 cells using a custom made cDNA array 
The table includes genes that have modulated expression levels of ≥ 1.5 and ≤ 0.6 fold 
compared to the medium control cells and are statistically significant. Significant 




name Descriptions Ratio SD P value Sign   
Metallothioneins           
MT2A Metallothionein 2A  6.11 2.74 0.003 ** ↑ 
              
NF-E2 gene family NRF1 and 2 mediated regulations           
FOS_2 c-Fos proto-oncogene   7.92 4.37 0.03 * ↑ 
              
Stress and Signal transduction           
Oxidative or Metabolic Stress            
HSPA5  Heat shock 70kDa protein 5  3.8 1.32 0.02 * ↑ 
              
Growth Arrest and Senescence           
DDIT3  DNA-damage-inducible transcript 3 2.21 0.47 0.02 * ↑ 
              
Miscellaneous (several functions)           
ARNT Aryl hydrocarbon receptor nuclear translocator  1.77 0.6 0.02 * ↑ 
BIRC4  Baculoviral IAP Repeast-Containing Protein 4 3.15 1.53 0.03 * ↑ 
              
Acetyltransferases           
ACAT2 Acetyl-Coenzyme A acetyltransferase 2  0.16 0.07 0.0007 *** ↓ 
              
Epoxide Hydrolases           
EPHX2 Epoxide hydrolase 2, cytoplasmic 0.25 0.06 0.0002 *** ↓ 
              
Glutathione S-Transferases           
GSTO1 Glutathione S-transferase omega 1 0.42 0.14 0.0019 ** ↓ 
MGST1 Microsomal glutathione S-transferase1 0.27 0.11 0.01 * ↓ 
MGST2 Microsomal glutathione S-transferase 2 0.15 0.06 0.0015 ** ↓ 
              
Methyltransferases           
COMT  Catechol-Omethyltransferase  0.22 0.08 0.001 ** ↓ 
              
Sulfotransferases           
SULT1A1 Sulfotransferase family, cytosolic, 1A 0.5 0.17 0.01 * ↓ 
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UDP Glycosyltransferases            
UGT1A7 UDP glycosyltransferase 1 family  0.49 0.18 0.03 * ↓ 
UGT2B17 UDP glycosyltransferase 2 family  0.57 0.18 0.02 * ↓ 
              
NF-E2 gene family NRF1 and 2 mediated regulations           
KEAP1 Kelch-like ECH-associated protein 1 0.5 0.17 0.01 ** ↓ 
NRF2 Nuclear factor (erythroid-derived 2)-like 2 0.39 0.14 0.0047 ** ↓ 
              
Stress and Signal transduction           
Oxidative or Metabolic Stress           
FMO5 Flavin containing monooxygenase 5 0.56 0.16 0.02 * ↓ 
GPX1 Glutathione peroxidase 1 0.46 0.15 0.02 * ↓ 
GPX2 Glutathione peroxidase 2  0.18 0.09 0.02 * ↓ 
HMOX1 Heme oxygenase (decycling) 1 0.48 0.24 0.05 * ↓ 
HSPA1A  Heat shock 70kDa protein 1A  3.8 1.32 0.02 * ↓ 
PRDX2 Peroxiredoxin 2 0.43 0.1 0.04 * ↓ 
DIA4 NAD(P)H Dehydrogenase 0.6 0.24 0.04 * ↓ 
              
DNA Damage and Repair            
XRCC2 X-ray repair complementing defective repair 0.43 0.08 0.0021 ** ↓ 
XRCC5 X-ray repair complementing defective repair  0.47 0.14 0.01 * ↓ 
              
Growth Arrest and Senescence           
CCND1 
(cyclin D1) Cyclin D1  0.45 0.32 0.04 *   
PCNA Proliferating cell nuclear antigen 0.32 0.17 0.01 ** ↓ 
              
Apoptosis Signaling           
CASP3 Caspase 3 0.59 0.17 0.02 * ↓ 
TNFRSF6 
(Fas) Fas (TNF receptor superfamily, member 6) 0.44 0.18 0.02 * ↓ 
TNFSF10 
(TRAIL) Tumor necrosis factor (ligand) superfamily 0.58 0.13 0.03 * ↓ 
CASP6  CASPASE-6 Precursor  0.34 0.12 0.01 ** ↓ 
BID: (BID)  BH3 interacting domain death agonist BID 0.5 0.13 0.03 * ↓ 
              
Cell Cycle Arrest-Regulation of cell cycle           
CCNB1 cyclin B1    0.4 0.23 0.03 * ↓ 
CCNB2 cyclin B2 0.53 0.23 0.02 * ↓ 
PIG3 tumor protein p53 inducible protein 3 0.35 0.17 0.04 * ↓ 
              
Metal storage and utilization           
FTL Ferritin, light polypeptide  0.6 0.25 0.05 * ↓ 
SLC11A2 
(DMT1) Solute carrier family 11  0.31 0.18 0.05 * ↓ 
              
Miscellaneous (several functions)           
GSS Glutathione synthetase  0.41 0.1 0.002 ** ↓ 
MCM7 MCM7 minichromosome maintenance deficient 7  0.23 0.12 0.01 ** ↓ 
NFKB1 
Nuclear factor of kappa light polypeptide gene 
enhancer  0.31 0.17 0.04 * ↓ 
TYMS Thymidylate synthetase  0.28 0.24 0.03 * ↓ 
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In contrast to SFS; incubation of FB resulted in up-regulation of 122 genes on the 
basis of our evaluation criteria but none of them was found to be statistically 
significant. However, among 12 genes genes down-regulted by FB in LT97 cells, 
four were found to be statistically significant namely Acetyl-Coenzyme A; ACTA2 
and Epoxide hydrolase 2; EPHX2 were down-regulated with a fold change of 0.39 
and 0.51 respectively, two genes with miscellaneous functions namely, 
minichromosome maintenance deficient; MCM7 and Thymidylate synthetase 
TYM8 were also down regulated significantly (fold change 0.28 and 0.35 
respectively) (Table 5). Detailed description of all the genes modulated by SFS and 
FB in LT97 cells are listed in Appendix E. 
 
Table 5 Gene expression analysis of fermentation blank (FB) treated LT97 cells 
using a custom made cDNA array 
The table includes genes that have modulated expression levels of ≥ 1.5 and ≤ 0.6 fold 
compared to the medium control cells and are statistically significant. Significant 





name Descriptions Ratio SD P value Sign   
Acetyltransferases           
ACAT2 Acetyl-Coenzyme A 0.39 0.2 0.01 * ↓ 
              
Epoxide Hydrolases           
EPHX2 Epoxide hydrolase 2 0.51 0.28 0.04 * ↓ 
              
Miscellaneous (several functions)           
MCM7 minichromosome maintenance deficient   0.28 0.14 0.02 * ↓ 
TYMS Thymidylate synthetase  0.35 0.08 0.0003 *** ↓ 
 
In HT29 cells custom array results also indicated significant up regulation of 7 genes 
out of total 97 genes up-regulated on the basis of evaluation criteria (≥ 1.5 or ≤ 0.6) 
after 24 h incubation with SFS. The significantly up-regulated genes were 
sulfotransferase; SULT1C1 (fold change 3.12), Metallothionein 2A; MT2 A (fold 
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change 2.56), Transcription Factor JUND (fold change 2.64), cyclin A; CCNA1 (fold 
change 1.86), Cyclin-dependent kinase inhibitor2B; CDKN2B (fold change 3.03), 
Ferritin, light polypeptide; FTL (fold change 2.21), and one gene with miscellaneous 
function namely Aryl hydrocarbon receptor nuclear translocator; ARNT (fold 
change 2.59) was also significantly altered.  
Among the 28 genes down-regulated by SFS in HT29 cells 6 genes were down- 
regulated significantly e.g. Methyl transferases; NNMT (fold change 0.58), DNA 
damage and repair gene; ERCC6 (fold change 0.43), Proliferating cell nuclear 
antigen; PCNA (fold change 0.26), Haeamochromatosis; HFE (fold change 0.54) and 
two genes with miscellaneous functions namely MCM7 minichromosome 
maintenance deficient; MCM7 and Nuclear factor of kappa light polypeptide gene 
enhancer;  NFKB1 (fold change 0.39 and 0.35 respectively) (Table 6). 
 
Table 6 Gene expression analysis of Synergy1 fermentation supernatant (SFS) 
treated HT29 cells using a custom made cDNA array 
The table includes genes that have modulated expression levels of ≥ 1.5 and ≤ 0.6 fold 
compared to the medium control cells and are statistically significant. Significant 




name Descriptions Ratio SD P value Sign   
Sulfotransferases           
SULT1C1 Sulfotransferase family, cytosolic, 1C, member 1 3.12 2.77 0.04 * ↑ 
              
Metallothioneins           
MT2A Metallothionein 2A  2.56 1.21 0.04 * ↑ 
              
CCAAT-enhancer-binding protein (C/EBP) mediated regulation           
JUND Transcription Factor JUND 2.64 0.37 0.003 ** ↑ 
              
Cell Cycle Arrest-Regulation of cell cycle            
CCNA1 cyclin A 1.86 0.36 0.04 * ↑ 
CDKN2B 
Cyclin-dependent kinase inhibitor 2B (p15, inhibits 
CDK4) 3.03 0.76 0.03 * ↑ 
Metal storage and utilization           
FTL Ferritin, light polypeptide  2.21 0.24 0.02 * ↑ 
Miscellaneous (several functions)           
ARNT aryl hydrocarbon receptor nuclear translocator  2.59 1.52 0.05 * ↑ 
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Methyltransferases           
NNMT Nicotinamide Nmethyltransferase 0.58 0.18 0.02 * ↓ 
              
DNA Damage and Repair           
ERCC6 
Excision repair cross-complementing rodent repair 
deficiency 0.43 0.06 0.04 * ↓ 
              
Growth Arrest and Senescence            
PCNA Proliferating cell nuclear antigen 0.26 0.14 0.0036 ** ↓ 
              
Metal storage and utilization           
HFE  Hemochromatosis  0.54 0.29 0.04 * ↓ 
              
Miscellaneous (several functions)           
MCM7 MCM7 minichromosome maintenance deficient  0.39 0.24 0.02 * ↓ 
NFKB1 
Nuclear factor of kappa light polypeptide gene 
enhancer  0.35 0.04 0.05 * ↓ 
 
Incubation with FB resulted in an up-regulation of 44 genes but similar to LT 97 
cells none of the up-regulated gene was significantly modulated. However, one of 
the five down-regulated genes namely Uracyl DNA glycolase was significantly 
down-regulated with a fold change 0.57 in HT29 cells after incubation with FB 
(Table 7). 
 
Table 7 Gene expression analysis of fermentation blank (FB) treated HT29 cells using a 
custom made cDNA array 
The table includes genes that have modulated expression levels of ≥ 1.5 and ≤ 0.6 fold 
compared to the medium control cells and are statistically significant. Significant 




name Descriptions Ratio SD P value Sign   
DNA Damage and Repair      





   
5 Discussion 
Tumourigenesis has long been thought to be a multistep process [Foulds, 1958]. 
However, only recently it has become possible to identify the molecular events that 
underlie the initiation and progression of human tumours. Large bowel cancer, 
especially in colon and rectum, is a leading cause of cancer mortality in the 
industrialised world [Dove-Edwin and Thomas, 2001]. The development of colorectal 
cancer is complex process, involving both environmental and genetic factors. 
However, casual associations obtained in epidemiological studies between large bowel 
cancer development and diets are controversial and still a subject to debate.  
Dietary fibres have been put forward as colon cancer protective food components 
[Burkitt, 1969; Hill, 1995]. The theory is that dietary fibre may protect against colon 
cancer through secondary events resulting from the fermentation of carbohydrates by 
the gut microflora. This leads to faecal bulking, increased speed of colonic transit, 
increase in nitrogen metabolism, increased bacterial load in the colon, acidification 
and, finally the production of SCFA [Harris and Ferguson, 1993]. Support for this 
concept comes from various animal and cell culture experiments reviewed earlier 
[Johnson, 1995; Velazquez et al., 1996]. One class of dietary fibres that could be 
excellently relevant in colon cancer prevention is the group of inulin-type fructans. 
Earlier studies showed a reduction of crypt numbers and multiplicity, when adding 10 
% inulin to the diet of rats [Rowland et al., 1998]. Accumulating evidence for a 
preventive effect of inulin against colon cancer in experimental animals has been 
reviewed in detail [Pool-Zobel, 2005; Pool-Zobel and Sauer, 2007]. These animal 
studies have shown that a functional intake of inulin type fructans is the inhibition of 
carcinogen mediated tumour formation. However, identifying potential anticancer 





   
expensive. Therefore, the present study was performed using in vitro cell culture 
approaches to elucidate in depth which functional consequences can ensue from 
inulin type fructans in human colon with regard to chemoprotection on the cellular 
level. For this, a fermentation supernatant simulating the conditions of the intestinal 
lumen was produced in vitro and used to treat human colon tumour cell lines to 
determine effects on diverse parameters of chemoprotection. These include 
parameters related to primary cancer prevention (which prevent cancer initiation by 
blocking carcinogens from damaging the cells) and secondary chemoprotection 
(neoplastic cells are suppressed from further progression).  
5.1 Fermentation of inulin type fructans 
 
Inulin enriched with oligofructose (Synergy1) is a source of prebiotic dietary fibre 
which yields high amounts of SCFA due to fermentation by gut bacteria [Sauer et al., 
2007b]. These SCFAs are able to reduce the conversion of primary to secondary bile 
acids in the colon [Bingham, 1996]. Our results indicate a 2.6 fold increase in SCFA 
and 3.4 fold reduction in the amount of DCA in SFS as compared to FB after in vitro 
fermentation of Synergy1. The total amounts of SCFA after fermentation of Synergy1 
(126 mM) observed in this study correspond to normal situation as the total amount of 
SCFA observed in vivo in the colon of human is estimated to range from 70-140 mM 
[Reddy, 1999]. Noteworthy, the absolute concentration of butyrate observed in the 
present study increased from 6.6 mM in FB to 26.4 mM in SFS accounting for almost 4 
fold increase. Additionally, the relative molar concentrations, with molar ratios for 
acetate, propionate and butyrate of FB (62:22:16) and SFS (65:14:21), also indicate a 
particular modified profile of propionate and butyrate. Thus, high production of SCFA 
in vitro is possibly also an indication of protective effects, because butyrate and 





   
et al., 2003]. Moreover, the analytical measurements of bile acids revealed a 
concentration of 12.3 mM in FB and 3.6 mM in SFS which are similar to the previous 
results with fiber rich diet [Alberts et al., 2003; Owen, 1997]. These results are 
noteworthy because bile acids have been shown to positively correlate with colon 
cancer incidence (Bernstein, 2005). Further, increased level of SCFA produced during 
fermentation reduces luminal pH and is responsible for a decreased conversion of 
primary to secondary bile acids [Bingham, 1996]. Therefore, these results indicate that 
fermentation of Synergy1 after ingestion may be inversely associated in terms of 
incidence of colon cancer.  
5.2 Growth inhibitory effects 
 
Inulin and oligofructose (Synergy1) has been the subject of various in vitro and in 
vivo studies [Roberfroid, 1993; Pool-Zobel, 2005]. It has been shown previously that 
gut fermentation products of inulin-type fructans beneficially modulated markers of 
tumour progression in human colon tumour cells [Klinder et al., 2004b]. Furthermore, 
in vivo studies also showed the incidence of carcinogen mediated colonic tumours 
reduced after life-long feeding of 10 % inulin to rats [Verghese et al., 2002]. Thus, 
these studies have shown that a functional result of consumption of Synergy1 is the 
inhibition of tumour formation. 
On the basis of our results, we found that fermentation of Synergy1 resulted in a 
distinct time and concentration dependant inhibition of cell growth in both cell lines. 
The reduction of cell growth in vitro, by fermentation samples in this study are in 
line with a similar previous in vitro [Klinder et al., 2004b] and in vivo studies [Femia 
et al., 2002]. Among SCFA, butyrate has been shown to be a potent inhibitor of cell 
growth. However, the impact on cell proliferation is additive with propionate in 





   
butyrate is a well recognised antiproliferative agent arresting cell growth in G1 and 
inducing differentiation [Wong et al., 2006]. We also observed an almost four fold 
increase in butyrate concentration after in vitro fermentation of Synergy1 which may 
contribute to the significant growth inhibition in both cell lines. Moreover, the 
distinct time dependency of inhibition of proliferation with SFS supports the 
production of effective metabolites produced during incubation of fermentation 
supernatant with colon cells [Klenow et al., 2008], which in turn could induce 
intracellular signal cascades. Interestingly, the fermentation sample from Synergy1 
and its corresponding synthetic mixture consisting of acetate, propionate, buyrate and 
DCA were of equal potency in mediating growth inhibition, reflecting the potential 
of SCFA in secondary chemoprevention. Furthermore, our data showed that the 
growth inhibitory effect of SFS is stronger in adenoma than in carcinoma cells. This 
difference in growth inhibition may potentially be explained by differences in the 
amount of butyrate uptake by both cell lines, which may be caused by the availability 
of monocarboxylate transporter 1 (MCT1) which is necessary for butyrate uptake and 
is down-regulated from normal cells to malignant cells [Daly et al., 2005;Cuff et al., 
2002]. Therefore, adenoma cells which represent an early stage of cancer might have 
consumed more butyrate and in turn their growth could be inhibited in a stronger 
manner in comparison to carcinoma cells. Altogether, this may have important 
implications on chemoprevention, as it indicates that fermentation products of 
Synergy1 could inhibit growth of adenoma cells, thus acting at an early stage of 
carcinogenesis and reducing the probability of the formation of malignant tumours. 
Additionally, the increase in metabolic activity of remaining cells after 72 h with SFS 
pointed towards nutrient effects and indicated that the remaining cells were 
metabolically more active after treatment with SFS. Moreover, increase in growth 





   
could be due to the presence of secondary bile acids which in small concentrations 
have been shown to increase the proliferation of HT29 cells [Milovic et al., 2002]. 
This increase in cellular growth was not visible with higher concentration of SFS or 
FB which may be due to the detoxification of secondary bile acids with SCFAs. 
Furthermore, since incubation of cells with FB also reduced cell growth, additional 
factors seem to be present in the feces supernatant bearing an effect on cells. Factors 
like sulphates, ammonia and products of bacterial metabolism, non-digested food 
residues and excretable metabolites could account for these effects [Cummings and 
Englyst, 1987]. 
5.3 Modulation of genotoxicity  
 
Although the colon epithelium is partly protected by its mucin layer, which can 
detoxify reactive substances, yet the cells are relatively susceptible to exogenous 
toxins. Compared to liver, they express only relatively small amounts of phase II 
enzymes, which inactivate many genotoxic carcinogens [Berlau et al., 2004]. 
Therefore, the possible causes of colorectal cancer could also be due to the lack of 
antioxidative potential of colonic mucosa. In the present study, physiologically 
relevant concentrations of H2O2 and HNE were used as model genotoxic substances. 
Both of these substances generate oxidative stress in the form of reactive oxygen 
species (ROS), which lead to experimentally induced DNA damage [Glei et al., 2006]. 
Pre-treating HT29 cells with SFS for 24 h, resulted in a significant decrease in DNA 
damage induced by subsequent H2O2 challenge whereas no such effect was visible in 
LT97 cells. This SFS treatment did not affect viability of both cell lines which 
demonstrates the absence of cytotoxic effects. The current findings thus disclose that 
SFS protects DNA of HT29 cells from H2O2 induced DNA damage. This could be a 





   
antioxidant defence sytems e.g. up-regulation of catalase, which in turn is responsible 
for decomposing H2O2 [Abrahamse et al., 1999]. In this context the antigenotoxic 
properties of SCFA especially butyrate and acetate are of special importance as both 
compounds are utilized by colonocytes as energy source [Clausen and Mortensen, 
1995]. However, the decrease in genotoxicity could not be confirmed for the 
prevention of HNE induced genotoxicity which may require a higher amount of 
SCFA especially butyrate or longer incubation times to reach this functional 
consequence. Additionally, in LT97 cells, SFS was unable to modulate the genotoxic 
effects of both model genotoxins which might be due to up-regulation of genes 
responsible for detoxification in HT29 cells. 
5.4 Effect on mRNA expression of GSTA4 and CAT and 
subsequent Enzyme activities 
 
In the present study, we observed a significant increase in GSTA4 mRNA expression 
in HT29 cells after preincubation with SFS. The products of this gene is known to 
protect against oxidative stress, endogenous aldehydes, quinones, epoxides and 
hydroperoxides formed as secondary metabolites during oxidative stress and can 
therefore protect from food contaminants, such as polycyclic aromatic hydrocarbons 
[Hayes and Pulford, 1995]. Since GSTA4 is the GST isoenzyme with the highest 
affinity for HNE, the lack of protection against HNE induced DNA damage was rather 
surprising and could be explained due to post transcriptional modification of this 
gene. Furthermore, a significant induction of GSTA4 mRNA after pretreatment of 
cells with faecal blank indicates the protective effects for e.g. products of bacterial 
metabolism of nondigested food residues and excretable metabolites which may have 
their origin from faecal samples rather than from fermented Synergy1 which need to 





   
Our results raise interesting questions regarding the mechanisms of GST mRNA 
induction in human colon cancer cells. The putative binding sites for transcription 
factors in the regulatory region of GSTA4 gene include AP1, STAT, and NFkB 
[Desmots et al., 1998]. In addition, butyrate activates ERK of the MAP kinase 
pathway which represents an important component of induction of the AP1 related 
transcription factors Jun and Fos [Ebert et al., 2001]. However, it must also be 
considered that our model (HT29 cells) represents transformed cells and that the 
dietary fibres mediated up-regulation of GSTA4 mRNA may potentially enhance 
survival of transformed cells. Accordingly, additional work is needed on how the 
relative mRNA expression levels in human primary cells may be influenced by dietary 
fibres which in turn could confer protection of these cells against transformation. In 
contrast to HT29 cells, no change in GSTA4 mRNA was observed in LT97 cells which 
could however be due to less expression of GSTs in LT97 cells in comparison to HT29 
cells [Schaeferhenrich et al., 2003]. 
At the enzymatic level, GSTs constitute the major family of phase II detoxification 
enzymes involved in the cellular protection against electrophilic intermediates by 
catalysing conjugation with GSH [Habig et al., 1974]. Accordingly, elevation of GST 
and GSH expression by chemopreventive agents can afford cellular protection against 
carcinogens. In this regard, several studies have provided evidence that GST 
isoenzymes may be induced by nutritional factors in vivo and in vitro [Knoll et al., 
2005; Pool-Zobel, 2005]. It has been shown previously in human colon cells that 
exposure to 4 mM butyrate induces total GST and catalytic activity [Ebert et al., 
2001]. However, we found no change in GST activity in both the cell lines after 24 h 
of treatment with SFS corresponding to a previous in vitro study [Beyer-Sehlmeyer et 





   
in the SFS; since butyrate induces GST activity at 4 mM [Glei et al., 2006] or by the 
presence of other inhibitory substances in the faeces. 
 
In addition to GSTs, catalase is also a phase II enzyme which represents one of the key 
defense systems against oxidative stress because it detoxifies H2O2 to oxygen and 
water [Chelikani et al., 2004]. A previous study showed a significant increase in the 
mRNA expression of the catalase gene (2.9 fold) and a 65 % increase in its enzymatic 
activity after incubation of primary colon cells of humans with 10 mM butyrate for 2h 
[Sauer et al., 2007a]. In the present study, only a non-significant increase in the 
mRNA expression of catalase was observed (fold change 1.85) but a significant 2 fold 
increase in catalase activity after incubation of carcinoma cells with SFS for 24h. This 
significant up-regulation of catalase activity suggests that catalase activity may not be 
regulated on the transcriptional level but by some yet unknown post translational 
mechanisms. Moreover, since catalase decomposes H2O2; induction of catalase can 
protect the cells against endogenous H2O2 induced DNA damage, risk of mutations 
and possibly initiation of cancer [Mates and Sanchez-Jimenez, 2000]. 
5.5 Induction of Apoptosis 
 
In addition to cell growth inhibition, induction of apoptosis in cancer cells is another 
important mechanism by which tumours can be prevented to grow further. 
Apoptosis, is a physiological process of selected cell deletion and is thus important for 
secondary cancer prevention, if activated in cancer cells [Kerr et al., 1972]. If 
apoptosis is suppressed (e.g. in cells with p53 mutations) this can result in the 
development of various tumours [Hollstein et al., 1991]. Cells committed to terminal 
differentiation undergo a genetically programmed death process that exhibits features 
of apoptosis such as cell shrinkage and nuclear DNA fragmentation [Hall et al., 1994]. 





   
in regulating cell fate in the intestinal epithelium [Kapiteijn et al., 2001]. 
Furthermore, both Bcl-2 and Bcl-XL, two antiapoptotic members of Bcl-2 family, 
have been found to be overexpressed in colon cancer [McEntee et al., 1999; Maurer et 
al., 1998]. Therefore, to study the impact of inulin type fructans on apoptosis, as a 
relevant mechanism for anti cancer properties of dietary fibres, colon adenoma and 
carcinoma cell lines were incubated with SFS and the effect on expression of 
proapoptic genes at mRNA and enzymatic level were investigated.  
5.6 Induction of PARP cleavage 
 
To analyse effects of SFS and FB on apoptosis, cleavage of Poly (ADP-ribose) 
polymerase (PARP) was measured. Inhibition of PARP by cleavage facilitates cellular 
disassembly and serves as a marker of cells undergoing apoptosis [Germain et al., 
1999]. In general, we observed a significant increase in cleaved PARP after incubating 
the adenoma cells with SFS. The association of PARP function with cell death is 
inferred from studies demonstrating that PARP is rapidly and specifically cleaved 
during apoptosis [Tewari et al., 1995; Lazebnik et al., 1994]. PARP has been proposed 
to act as a critical death substrate, because it is rapidly cleaved by caspase-3, a 
mammalian ICE-related protease involved in apoptosis [Nicholson et al., 1995]. 
Therefore, the observed significant increase in PARP cleavage indicates that dietary 
fibers may have beneficial chemopreventive effects by inducing apoptosis in colon 
cancer cells. The mechanism by which inulin type fructans induce PARP cleavage is 
still unclear. It has been shown previously that butyrate induced apoptosis is 
mediated via activation of the caspase-cascade and a key event was the proteolytic 
activation of caspase-3, triggering degradation of PARP [Ruemmele et al., 1999]. 
Furthermore, we were able to show that SCFA alone also significantly increased 





   
used, induction of apoptosis was less pronounced. DCA has been shown previously to 
cause degradation of p53 [Bernstein et al., 2005] which in turn increases genomic 
instability because of reduced apoptotic removal of cells with DNA damage. Thus, 
DCA might have inhibited the apoptosis inducing effect of SCFA when present 
together with SCFA [McMillan et al., 2000]. In vivo both SCFA and bile acids are 
present together in the colon so this apoptosis inhibiting effect of bile acids could be 
significant in colonic tissue which turns over very rapidly. Moreover, in comparison 
to SFM, the complex SFS induced apoptosis in a stronger way which is a hint towards 
the role of some other not yet identified substances. The so called “added value” of the 
complete fermentation samples could be due to an increase in antioxidants and anti-
mutagenic compounds like hydroxycinnamic acids which occur in cell walls of some 
species of food plants and may be released after microbial fermentation [Ferguson and 
Harris, 2003]. As a result, such compounds could, at least theoretically, inhibit the 
development of colon cancer. Additionally, the increased sensitivity of LT97 cells to 
be triggered to go into apoptosis may have important implications for possible 
chemopreventive activities in earlier stages of the cancer process, because it is of high 
benefit to induce apoptosis in adenoma cells and thereby reduce the formation of 
more degenerated carcinoma cells. Altogether, the investigation revealed a further 
important mechanism of secondary chemoprevention by complex fermentation 
samples by induction of apoptosis. This effect was primarily mediated by SCFA and 
suppressed by DCA. 
5.7 Modulation of Caspase activity  
 
In addition to PARP cleavage, most apoptosis signaling pathways ultimately result in 
the activation of caspases, a family of cysteine proteases that act as common death 





   
caspases can principally be triggered by at least two distinct, but interconnected 
pathways that activate different initiator caspases, that is caspase-8 and -9 which 
converge at the level of executor caspase -3, -6, and -7 [Li et al., 1998]. The 
simultaneous activation of both pathways is thought to result in a strong amplification 
of original apoptosis signal. Therefore, activity of different caspases was measured in 
order to get more information on the mechanisms of how the complex fermentation 
sample induced apoptosis. Here, we observed that treatment of both carcinoma and 
adenoma cell lines with SFS and SFM induced the activation of caspase-3, which is 
consistent with the previous studies where apoptosis was induced by short chain fatty 
acids especially butyrate [vivi-Green et al., 2000; Mandal et al., 2001]. This 
observation is also in accordance with the results obtained from PARP cleavage 
studies whichis is known to be a substrate of caspase-3 [Yang et al., 2001]. Caspase-3, 
a member of executior caspases [Kumar S, 2007] can be activated by several routes 
which include ligation of cell surface receptors such as Fas which are associated with 
caspase-8; or by factors released from mitochondria, that is cytochrome c, in response 
to cellular stress, which in turn activate caspase-9 [Enari et al., 1996]. It has been 
recently shown recently that sodium butyrate could induce the conversion of the 
proenzyme form of caspase-3 to the catalytically active effector protease through 
histone deacetylase inhibition which sensitises tumour cells to induction of apoptosis 
[Medina et al., 1997]. Beside Caspase-3; Caspase-8 and -9 were also investigated after 
incubation of both cell lines with SFS and FB. However, incubation of both cell lines 
with SFS or FB resulted in either no or non-significant increase in cleavage of caspase 
-8 and-9. Recently, studies have identified caspase-10 as an important initiator 
caspase, in addition to caspase-8 and-9, in death receptor signaling pathways 





   
or caspase-1 [Harvey et al., 1998] may play an important role as the major executer 
together with caspase-3 in SFS-induced colon cancer cells apoptosis. 
 
5.8 Modulation of Apoptosis relevant genes 
In addition to involvement of caspases recent studies have begun to dissect the 
molecular mechanisms by which apoptosis is induced in tumour cells. In this regard, 
Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is an 
attractive candidate for cancer prevention due to its ability to induce apoptosis 
selectively in cancer cells [Walczak et al., 1999; Lawrence et al., 2001]. Death receptor 
4 (DR4) and Death receptor 5 (DR5) are members of the TNF receptor family and are 
receptors for TRAIL. DR5 and DR4 mediate TRAIL-induced apoptosis through the 
formation of a death-inducing signaling complex (DISC) containing the death 
receptor, adaptor proteins, such as Fas-associated death domain (FADD), and certain 
initiator caspases, such as procaspase-8 [Ashkenazi and Dixit, 1998] or procaspase-10 
[Kischkel et al., 2001]. Furthermore, proteins of Bcl-2 family also play a pivotal role in 
the regulation of apoptosis. The family Bcl-2 can be subdivided into pro-and anti-
apoptotic proteins. The anti apoptotic members include Bcl-2, Bcl-XL whereas the 
proapoptotic members include Bak, Bax, Bid [Cory and Adams, 2002].  
The results of this study demonstrated a significant increase in mRNA expression of 
DR5 and Bax in HT29 colon carcinoma cells after incubation with SFS. Death 
receptors DR4 and DR5 have been demonstrated previously to play a crucial role in 
synergistic cytotoxicity with TRAIL and butyrate to induce apoptosis [Hernandez et 
al., 2001]. It has been postulated that the interaction of TRAIL with death receptors 
DR4/DR5 activates the caspase cascade, which in turn results in apoptosis [Walczak 
and Krammer, 2000]. However, TRAIL can induce apoptosis through DR4 and DR5 





   
than to DR4 [Truneh et al., 2000]. In contrast to HT29 cells this increase in DR4 and 
DR5 receptors was not observed in LT97 cells. Although this has not been studied 
very well, there are indications that in some cell lines, these death receptors are more 
efficient in death signalling than the other [van Geelen et al., 2004]. Moreover, a 
different redistribution of TRAIL receptors to the cell membrane of LT97 cells after 
treatment with SFS might be responsible for effects observed in this study. 
Furthermore, in addition to TRAIL receptors; Bax a proapoptotic member of the Bcl2 
has also been shown to be one of the major players in mitochondria-mediated cell 
apoptosis either by down-modulation of Bax-antagonists such as Bcl-XL [Vander 
Heiden and Thompson, 1999] or by cytochrome c release from mitochondria. It has 
been proposed that after stimulation with butyrate the mitochondrial Bcl-2 is shifted 
towards a proapoptotic constellation, with markedly increased mitochondrial bak and 
bax levels and decreased bcl-xL levels. This shift allows the translocation of 
cytochrome-c from the mitochondria to the cytosol, allowing the formation of an 
apoptosome and upregulating caspase cascade leading to apoptotic cell death 
[Ruemmele et al., 2003]. Thus, results of the present study suggest that fermentation 
supernatant induced apoptosis is mediated by both TRAIL and Bcl-2 route in HT29 
cells. Furthermore, these results also suggest that a combination of HDACIs and 
TRAIL thus might be useful as a promising strategy for cancer therapeutics and 
prevention. However, the non-observance in the up-regulation of TRAIL receptors 
and Bcl-2 members does not rule out the possibility to enhance TRAIL-induced 
apoptosis by regulating the expression of other proteins pertinent to the extrinsic or 
intrinsic pathway in LT97 cells. Further, the increase in TRAIL sensitivity which 
occurs during transition from an adenoma to a carcinoma stage could also be 





   
In addition our investigation also suggests no changes of Bid either at mRNA level or 
at protein level in both cell lines. Bid is a unique BH3 only proapoptotic protein and 
unlike others activation of Bid depends on the proteolytic processing of intact Bid 
into truncated Bid which in turn leads to a release of apoptogenic molecules such as 
cytochrome c [Luo et al., 1998]. In contrast to the present study a significant increase 
in Bid cleavage was observed in LT97 cells after incubation with 10mM butyrate for 
24 h (Scharlau et al. unpublished). This could however be explained by either too low 
butyrate concentration in our fermentation supernatant or inhibition of Bid cleavage 
by other members of Bcl-2 family [Yi et al., 2003]. 
5.9 Analysis of other genes relevant to growth 
inhibition and apoptosis by custom array 
 
We used a custom array with more than 300 genes with a known identity to analyse 
mRNA expression of genes after SFS treatment. In general, in both cell lines the 
expression of the majority of genes remained unchanged following treatment with 





In LT97 cells SFS treatment lead to an up-regulation of 37 genes. Out of these genes 
only 6 were found to be significantly modulated. The significantly upregulated genes 
included metallothioneins MT2A and a FOS gene family member FOS_2, Heat shock 
protein HSPA5, DNA-damage-inducible transcript 3; DDIT3 and two genes with 





   
Metallothioneins belong to a family of cysteine-rich low molecular weight metal 
binding proteins and participate in detoxification of toxic metals and help in 
protection of cells against reactive oxygen species [Nordberg, 1998; Yi et al., 2003]. 
Furthermore, the, Fos gene family proteins have been implicated as regulators of cell 
proliferation, differentiation and transformation [Sugio et al., 1988] and considered to 
be good prognostic marker for patients with colorectal carcinoma. Additionally, 
DDIT3 has been shown to act in response to the stress of chemical exposure and other 
events blocking the proliferation at G1 and G2 check points [Fornace, Jr. et al., 1989]. 
It also binds to various transcription factors, resulting in induction of apoptosis.  
Incubation of SFS also resulted in a down-regulation of 53 genes of which 36 genes 
were significantly modulated. These include ACAT2; EPHX2, three genes of 
Glutathione S transferase family, GSTO1, MGST1, MGST2; COMT; SULT1A1 two 
UDP glucosyltransferase, UGT1A7, UGT2B17; KEAP1 and NRF2; all seven genes 
related to oxidative and metabolic stress e.g. GPX1, GPX2, FMO5, HMOX1, HSPA1A, 
PRDX2, DIA4; two DNA damage repair genes namely XRCC2, XRCC5 respectively, 
two genes related to growth arrest CCND1, PCNA; apoptosis signaling genes namely 
CASP3 and 6; TNFSF6 and TNFSF10; Bid two cell cycle arrest genes CCNB1, CCNB2; 
tumour protein; PIG3; two metal storage genes; FTL and SLC11A2 and four genes 
with miscellaneous functions namely: GSS, MCM7, NFKB1, TYMS  
Among growth inhibitory genes Cyclins are important as they constitute a group of 
proteins which are potentially synthesized and degraded during the cell cycle. This 
enables them to activate the cyclin dependant kinases at appropriate times whose 
activity is needed to drive the cells through the cell cycle [Desdouets et al., 1995]. 
Furthermore, the role of PCNA in cell cycle control is related to its interaction with 
cyclin [Paunesku et al., 2001]. Therefore, the down-regulation of cyclin A and PCNA 





   
PCNA gene transcription. Furthermore, decreased CCNB1 and CCNB2 after 
incubation with SFS could impair CDK1 activation altering mitotic progression 
[Berger et al., 2006]. 
In contrast to SFS, treatment of FB did not result in any significant up/down-
regulation of any of the growth arrest or apoptosis inducing genes. 
 
HT29 cells 
SFS treatment leads to a significant up-regulation of 97 genes in HT29 cells. However, 
only 7 were found to be statistically significant which include SULT1C1, MT2 A, 
JUND, CCNA1, CDKN2B, FTL, and ARNT. It has been shown previously that 
activation of cyclin A which drives the cells into cell cycle by activated cAMP is also 
accompanied by inhibition of cyclin D1 expression [Desdouets et al., 1995]. The 
growth factor induced cyclin D expression is repressed upon treatment with cAMP 
analogues, thus leading to an arrest during the G0/G1 transition [Sewing et al., 1993]. 
Therefore, induction of both CCNA1 after incubation with SFS seems to be positive in 
terms of chemoprevention.  
Moreover, transcription factor JunD is highly expressed in intestinal epithelial cells, 
but its exact role in maintaining the integrity of the intestinal epithelial barrier 
remains unknown. Although c-jun and junB behave as immediate early response 
genes and enhance the G1 to S phase transition of the cell cycle upon mitogenic 
stimulation [Ryder et al., 1988] yet the function of JunD is much less clear and several 
studies have suggested that it may actually function to inhibit cell proliferation. Thus 
these findings are partially consistent with the growth inhibitory effect of SFS in 
HT29 cells. However, the contribution of signalling pathway to cell growth may 





   
consideration in further investigation. Furthermore, incubation of HT29 cells with 
SFS also resulted in a non-significant up-regulation of caspase-8,-9 which is consistent 
with our real time PCR results.  
Among 28 genes down-regulated by SFS in HT29 cells, only 6 were found to be 
significantly modulated, which included NNMT, ERCC6, PCNA, HFE and two genes 
with miscellaneous functions namely MCM7 and NFKB1. Of all these 6 genes only 
PCNA has been thought to be responsible to inhibit growth of tumour and inhibit 
apoptosis (Paunesco 2001) and therefore could serve as a possible candidate for 
chemoprevention if down-regulated at mRNA level. Furthermore, NNMT has also 
been identified as a novel serum marker for human colorectal cancers [Roessler et al., 
2005] and the up-regulation of NNMT has been found to be positively correlated with 
colorectal cancer and is required during initial phase of malignant conversion. [Kim et 
al., 2009].Therefore, these results hint that SFS might reduce the probability of 
colorectal tumour progression. Similar to LT97 cells, there was no significant up-
regulation/down-regulation of genes related to growth inhibition or apoptosis 
induction after treatment of FB. 
Collectively our results demonstrate marked heterogeneity between adenoma and 
carcinoma cell lines in the responsiveness of growth inhibition and apoptosis gene 
induction which could be due to the difference in availability of fermentation 
products in both cells lines or to the significant differences between adenoma and 
carcinoma cells in general. However, these results should be validated with real time 








   
6 Abstract  
 
Introduction Epidemiological studies suggest that a diet rich in fat and red meat may 
increase the risk of colon cancer, whereas a high intake of fibre and complex 
carbohydrates may protect against it. One of the potentially protective groups of 
dietary constituents are prebiotics which are non-digestible food ingredients that 
beneficially affect the host by selectively stimulating the growth and/or activity of 
certain groups of beneficial bacteria while maintaining potential pathogens at low 
levels. Among various prebiotics inulin and oligofructose has been the subject of 
extensive research. Inulin type fructans are the natural constituents of a wide range of 
common vegetables and fruits. Potential fermentation products of inulin in the gut 
include SCFA, especially an increased relative proportion of butyrate. These 
fermentation products are shown to be protective in different stages of cancer onset 
since they regulate colonic epithelial turnover and induce apoptosis in colon adenoma 
and cancer cell lines.  
 
Aims The aim of this study was to characterise the fermentation supernatant of 
Synergy1 (SFS) for parameters of chemoprotection, mainly inhibition of tumour cell 
growth, induction of apoptosis and modulation of genetic damage. Moreover, we 
compared functional consequences of this supernatant using two different colon 
cancer cell lines namely LT97 (preneoplastic adenoma cells) and HT29 (highly 
transformed adenocarcinoma cells) to obtain new information on the molecular 
mechanisms of tumour suppression. Furthermore, a synthetic fermentation mixture 
(SFM) mimicking the SFS in the amount of short chain fatty acids (SCFA) and the 
secondary bile acid desoxycholic acid (DCA) was also prepared to investigate the 





   
Methods Synergy fermentation supernatant (SFS) and feces blank (FB) were 
characterised for the contents of short chain fatty acids (SCFA) and desoxycholic acid 
(DCA). Both HT29 and LT97 cells were treated with SFS and FB for 24 h. The effect 
on metabolic activity was measured by cell titer blue assay whereas the effect on cell 
growth was measured by DAPI assay. SFS and FB treated cells were challenged with 
genotoxic compounds namely H2O2 and HNE and effect on DNA damage was 
determined with the Comet assay to determine the possible protective effects of SFS 
against DNA damage. GST and catalase enzyme activity assays were performed to 
investigate the possible mechanisms of detoxification. Induction of apoptosis was 
measured by poly (ADP-ribose) polymerase (PARP) cleavage and Bid cleavage by 
Western blot and by measuring caspase activity. Real-time RT-PCR and cDNA 
microarrays were done to determine mRNA expression of genes involved in apoptosis 
and cell proliferation. 
 
Results Fermentation of Synergy1 increased the yields of total SCFA in SFS in 
comparison to the control (FB). In SFS, the total amount of SCFA was 127.6 mmol/l 
whereas only 48.1 mmol/l was detected in FB. Furthermore, the content of DCA was 
reduced from 12.3 mmol/l in FB to 3.6 mmol/l in SFS. Therefore, the increase in 
chemoprotective SCFA and the reduced formation of the potentially toxic secondary 
bile acid DCA, indicate that fermentation products of Synergy1 may be inversely 
associated in terms of progression of colon cancer.  
The growth of both cell lines was efficiently reduced after incubation with SFS in a 
concentration and time dependant manner. Interestingly, the SFS and SFM were 
equally effective in mediating growth inhibition, reflecting the potential of SCFA in 
secondary chemoprevention. Furthermore, the data showed that the growth 





   
Pre-incubation with SFS resulted in significantly reduced levels of H2O2-induced 
DNA strand breaks (39 % in medium control to 22 % in SFS) in HT29 cells (p ≤0.01) 
whereas this effect was not significant in LT97 cells.  
Incubation with SFS resulted in a significant up-regulation of GSTA4 in HT29 tumour 
cells. The products of this gene are known to protect against oxidative stress and 
detoxify endogenous aldehydes, quinones, epoxides and hydroperoxides formed as 
secondary metabolites during oxidative stress and can therefore reduce carcinogenic 
compounds. Additionally the FB also tended to significantly increase GSTA4 gene 
expression in HT29 cells, which indicates the presence of other metabolites that may 
have their origin from faecal samples rather than from fermented Synergy1. 
SFS treatment did not significantly influence expression of catalase gene but resulted 
in a significant induction of catalase activity in HT29 cells. This suggests that catalase 
activity is not regulated by up-regulation of transcription but by some yet unknown 
post-transcriptional or post-translational mechanisms.  
The Western blot analysis showed that treatment of LT97 cells for 24 h with SFS 
significantly increased cleavage of PARP when compared to medium control. 
However, in HT29 cells, 24 h treatment did not lead to an increase of PARP cleavage 
indicating that HT29 cells were not sensitive towards SFS-induced apoptosis after 
24 h of incubation. Furthermore, incubation of LT97 cells for 24 h with synthetic 
SCFA also resulted in a significant increase in PARP cleavage. However, the levels of 
cleaved PARP after treatment with SFM were lower in comparison to SFS which 
points to the role of some additional apoptosis inducing substances in SFS. There was 
however, no significant change in the level of full length Bid after incubating both 
cell lines with SFS 10% for 24h. 
Further, the activity of caspase-3 was clearly modulated after incubation of both cell 





   
lines. Additionally, incubation of both cell lines with SFM also resulted in a 
significant increase in the activity of caspase-3.  
In LT97 cells a significant down-regulation of mRNA expression of DR4 and Bax (fold 
change 0.13 and 0.2 respectively) were observed whereas in HT29 cells a significant 
up-regulation of mRNA expression of DR5 gene (fold change 2.15) and Bax gene (fold 
change 1.68) and a significant down-regulation of DR4 gene (fold change 0.33) was 
observed when compared to medium control.  
In LT97 cells custom array results indicated that mRNA expression of 37 genes were 
up-regulated whereas 53 genes were down-regulated on the basis of the evaluation 
criteria (≥1.5 or ≤ 0.6) in response to treatment with SFS 10 % for 24 h. Among them 
only 6 were found to be significantly up-regulated and 36 were significantly down-
regulated after incubating with SFS 10 % for 24 h. In contrast, in HT29 cells custom 
array results indicated a significant up-regulation only of 7 genes out of total 97 genes. 
Among the 28 genes down-regulated by SFS 10 % in HT29 cells 6 genes were 
modulated significantly.  
Conclusions The results of the present study on fermentation supernatant of inulin 
revealed valuable information about the role of prebiotics in cancer prevention 
possibly by increase in SCFA production, decrease in toxic secondary bile acids, 
inhibition of cell growth, induction of apoptosis and reduction of the exposure of 
genotoxins in human colon tumour cells. Furthermore, the approach to determine the 
profile of gene expression in human colon cancer cells provides a relevant possibility 
to identify target genes and agents that could contribute to chemoprotection in 






   
7 Zusammenfassung 
 
Einleitung Epidemiologische Studien deuten darauf hin, dass eine Diät reich an Fett 
und rotem Fleisch das Risiko von Darmkrebs erhöhen kann, während eine hohe 
Aufnahme von Ballaststoffen und komplexen Kohlenhydraten dagegen schützend 
wirken kann. Eine der potenziell schützenden Gruppen von Nahrungsbestandteilen 
sind Präbiotika, nicht-verdaulich Nahrungsinhaltsstoffe, die sich positiv auf das 
Wachstum und / oder die Aktivität von bestimmten positiven Darmbakterien 
auswirken und gleichzeitig potenzielle Krankheitserreger auf einem niedrigen Niveau 
halten. Unter den verschiedenen Präbiotika sind Inulin und Oligofructose die am 
Besten untersuchten. Fruktane des Inulin-Typs sind die natürlichen Bestandteile 
eines breiten Spektrums von Gemüse und Früchten. Potenzielle Produkte der 
Fermentation von Inulin sind SCFA und vor allem ein erhöhter relativer Anteil an 
Butyrat. Diese Fermentationsprodukte zeigten protektive Wirkungen auf 
unterschiedliche Stadien der Krebsentwicklung, z.B. durch Inhibierung der 
Zellproliferation und Induktion der Apoptose in Kolon Adenom- und 
Karzinomzelllinien. 
Ziel Das Ziel dieser Studie war die Charakterisierung von Synergy1-
Fermentationsüberständen (SFS) hinsichtlich einer Hemmung des Tumor-Zell-
Wachstums, Induktion der Apoptose und Modulation von DNA- Schäden. Außerdem 
die funktionellen Konsequenzen einer Inkubation dieser Überständen wurde in zwei 
verschiedenen Darmkrebs Zelllinien verglichen nämlich LT97 (präneoplastische 
Adenom-Zellen) und HT29 (hoch transformierte Adenokarzinom-Zellen), um 
Aussagen über die Mechanismen der Chemoprävention treffen zu können. Darüber 
hinaus wurde ein synthetischer Fermentationsüberstand (SFM), der identische 





   
enthielt wie der SFS, hergestellt und die Effekte dieses SFM auf Zellwachstum und 
Apoptose analysiert. 
Methoden Die Konzentrationen an SCFA und DCA im SFS und einer 
Negativkontrolle (Fäzesblank, FB) wurden mittels Gaschromatographie bestimmt. 
HT29 und LT97-Zellen wurden mit SFS und FB für 24 h inkubiert. Der Einfluss auf 
die metabolische Aktivität der Zellen wurde mit Hilfe des cell titer blue assays, die 
Modulation des Zellwachstums unter Verwendung des DAPI-assay bestimmt. 
Mögliche protektive Effekte von SFS und FB vor H2O2- und HNE-induzierten DNA-
Schäden wurden mittels Comet-Assay ermittelt. Zur Untersuchung von 
Mechanismen der Entgiftung wurden Enzymaktivitätsassays (GST und Katalase) 
durchgeführt. Die Induktion der Apoptose wurde durch Detektion von gespaltener 
Poly (ADP-Ribose) Polymerase (PARP) im Western Blot sowie durch Caspase-
Aktivitäts-Experimente analysiert. Der Einfluss auf die Genexpression von Genen der 
Entgiftung und der apoptotischen Signaltransduktion wurde mit cDNA microarrays 
und quantitativer real-time RT-PCR bestimmt. 
Ergebnisse Die Konzentrationen an SCFA waren im SFS im Vergleich zum FB 
deutlich erhöht In SFS lag die Gesamtmenge an SCFA bei 127,6 mmol/l, während nur 
48,1 mmol/l im FB detektiert wurden. Ferner wurde der Gehalt an DCA von 12,3 
mmol/l im FB auf 3,6 mmol/ l im SFS reduziert. Die Zunahme chemopräventiver 
SCFA und die Reduktion karzinogener sekundärer Gallensäuren deuten darauf hin, 
dass Fermentationsprodukte von Synergy1 die Progression von Kolontumoren 
einschränken könnten. 
Das Wachstum von beiden Zellenlinien wurde nach Inkubation mit SFS in einer 
konzentrations- und zeitabhängigen Weise reduziert. Da SFM genauso effektive 
reduzierende Effekte auf das Wachstum zeigte, scheinen vor allem die SCFA 





   
wachstumshemmende Wirkung von SFS in Adenomzellen stärker ausgeprägt ist als in 
Karzinomzellen.  
Eine vorinkubation mit SFS verringerte in HT29 Zellen signifikant(p ≤0.01) H2O2-
induzierte DNA-Strangbrüche (tail intensity: 39% in Mediumkontrolle, 22% in SFS) 
wohingegen dieser Effekt in LT97-Zellen nicht signifikant war. 
Inkubation mit SFS führte zu einer signifikanten Hochregulierung der GSTA4-
Expression in HT29-Zellen. Die Produkte dieser Gene dienen bekanntermaßen dem 
Schutz gegen oxidativen Stress, endogenen Aldehyde, Quinone, Epoxide und 
Hydroperoxide, und können daher karzinogene Metabolite entgiften. Zusätzlich 
führte auch der FB zu einer Zunahme der GSTA4 Gen-Expression in HT29 Zellen, 
was auf das Vorhandensein weiterer aktiver Metabolite hindeuted. 
Die Genexpression von Katalase wurde durch SFS nicht reguliert, wohl aber die 
Enzymaktivität. Dies deutet daraufhin, dass keine transkriptionelle Regulation, 
sondern noch unbekannte Post-translationale Mechanismen bei der Regulation von 
Bedeutung sind.  
Die Western-Blot-Analysen zeigten, dass eine Behandlung von LT97 Zellen für 24 h 
mit SFS zu einer signifikanten Spaltung von PARP führten. Im Gegensatz dazu 
wurde in SFS-inkubierten HT29 Zellen keine PARP-Spaltung nachgewiesen, in 
diesen Zellen wurde unter diesen Bedingungen keine Apoptose induziert. Eine 
Inkubation von LT97 Zellen für 24 h mit SFM führte darüberhinaus ebenfalls zu 
einem signifikanten Anstieg der PARP-Spaltung. Allerdings war die Spaltung von 
PARP nach der Behandlung mit SFM niedriger im Vergleich zu SFS. Im SFS sind also 
zusätzliche Apoptose-induzierende Bestandteile enthalten. Die Aktivität der Caspase-
3 wurde in beiden Zelllinien durch SFS signifikant erhöht, was darauf hindeutet, dass 
in beiden Zelllinien Apoptose induziert wurde. Eine, Inkubation der Zellen mit SFM 





   
Zelllinien mit SFS 10% für 24 Stunden konnte kein Einfluss auf die Bid-Spaltung 
nachgewiesen werden.  
In LT97 Zellen wurde eine signifikante Runterregulierung der mRNA Expression von 
DR4 (0.13 fach) und Bax (0.2 fach) durch Behandlung mit SFS festgestellt. Im 
Gegensatz dazu wurde in HT29 Zellen wurde eine signifikante Hochregulierung der 
mRNA Expression von DR5 (2,15 fach) und Bax (1,68) und eine deutliche 
Verminderung der Expression von DR4 (0,33-fach) durch Behandlung mit SFS 
festgestellt.  
Die Auswertung der cDNA microarrays zeigte, dass in LT97-Zellen die Expression 
von 37 Genen gesteigert und von 53 Genen durch die Behandlung mit 10% SFS für 
24  h gesenkt wurde (>1,5 bzw. < 0,6). Nur 6 der hochregulierten Gene und 36 der 
runterregulierten Gene wurden signifikant moduliert. Im Gegensatz dazu wurden in 
HT29-Zellen 97 Gene hochreguliert (davon 6 signifikant) und 28 Gene 
herunterreguliert (davon 6 signifikant). 
Schlussfolgerung Die Ergebnisse der vorliegenden Studie liefern wertvolle 
Informationen über die Rolle des Präbiotikums Synergy1 in der Krebs-Prävention z.B. 
durch Erhöhung der SCFA Produktion, Verringerung der toxischen sekundären 
Gallensäuren, Hemmung des Wachstums, Induktion der Apoptose und der 
Verringerung der Exposition mit Genotoxinen in menschlichen Dickdarm-Tumor-
Zellen. Weiterhin bietet die Bestimmung des Profils der Genexpression in 
menschlichen Dickdarm-Krebs-Zellen eine Möglichkeit, relevante Gene bzw. 
Agenzien zu identifizieren, die dazu beitragen könnten in vivo um chemoprotektiv in 
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HT29 cell growth medium 
450 ml  DMEM 
50 ml  FCS 
Stored at 4°C 
 
Trypsin-Versen 
10 ml  Trypsin [10x] 25g/ml in physiologic saline  
100 ml  Versen [1x] 0.2g/l in isotonic saline 
Stored at 4°C 
 
Phosphate buffer saline (PBS) 
8.0 g  NaCl  
0.2 g/l  KCl 
0.2 g/l  KH2HPO4 
111.15 g/l Na2HPO4 x 2 H2O 
pH 7.3; autoclaved; Stored at 4°C 
 
PBS + Ca2+ + Mg2+ 
PBS along with addition of: 
0.13 g/l CaCl2 x 2 H2O 
0.1 g/l  MgCl2 x 2 H2O 
pH 7.3; sterile filtration; Stored at 4°C 
 
PBS + Ca2+ + Mg2+ + BSA 
PBS + Ca2+ + Mg2+ along withaddition of 
5.0 g/l  BSA 










   
Stored in dark at -20°C 
 
DAPI-working solution 
0.02 mM DAPI-Stem solution 
in PBS + Ca2+ + Mg2+. 
Prepared fresh before use 
 
Comet-Assay 
Normal Melting Agarose (NMA, 0.5 %) 
50 mg NMA  
+ 10 ml PBS 
Melt it in microwave and keep it in water bath at 60°C  
 
Low Melting Agarose (LMA, 0.7 %) 
70 mg LMA  
+ 10 ml PBS 
Melt it in microwave and keep it in water bath at 40°C 
 
Lysis buffer (stem buffer) (pH 10) 
146.1 g/l NaCl (2.5 M) 
+ 37.2 g/l Na2EDTA (100 mM) 
+ 1.2 g/l Tris-Base (10 mM) 
Adjust pH-value at 10 with approx. 8g 1N NaOH, Add 10g Na-Lauroylsarcosinate (1 
%), sterile filtered and kept at room temperature 
 
Lysis buffer (working buffer) 
4 ml Triton-X (1 %) 
+ 40 ml DMSO (10 %)  
+ 356 ml Lysistembuffer (89 %) 
Always prepare fresh before use and store it at 4°C  
 
NaOH-Stem solution 
400 g/L NaOH (10M) 
+ 74.4 g/L Na2EDTA (200mM) 
 





   
60 ml NaOH-Stem solution (300mM) 
+ 10 l Na2EDTA-Stem solution (1mM) 
+ 1930 ml Milli-Q-Wasser 
Always prepare fresh before use and store it at 4°C  
Neutralisations buffer (pH 7.5) 
 Dissolve 48.5 g/l Tris-Base in Milli-Q-Wasser (0.4mM) and adjust pH to 7.5 with 
concentrated HCl. Autoclave and store it at 4°C  
 
Antifade-Buffer 
2.5 g DABCO  
+ TAE-Puffer (pH 8, 10 mM Tris-HCl, 1mM EDTA) 
50ml Glycerol 
Store at 4°C  
 
SYBR Green®-solution 
999 µl Antifade-Buffer 
+1 µl SYBR Green®-Stem solution 




50 mg  Coomassie Brilliant Blue G250 [0.01 %] 
23.5 ml EtOH abs. [0.8 M] 
50 ml  Phosphoric acid [1.6 M] 
Ad 500 ml H2O bidest 
Stored in brown bottle at 4°C, for couple of months. 
 
Stem buffer for separating gel (1.5M Tris) 
36.6 g  Tris (Base) 
Ad 200 ml H2O bidest 
Adjust pH 8.8 with HCl; Stored at 4°C, 6 weeks 
 
Stem buffer for collecting gel (0.5 M Tris) 
3 g  Tris (Base) 
Ad 50 ml H2O bidest 
Adjust pH 6.8 with HCl; Stored at 4°C, 6 weeks 
 





   
30 g  Tris (Base) 
144 g  Glycine  
Ad 1 l  H20 bidest 
pH control (pH approx. 8,8); Stored at 4°C, few weeks. 
 
SDS (Sodiumdodecylsulfate) Stem solution (10 %) 
25 g  SDS 
Ad 250 ml H2O bidest 
Stored in dark at 20°C 
 
APS (Ammoniumperoxidisulfate) Stem solution (10 %) 
1 g  APS 
Ad 5 ml H2O bidest 
Stored at -20°C, can be stored for long periods 
 
Bromphenolblue Stem solution (0.6 %) 
60 mg  Bromphenolblue 
Ad 10 ml H2O bidest 
Filtered and kept at 4°C in dark 
 
DTT (Dithiothreithol) Stem solution 
3.7 g  DTT 
Ad 10 ml H2O bidest 
Sterile filtration; Stored at -20°C 
 
Working solution 
Separating gel (10 %): Total Volume 15 ml 
5.935 ml H2O bidest 
3.750 ml Separating gel –Stem buffer (1.5 M) 
5 ml  Rotiphorese Gel 30 (30 %) 
150 μl  SDS Stem solution (10 %) 
150 μl  APS Stem solution (10 %) 
15 μl  Tetramethylethylenediamine (TEMED) 
Polymerisation time approx. 10-15 min 
 
Collecting gel (3 %): Total Volume 5ml 
3.05 ml H2O bidest 
1.2 ml  Collecting gel stembuffer (0.5 M) 





   
50 μl  SDS Stemsolution (10 %) 
50 μl  APS Stemsolution (10 %) 
10 μl  TEMED 
Polymerisation time approx. 10-15 min 
 
SDS-Page-Loading buffer: Total Volume 10 ml 
2.5 ml  Collecting gel-Stemsolution (0.5 M) 
2 ml  SDS Stemsolution (10 %) 
1 ml  Glycerol (99 %) 
3.6 g  Urea (6 M) 
10 mg  Bromphenolblue Stemsolution (0.1 % M) 
500 mg DTT Stemsolution (324 mM) 
1.5 ml H2O bidest 
 
Elektrophoresisbuffer: 1-2 Gels 
70 ml  10x Elektrophoresis stem buffer 
7 ml  SDS Stemsolution (10 %) 
Add 700 ml H2O bidest 
Always prepare fresh 
 
Transferbuffer (10 %) 
200 ml  10 x Elektrophoresistembuffer 
200 ml  Methanol 
Ad 2 l  H2O bidest 
Stored at 4°C 
 
10 x TBS (Tris-buffered saline) 
60 g   Tris base 
160 g   NaCl 
1600 ml H2O bidest 
Adjust pH at 7.4 with HCl  
Ad 2 l  H2O bidest 
Autoclaved; Stored 4°C 
 
TBS-T (1 x TBS + 0.05 % Tween 20) 
100 ml  10 x TBS 
0.5 ml  Tween 20 
Ad 1 l   H2O 





   
Ponceau-Red solution 
0.4 g  Ponceau-Red 
10 ml  Acetic acid 5 % 
Ad 200 ml H2O bidest 
Stored at room temperature 
 
Blockingbuffer: 5 % Milk powder 
2.5 g  Milk powder 
Ad 50 ml 1 x TBS 
Stored at -20°C 
 
2 x Lysebuffer without Nonidet 
4 ml  Tris/HCl [20 mM] 
1.752 g NaCl [150 mM] 
20 ml  Glycerin [10 %] 
0.116 g EDTA [2 mM] 
Stored at 4°C. Shortly before use add DTT, Protease- and Phosphatase inhibitors 
namely 
20 μl  Nonidet P4 0 1 % 
2 μl  Pefabloc SC [0.5 mM] 
20 μl  PMSF [1 mM] 
2 μl  Pepstatin A [1 μg/ml] 
2 μl  Leupeptin [1 μg/ml] 
20 μl  Sodiumorthovanadate [1 mM] 




Hepes Buffer [1 M] 
23.83 g  Hepes 
Adjust pH at 7.4 with KOH  
Add 100 ml H2O bidest 
Stored at 4°C 
 
CHAPS [100 mM] 
0,615 g CHAPS 
Ad 10 ml H2O bidest 






   
Reactionsbuffer 
4 ml  Hepes Stembuffer [1 M] 
20 ml  Glycerine 100 % 
Ad 100 ml H2O bidest 
Stored at 4°C  
 
Working solutions 
Lysisbuffer: Total 3.5 ml 
875 μl  Hepes Stem buffer [1 M] 
875 μl  CHAPS Stem buffer [100 mM] 
87.5 μl  DTT Stemsolution [1 M] 
3.5 μl  Leupeptin [1 mg/ml] 
3.5 μl  Pepstatin A [1 mg/ml] 
3.5 μl  Pefabloc [100 mg/ml] 
35 μl  Sodiumorthovanadate [100 mM] 
35 μl  PMSF in Methanol [100 mM] 
1582 μl H2O bidest 
 
Substrate Reactionsbuffer (25 μM): Total 1.7 ml 
6.8 μl  DTT [1 M] 
1629.45 μl Reactions buffer 
63.75 μl Substrate (Caspase 9, 3, 8) [1 mM] 
 
Substrate Reactionsbuffer (0 μM): Total 0.5 ml 
2 μl  DTT [1 M] 
498 μl  Reactions buffer 
 
Stem solution Inhibitors (1 mM): 1315 ml 
1310 μl PBS 
5 μl  Inhibitor (Caspase 9, 3, 8) 
 
Real-time PCR Gel electrophoresis 
Tris-Acetate-EDTA-Buffer- (TAE-Buffer-) Stem solution [50 x] 
242.2 g/l Tris-Base 
14.6 g/l EDTA 
47.2 ml/l Acetic acid 
pH 8.3; Stored at room temperature 
 





   
20 ml  TAE-Buffer [50 x] 
980 ml  Milli-Q Water 
Stored at room temperature 
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Appendix B List of Primers 
 
Primer Sequence [5’-…-3’] Firm 
GAPDH_F ACC CAC TCC TCC ACC TTT GAC MWG-Biotech AG, Ebersbach 
GAPDH_R TCC ACC ACC CTG TTG CTG TAG MWG-Biotech AG, Ebersbach 
DR4_F TGT CCA CTT TCG TCT CTG AG MWG-Biotech AG, Ebersbach 
DR4_R ACA GCA TCA GAG TCT CAG TG MWG-Biotech AG, Ebersbach 
DR5_F CCA CCT GGA CAC CAT ATC TC MWG-Biotech AG, Ebersbach 
DR5_R TAC AAT CAC CGA CCT TGA CC MWG-Biotech AG, Ebersbach 
Bid_F GAC ATG GAG AAG GAG AAG AC MWG-Biotech AG, Ebersbach 
Bid_R TTC ACT CCA TCC CAT TTC TC MWG-Biotech AG, Ebersbach 
GSTA4_F CCG GAT GGA GTC CGT  GAG ATG G’ MWG-Biotech AG, Ebersbach 
GST44_R CCA TGG GCA CTT GTT GGA ACA GC MWG-Biotech AG, Ebersbach 
CAT_F TGG ACA AGT ACA ATG CTG AG MWG-Biotech AG, Ebersbach 
CAT_R TTA GGA TGA ACG CTA AG MWG-Biotech AG, Ebersbach 
BaX_F TCT GAC GGC AAC TTC AAC TG MWG-Biotech AG, Ebersbach 
BaX_R GGA GGA AGT CCA ATG TCC AG-3 MWG-Biotech AG, Ebersbach 
 
Appendix C Materials used during the study 
 
Name Firm 
CASY®cups Innovatis AG (CASY®-Technology), 
Reutlingen 
Gloves Fisher Scientific GmbH, Schwerte 
Pipettes (2ml -50ml), sterile Fisher Scientific GmbH, Schwerte 
Falcon-Tubes (15ml & 50ml) Eppendorff Vertrieb Deutschland, Hamburg 
Filterpapers (S & S, GB004) Whatman, Dassel 
iCycler iQ PCR-Plates Bio-Rad Laboratories GmbH, München 
Western blot Combs  Biometra, Göttingen 
Mikrotiterplates (6- & 96-Well) Nunc GmbH & Co. KG, Wiesbaden 
Nitrocellulose membrane (0.45 μm pore size) Whatman, Dassel 
Pasteurpipettes NeoLab, Heidelberg 
PCR- tubes (0,2ml & 0,5ml), sterile Fisher Scientific GmbH, Schwerte 
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Pipettetips Fischer Scientific GmbH, Schwerte 
Accu-Jet Brand GmbH und Co., Wertheim 
Eppendorff tubes (1,5ml & 2,0ml) Eppendorff-Netheler-Hinz GmbH, 
Hamburg 
Eppendorff tubes (1,5ml &2,0ml), safe lock Eppendorff-Netheler-Hinz GmbH, 
Hamburg 
Cell culture (25cm2 & 75cm2) Fisher Scientific GmbH, Schwerte 
Cell scrubber Greiner Bio-One, Frickenhausen 
Weighing Balance    Sartorius AG,Göttingen 
Elektrophoresis chamber  Biometra, Göttingen 
Fluorescencemicroscope Axiolab HBO 50 Carl Zeiss,Jena 
Incubator Forma Scientific, Inc., Marietta, Ohio 
Lightmicroscope Axiovert 25 Carl Zeiss,Jena 
Multipipette Eppendorff-Netheler-Hinz GmbH, 
Hamburg 
Thermomixer  Eppendorff-Netheler-Hinz GmbH, 
Hamburg 
Tablecentrifuge Biofuge fresco Heraeus Instruments GmbH, Hanau 
Waterbath Memert GmbH, Göttingen 
Wamplate  Labotech GmbH, Göttingen 
Centrifuge  Heraeus Instruments GmbH, Hanau 
 
Appendix D  Computer Software used during the study 
 
Name Firm 
Cell Lab QuantaTM SC-MPL 1.0 Beckman Coulter Inc., Fullerton, 
USA 
Graph Pad PRISMTM 4.0 & 5.0 GraphPad Software, San Diego, 
USA 
icycler Software 3.1 Bio-Rad Laboratories, München 
Microsoft® Office Paket 2007 Microsoft Corporation, USA 
Nanodrop-Software 3.2.0 Peqlab Biotechnologie GmbH, 
Erlangen 
Quantity OneTM 4.0.1 Bio-Rad Laboratories, München 
XFLUORTM Tecan AG, Crailsheim 
2100 Expert Software Agilent Technologies, Santa Clara, 
USA 
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Comet assay analysis system (Comet Assay II 1.03) Perceptive instruments 
 
Appendix E.1  Genes upregulated by SFS in HT29 cells 
 
Gene name Descriptions Ratio SD P value Sign   
Phase I             
CYBRD1 Cytochrome b reductase 1 2.65 2.01 0.11 ns ↑ 
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 2.21 0.88 0.17 ns ↑ 
CYP24A1 Cytochrome P450, family 24, subfamily A,polypeptide 1 2.00 1.02 0.23 ns ↑ 
CYP2A6 Cytochrome P450, family 2, subfamily A, polypeptide 6 4.97 5.79 0.27 ns ↑ 
CYP2E1 Cytochrome P450, family 2, subfamily E, polypeptide 1 3.92 3.55 0.16 ns ↑ 
CYP2F1 Cytochrome P450, family 2, subfamily F, polypeptide 1 1.65 0.63 0.09 ns ↑ 
CYP3A7  Cytochrome P450, family 3, subfamily A, polypeptide 7 11.35 8.65 0.15 ns ↑ 
CYP4A11 Cytochrome P450, family 4, subfamily A, polypeptide 11 44.70 69.84 0.14 ns ↑ 
CYP4F2 Cytochrome P450, subfamily 4 F, polypeptide 3 2.81 1.73 0.29 ns ↑ 
CYP7A1 Cytochrome P450, family 7, subfamily A, polypeptide 1 1.92 1.17 0.36 ns ↑ 
POR  NADPH-Cytochrome P450 Reductase 2.23 1.34 0.25 ns ↑ 
              
Phase II             
Acetyltransferases           
MYSTA4  Histone Acetyltransferase MYST4 1.80 1.01 0.38 ns ↑ 
ODP2 
 Dihydrolipomide Acetyltransferase  Pyruvate Dehydrogenase 
complex  2.15 1.76 0.24 ns ↑ 
              
Epoxide Hydrolases           
EPHX1 Epoxide hydrolase 1, microsomal  1.82 0.78 0.40 ns ↑ 
EPHX2 Epoxide hydrolase 2, cytoplasmic 2.32 0.99 0.10 ns ↑ 
              
Glutathione S-Transferases           
GSTA1 Glutathione S-transferase A1 1.55 0.23 0.27 ns ↑ 
GSTA4 Glutathione S-transferase A4 1.78 0.24 0.31 ns ↑ 
GSTM1 Glutathione S-transferase M1  2.18 1.37 0.11 ns ↑ 
GSTM2 Glutathione S-transferase M2 (muscle) 1.84 1.06 0.39 ns ↑ 
GSTM4 Glutathione S-transferase M4  2.01 0.98 0.43 ns ↑ 
GSTM5 Glutathione S-transferase M5 3.95 3.52 0.27 ns ↑ 
GSTT2 Glutathione S-transferase theta 2 4.10 3.69 0.17 ns ↑ 
              
Methyltransferases           
HNMT Histamine Nmethyltransferase 1.79 1.84 0.50 ns ↑ 
              
Sulfotransferases           
CHST7 Carbohydrate sulfotransferase 7 14.17 20.31 0.18 ns ↑ 
CHST8 Carbohydrate sulfotransferase 8 2.05 1.97 0.44 ns ↑ 
SULT1C1 Sulfotransferase family, cytosolic, 1C, member 1 3.12 2.77 0.04 * ↑ 
SULT2B1  Sulfotransferase family,cytosolic, 2B, member 1 1.70 0.19 0.28 ns ↑ 
TPST1 Tyrosylprotein sulfotransferase 1 2.26 2.39 0.44 ns ↑ 
TPST2 Tyrosylprotein sulfotransferase 2 1.98 1.56 0.72 ns ↑ 
GAL3ST1 galactosylceramide Sulfotransferase 4.02 4.64 0.24 ns ↑ 
GN6ST Carbohydrate sulfotransferase 2 1.95 1.22 0.25 ns ↑ 
UDP Glycosyltransferases           
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UGT1A3 UDP glycosyltransferase 1 family, polypeptide A3  1.62 0.78 0.19 ns ↑ 
UGT1A4 UDP glycosyltransferase 1 family, polypeptide A4  1.51 0.48 0.46 ns ↑ 
UGT2B15 UDP glycosyltransferase 2 family, polypeptide B15  1.85 1.19 0.54 ns ↑ 
UGT2B7 UDP glycosyltransferase 2 family, polypeptide B7  6.06 7.98 0.18 ns ↑ 
              
Phase III drug transporters           
Metallothioneins:            
MT2A Metallothionein 2A  2.56 1.21 0.04 * ↑ 
              
P-glycoproteins           
ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP) 3.19 2.33 0.26 ns ↑ 
ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP) 2.68 1.72 0.34 ns ↑ 
              
Phase II gene regulation pathway           
CCAAT-enhancer-binding protein (C/EBP) mediated regulation           
FOSB  FOSB Protein 1.77 0.97 0.31 ns ↑ 
E2F2 E2F transcription factor 2 15.48 23.50 0.16 ns ↑ 
E2F3 E2F transcription factor 3 1.75 0.96 0.42 ns ↑ 
ERK1  Extracellular signal-regulated kinase 3 1.90 0.17 0.06 ns ↑ 
K-RAS V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog  1.69 1.37 0.45 ns ↑ 
JUND Transcription Factor JUND 2.64 0.37 0.003 ** ↑ 
              
Stress and Signal transduction           
Oxidative or Metabolic Stress           
GSR Glutathione reductase 1.57 0.45 0.23 ns ↑ 
HMOX1 Heme oxygenase (decycling) 1 2.19 0.61 0.29 ns ↑ 
NOS2A nitric oxide synthase 2A (inducible, hepatocytes) 6.11 7.89 0.33 ns ↑ 
PRDX1 Peroxiredoxin 1 1.72 0.49 0.19 ns ↑ 
PGH2 
Prostaglandin Syththetase 2 precursor   (COX-2) 
(prostaglandin EN 2.27 1.07 0.29 ns ↑ 
NMOR2  NRH dehydrogenase 2 1.87 0.45 0.14 ns ↑ 
              
DNA Damage and Repair           
ATM  
Ataxia telangiectasia mutated (includes complementation 
groups A, C and D) 2.71 2.81 0.68 ns ↑ 
ERCC4 
Excision repair cross-complementing rodent repair 
deficiency, complementation group 4 1.95 1.14 0.64 ns ↑ 
              
Growth Arrest and Senescence            
EGR1 Early growth response 1 1.52 0.77 0.58 ns ↑ 
GADD45A Growth arrest and DNA-damage-inducible, alpha 2.03 0.78 0.34 ns ↑ 
              
Apoptosis Signaling           
APAF1 apoptotic protease activating factor 4.82 5.37 0.33 ns ↑ 
CASP8  Caspase 8, apoptosis-related cysteine protease 2.66 1.42 0.40 ns ↑ 
TNFRSF10D_HUMAN:  TNF Receptor Superfamily Member 10D  1.67 0.91 0.31 ns ↑ 
PPP1R13B Apoptosis Stimulating of P53 Protein 1 1.69 0.90 0.34 ns ↑ 
CASP9 CASP9:  CASPASE 9 Precursor  1.76 0.73 0.28 ns ↑ 
BAK1  BCL-2 Homologus Antagonist killer  1.54 0.71 0.46 ns ↑ 
              
Wnt receptor signaling           
FRZB Frizzled-related protein 2.19 1.20 0.71 ns ↑ 
WNT5A Wingless-type MMTV integration site family, member 5A 1.80 0.78 0.31 ns ↑ 
WNT5B Wingless-type MMTV integration site family, member 5B 2.24 1.80 0.37 ns ↑ 
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Protein-Tyrosin Phosphatase with potential role in tumorsupressor in colon         
PTPRF Protein tyrosine phosphatase, receptor type, F 1.51 0.52 0.34 ns ↑ 
PTPRG Protein tyrosine phosphatase, receptor type, G 4.01 2.89 0.33 ns ↑ 
PTPN6 Protein tyrosine phosphatase, non-receptor type 6 2.03 0.56 0.17 ns ↑ 
              
Cell Cycle Arrest-Regulation of cell cycle            
CCNA1 cyclin A 1.86 0.36 0.04 * ↑ 
CDK6 cyclin-dependent kinase 6 6.66 8.87 0.28 ns ↑ 
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 3.11 1.19 0.12 ns ↑ 
CDKN1B Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 1.62 0.71 0.38 ns ↑ 
CDKN2B Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 3.03 0.76 0.03 * ↑ 
CDKN2D Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 2.84 2.00 0.13 ns ↑ 
CGRRF1 Cell growth regulator with ring finger domain 1 1.83 1.17 0.19 ns ↑ 
TGFA Transforming growth factor, alpha 1.57 0.60 0.23 ns ↑ 
TP53I3  Tumor Protein 53 Inducible protein P53 2.39 2.89 0.81 ns ↑ 
PIK3R3  Phosphytidyl inositol 3-Kinase regulatory alpha subunit 1.55 0.44 0.48 ns ↑ 
CDK1  Cell Division Contriol Protein 2 1.76 1.39 0.51 ns ↑ 
       
Metal storage and utilization           
FECH Ferrochelatase (protoporphyria)  2.32 1.62 0.37 ns ↑ 
FTH1 Ferritin, heavy polypeptide 1 1.58 0.36 0.18 ns ↑ 
FTL Ferritin, light polypeptide  2.21 0.24 0.02 * ↑ 
SLC11A1  
Solute carrier family 11 (proton-coupled divalent metal ion 
transporters), member 1 2.63 2.15 0.10 ns ↑ 
SLC11A2  
Solute carrier family 11 (proton-coupled divalent metal ion 
transporters), member 2 1.58 1.35 0.88 ns ↑ 
TF Transferrin 1.94 1.48 0.33 ns ↑ 
HFE_2 Heredirtary Hemochromatiosis Protein Precursor 7.90 10.67 0.20 ns ↑ 
HFE_3 Heredirtary Hemochromatiosis Protein Precursor. 1.73 0.79 0.24 ns ↑ 
HFE_4 HFE_4: Heredirtary Hemochromatiosis Protein Precursor 2.82 2.32 0.12 ns ↑ 
              
Miscellaneous (several functions)           
AHR Arylhydrocarbon 2.27 0.89 0.27 ns ↑ 
ARNT aryl hydrocarbon receptor nuclear translocator  2.59 1.52 0.05 * ↑ 
ATF2 activating transcription factor 2 2.25 1.67 0.38 ns ↑ 
ESR1  estrogen receptor 1 (ER alpha) 2.71 2.35 0.43 ns ↑ 
ESR2  estrogen receptor 2 (ER beta) 2.22 1.23 0.13 ns ↑ 
TRAF1 TNF receptor-associated factor 1 2.36 2.54 0.38 ns ↑ 
UBE2D1  
Ubiquitin-conjugating enzyme E2D 1 (UBC4/5 homolog, 
yeast) 2.32 2.17 0.78 ns ↑ 
XDH xanthine dehydrogenase  2.10 1.58 0.65 ns ↑ 
IAP1  
Baculoviral IAP Repeat Containing Protein 3 (inhibitor of 
Apoptosis) 1.91 0.41 0.31 ns ↑ 
BIRC6 
Baculoviral IAP Repeat Containing Protein 6 (inhibitor of 
Apoptosis) 5.20 4.07 0.26 ns ↑ 
BIRC7 
Baculoviral IAP Repeat Containing Protein 7 (inhibitor of 
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Appendix E.2 Genes down-regulated by SFS in HT 29 cells 
 
Gene name Descriptions Ratio SD Pvalue Sign  
Phase I       
CYP11A Cytochrome P450, family 11, subfamily A, polypeptide 1 0.56 0.13 0.06 ns ↓ 
       
Phase II       
Acetyltransferases:       
ACAT2 Acetyl-Coenzyme A acetyltransferase 2  0.30 0.08 0.09 ns ↓ 
       
Glutathione S-Transferases      
GSTO1 Glutathione S-transferase omega 1 0.44 0.19 0.07 ns ↓ 
MGST1 Microsomal glutathione S-transferase1 0.28 0.08 0.08 ns ↓ 
MGST2 Microsomal glutathione S-transferase 2 0.42 0.08 0.22 ns ↓ 
       
Methyltransferases      
COMT  Catechol-Omethyltransferase  0.45 0.18 0.25 ns ↓ 
NNMT Nicotinamide Nmethyltransferase 0.58 0.18 0.02 * ↓ 
       
Sulfotransferases       
CHST10 Carbohydrate Sulfotransferase 10 0.55 0.18 0.11 ns ↓ 
       
UDP Glycosyltransferases      
UGT1A7 UDP glycosyltransferase 1 family, polypeptide A7  0.52 0.04 0.43 ns ↓ 
       
Stress and Signal transduction      
Oxidative or Metabolic Stress       
DNAJA1  DnaJ (Hsp40) homolog, subfamily A, member 1 0.52 0.18 0.16 ns ↓ 
GPX1 Glutathione peroxidase 1 0.27 0.09 0.08 ns ↓ 
HSPD1  Heat shock 60kDa protein 1 (chaperonin)  0.37 0.20 0.13 ns ↓ 
       
DNA Damage and Repair      
ERCC6 
Excision repair cross-complementing rodent repair 
deficiency 0.43 0.06 0.04 * ↓ 
UNG Uracil-DNA glycosylase 0.30 0.09 0.07 ns ↓ 
XRCC5 X-ray repair complementing defective repair 0.48 0.22 0.30 ns ↓ 
       
Growth Arrest and Senescence       
PCNA Proliferating cell nuclear antigen 0.26 0.14 0.0036 ** ↓ 
       
Apoptosis Signaling      
BID   BH3 Interacting Domain Death Agonist 0.45 0.04 0.18 ns ↓ 
       
Cell Cycle Arrest-Regulation of cell cycle      
CCNB1 cyclin B1    0.55 0.24 0.43 ns ↓ 
CDK4 cyclin-dependent kinase 4 0.58 0.18 0.12 ns ↓ 
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) 0.42 0.08 0.18 ns ↓ 
       
Metal storage and utilization      
HFE  Hemochromatosis  0.54 0.29 0.04 * ↓ 
TFRC  Transferrin receptor (p90, CD71)  0.59 0.15 0.54 ns ↓ 
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Miscellaneous (several functions)      
BRCA1 breast cancer 1, early onset  0.50 0.24 0.06 ns ↓ 
MCM4 MCM4 minichromosome maintenance deficient 4 0.37 0.08 0.05 ns ↓ 
MCM7 MCM7 minichromosome maintenance deficient  0.39 0.24 0.02 * ↓ 
NFKB1 
Nuclear factor of kappa light polypeptide gene enhancer in 
B-cells 1 (p105) 0.35 0.04 0.05 * ↓ 
TYMS Thymidylate synthetase  0.06 0.01 0.06 ns ↓ 
BIRC5 
Baculoviral IAP Repeat Containing Protein 6 (inhibitor of 
Apoptosis) 0.59 0.04 0.37 ns ↓ 
 
Appendix E.3 Genes up-regulated by FB in HT 29 cells 
 
Gene name Descriptions Ratio SD Pvalue Sign  
Phase I       
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 1.82 0.61 0.61 ns ↑ 
CYP2A6 Cytochrome P450, family 2, subfamily A, polypeptide 6 2.76 2.58 0.85 ns ↑ 
CYP2B6 Cytochrome P450, family 2, subfamily B, polypeptide 6 8.43 9.53 0.81 ns ↑ 
CYP2D6 Cytochrome P450, family 2, subfamily D, polypeptide 6 7.90 9.09 0.91 ns ↑ 
CYP2E1 Cytochrome P450, family 2, subfamily E, polypeptide 1 20.14 26.03 0.70 ns ↑ 
CYP3A7  Cytochrome P450, family 3, subfamily A, polypeptide 7 5.39 4.54 0.78 ns ↑ 
CYP4F2 Cytochrome P450, subfamily 4 F, polypeptide 3 3.21 3.06 0.76 ns ↑ 
CYP7A1 Cytochrome P450, family 7, subfamily A, polypeptide 1 2.08 1.20 0.80 ns ↑ 
       
Phase II       
PIK3CG Phosphoinositide-3-kinase, catalytic, gamma polypeptide  7.10 8.29 0.88 ns ↑ 
       
Glutathione S-Transferases      
GSTM4 Glutathione S-transferase M4  1.66 0.59 0.82 ns ↑ 
GSTM5 Glutathione S-transferase M5 1.69 0.88 0.90 ns ↑ 
       
Methyltransferases      
HNMT Histamine Nmethyltransferase 1.62 0.95 0.91 ns ↑ 
       
Sulfotransferases      
CHST7 Carbohydrate sulfotransferase 7 2.09 0.93 0.96 ns ↑ 
CHST8 Carbohydrate sulfotransferase 8 1.52 0.82 0.94 ns ↑ 
SULT1B1 Thyroid hormone slfotransferase 18.34 20.57 0.76 ns ↑ 
SULT2B1  Sulfotransferase family,cytosolic, 2B, member 1 1.51 0.27 0.52 ns ↑ 
       
UDP Glycosyltransferases       
UGT1A6 UDP glycosyltransferase 1 family, polypeptide A6  1.91 0.80 0.66 ns ↑ 
UGT2B15 UDP glycosyltransferase 2 family, polypeptide B15  2.63 2.19 0.96 ns ↑ 
       
P-glycoproteins      
ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1  1.53 0.71 0.83 ns ↑ 
ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 45.72 62.87 0.98 ns ↑ 
       
NF-E2 gene family NRF1 and 2 mediated regulations      
E2F2 E2F transcription factor 2 10.15 12.10 0.94 ns ↑ 
ERK1  Extracellular signal-regulated kinase 3 1.57 0.29 0.61 ns ↑ 
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Stress and Signal transduction      
Oxidative or Metabolic Stress:       
FMO1 Flavin containing monooxygenase 1 2.89 0.93 0.59 ns ↑ 
NOS2A nitric oxide synthase 2A (inducible, hepatocytes) 5.50 3.52 0.77 ns ↑ 
       
Growth Arrest and Senescence      
GADD45B Growth arrest and DNA-damage-inducible, beta 2.03 0.90 0.74 ns ↑ 
       
Apoptosis Signaling      
APAF1 apoptotic protease activating factor 2.97 2.70 0.85 ns ↑ 
CASP8   Caspase 8, apoptosis-related cysteine protease 1.79 1.07 1.00 ns ↑ 
TNFSF6  Tumor necrosis factor (ligand) superfamily, member 6 1.58 0.85 0.86 ns ↑ 
       
Wnt receptor signaling      
CTNNB1 Catenin (cadherin-associated protein), beta 1, 88kDa 2.22 1.01 0.96 ns ↑ 
WNT5B Wingless-type MMTV integration site family, member 5B 1.51 0.50 0.81 ns ↑ 
       
Cell Cycle Arrest-Regulation of cell cycle       
CCNA1 cyclin A 21.94 28.89 0.95 ns ↑ 
CDK6 cyclin-dependent kinase 6 1.53 0.82 0.99 ns ↑ 
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 1.80 0.88 0.99 ns ↑ 
CDKN2B Cyclin-dependent kinase inhibitor 2B (p19, inhibits CDK4) 2.57 1.66 1.00 ns ↑ 
       
Metal storage and utilization      
FECH Ferrochelatase (protoporphyria)  1.86 0.90 0.85 ns ↑ 
SLC11A2 Solute carrier family 11  5.97 6.60 0.82 ns ↑ 
HFE_2 Heredirtary Hemochromatiosis Protein Precursor 1.85 0.52 0.76 ns ↑ 
       
Miscellaneous (several functions)      
AHR Arylhydrocarbon 1.69 0.46 0.85 ns ↑ 
ARNT aryl hydrocarbon receptor nuclear translocator  2.53 2.15 0.96 ns ↑ 
ATF2 activating transcription factor 2 2.27 1.49 1.00 ns ↑ 
ESR1  estrogen receptor 1 (ER alpha) 7.95 8.63 0.78 ns ↑ 
TRAF1 TNF receptor-associated factor 1 2.17 1.13 0.93 ns ↑ 
BIRC4 
Baculoviral IAP Repeat Containing Protein 4 (inhibitor of 
Apoptosis) 2.59 2.85 0.53 ns ↑ 
BIRC6 
Baculoviral IAP Repeat Containing Protein 6 (inhibitor of 
Apoptosis) 1.64 0.88 0.88 ns ↑ 
BIRC7 
Baculoviral IAP Repeat Containing Protein 7 (inhibitor of 
Apoptosis) 2.46 1.59 0.98 ns ↑ 
 
Appendix E.4: Genes down-regulated by FB in HT 29 cells 
 
Gene name Descriptions Ratio SD Pvalue Sign  
Glutathione S-Transferases      
MGST2 Microsomal glutathione S-transferase 2 0.60 0.18 0.11 ns ↓ 
       
Stress and Signal transduction      
Oxidative or Metabolic Stress:       
GPX1 Glutathione peroxidase 1 0.52 0.13 0.36 ns ↓ 
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DNA Damage and Repair      
UNG Uracil-DNA glycosylase 0.57 0.07 0.04 * ↓ 
       
Miscellaneous (several functions)      
NFKB1 
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
1  0.60 0.03 0.19 ns ↓ 
TYMS Thymidylate synthetase  0.50 0.15 0.41 ns ↓ 
 
Appendix E.5 Genes up-regulated by SFS in LT 97 cells 
 
Gene name Descriptions Ratio SD Pvalue Sign  
Phase I P450 gene family       
CYP2A6 
Cytochrome P450, family 2, subfamily A, 
polypeptide 6 2.38 1.46 0.38 ns ↑ 
CYP3A7 
Cytochrome P450, family 3, subfamily A, 
polypeptide 7 2.42 2.44 0.32 ns ↑ 
       
Glutathione S-Transferases       
GSTM3 Glutathione S-transferase M3 (brain) 1.89 0.60 0.25 ns ↑ 
       
Sulfotransferases       
SULT1B1 Thyroid hormone slfotransferase 3.26 3.56 0.24 ns ↑ 
       
UDP Glycosyltransferases        
UGT2B15 UDP glycosyltransferase 2 family, polypeptide B15  1.52 0.94 0.33 ns ↑ 
UGT2B4 UDP glycosyltransferase 2 family, polypeptide B4  4.40 3.37 0.14 ns ↑ 
       
Phase III drug transporters       
Metallothioneins       
MT2A Metallothionein 2A  6.11 2.74 0.003 ** ↑ 
       
P-glycoproteins       
ABCB4 ATP-binding cassette, sub-family B (MDR/TAP) 2.20 1.28 0.21 ns ↑ 
ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP) 2.17 1.14 0.07 ns ↑ 
       
NF-E2 gene family NRF1 and 2 mediated regulations      
FOS_2 c-Fos proto-oncogene   7.92 4.37 0.03 * ↑ 
E2F2 E2F transcription factor 2 1.85 0.97 0.31 ns ↑ 
       
Stress and Signal transduction      
Oxidative or Metabolic Stress        
FMO1 Flavin containing monooxygenase 1 2.70 2.95 0.43 ns ↑ 
HSPA5  Heat shock 70kDa protein 5  3.80 1.32 0.02 * ↑ 
NOS2A nitric oxide synthase 2A (inducible, hepatocytes) 1.52 0.19 0.65 ns ↑ 
PRDX1 Peroxiredoxin 1 1.61 0.78 0.21 ns ↑ 
       
DNA Damage and Repair        
ATM  Ataxia telangiectasia mutated  1.70 1.16 0.35 ns ↑ 
       
Growth Arrest and Senescence      
DDIT3  DNA-damage-inducible transcript 3 2.21 0.47 0.02 * ↑ 
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GADD45A Growth arrest and DNA-damage-inducible, alpha 1.96 0.63 0.07 ns  
GADD45B Growth arrest and DNA-damage-inducible, beta 3.47 2.57 0.16 ns ↑ 
       
Apoptosis Signaling       
APAF1 apoptotic protease activating factor 1.92 1.08 0.09 ns ↑ 
BAX  BCL2-associated X protein 1.53 0.62 0.34 ns ↑ 
CASP8   Caspase 8, apoptosis-related cysteine protease 3.76 2.72 0.14 ns ↑ 
       
Protein-Tyrosin Phosphatase with potential role in tumorsupressor in colon      
PTPN14 Protein tyrosine phosphatase, non-receptor type 14  4.34 3.22 0.08 ns ↑ 
       
Cell Cycle Arrest-Regulation of cell cycle:       
CDK6 cyclin-dependent kinase 6 1.70 0.67 0.33 ns ↑ 
CDKN2B Cyclin-dependent kinase inhibitor 2B  2.08 0.55 0.15 ns ↑ 
CDKN2D Cyclin-dependent kinase inhibitor 2D  2.58 0.33 0.18 ns ↑ 
CGRRF1 Cell growth regulator with ring finger domain 1 1.74 1.66 0.74 ns ↑ 
PIK3R1  Phosphatidylinositol 3-Kinase  1.57 0.48 0.42 ns ↑ 
       
Metal storage and utilization       
EPO erythropoietin 2.19 1.00 0.16 ns ↑ 
HFE  Hemochromatosis  1.72 1.26 0.31 ns ↑ 
       
Miscellaneous (several functions)      
ALAS1 Aminolevulinate, delta-, synthase 1 1.67 0.42 0.21 ns ↑ 
ARNT aryl hydrocarbon receptor nuclear translocator  1.77 0.60 0.02 * ↑ 
ATF2 activating transcription factor 2 2.81 1.54 0.11 ns ↑ 
TRAF1 TNF receptor-associated factor 1 3.66 4.29 0.26 ns ↑ 
IAP1  Baculoviral IAP Repeast-Containing Protein 3  1.85 0.67 0.11 ns ↑ 
BIRC4  Baculoviral IAP Repeast-Containing Protein 4 3.15 1.53 0.03 * ↑ 
BIRC6 Baculoviral IAP Repeat-Containing Protein 6  1.91 0.91 0.21 ns ↑ 
 
Appendix E.6 Genes down-regulated by SFS in LT 97 cells 
 
Gene name Descriptions Ratio SD Pvalue Sign  
Phase I P450 gene family       
CYP11A Cytochrome P450 0.59 0.20 0.08 ns ↓ 
CYP2E1 Cytochrome P450 0.46 0.19 0.08 ns ↓ 
       
Phase II       
Acetyltransferases       
ACAT2 Acetyl-Coenzyme A acetyltransferase 2  0.16 0.07 0.0007 *** ↓ 
       
Epoxide Hydrolases       
EPHX2 Epoxide hydrolase 2, cytoplasmic 0.25 0.06 0.0002 *** ↓ 
       
Glutathione S-Transferases       
GSTO1 Glutathione S-transferase omega 1 0.42 0.14 0.0019 ** ↓ 
GSTP1 Glutathione S-transferase pi 0.37 0.16 0.17 ns ↓ 
MGST1 Microsomal glutathione S-transferase1 0.27 0.11 0.01 * ↓ 
MGST2 Microsomal glutathione S-transferase 2 0.15 0.06 0.0015 ** ↓ 
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Methyltransferases       
COMT  Catechol-Omethyltransferase  0.22 0.08 0.011 ** ↓ 
       
Sulfotransferases       
CHST4 Carbohydrate sulfotransferase 4 0.53 0.13 0.08 ns ↓ 
SULT1A1 Sulfotransferase family, cytosolic, 1A 0.50 0.17 0.01 * ↓ 
       
UDP Glycosyltransferases        
UGT1A7 UDP glycosyltransferase 1 family  0.49 0.18 0.03 * ↓ 
UGT2B17 UDP glycosyltransferase 2 family  0.57 0.18 0.02 * ↓ 
       
P-glycoproteins       
ABCC3 ATP-binding cassette, sub-family C  0.42 0.30 0.09 ns ↓ 
       
NF-E2 gene family NRF1 and 2 mediated regulations      
ERK1  Extracellular signal-regulated kinase 3 0.49 0.20 0.16 ns ↓ 
KEAP1 Kelch-like ECH-associated protein 1 0.50 0.17 0.01 ** ↓ 
NRF2 Nuclear factor (erythroid-derived 2)-like 2 0.39 0.14 0.0047 ** ↓ 
       
Stress and Signal transduction       
Oxidative or Metabolic Stress       
FMO5 Flavin containing monooxygenase 5 0.56 0.16 0.02 * ↓ 
GPX1 Glutathione peroxidase 1 0.46 0.15 0.02 * ↓ 
GPX2 Glutathione peroxidase 2  0.18 0.09 0.02 * ↓ 
HMOX1 Heme oxygenase (decycling) 1 0.48 0.24 0.05 * ↓ 
HSPA1A  Heat shock 70kDa protein 1A  3.80 1.32 0.02 * ↓ 
PRDX2 Peroxiredoxin 2 0.43 0.10 0.04 * ↓ 
DIA4 NAD(P)H Dehydrogenase 0.60 0.24 0.04 * ↓ 
       
DNA Damage and Repair        
RAD51 RAD51 homolog  0.58 0.20 0.06 ns ↓ 
XRCC2 X-ray repair complementing defective repair 0.43 0.08 0.0021 ** ↓ 
XRCC5 X-ray repair complementing defective repair  0.47 0.14 0.01 * ↓ 
       
Growth Arrest and Senescence       
CCND1 (cyclin D1) Cyclin D1  0.45 0.32 0.04 * ↓ 
IGFBP6 Insulin-like growth factor binding protein 6 0.54 0.31 0.08 ns ↓ 
PCNA Proliferating cell nuclear antigen 0.32 0.17 0.01 ** ↓ 
PAG608: (PAG608) P53 Target Zinc Finger Protein 0.57 0.20 0.10 ns ↓ 
       
Apoptosis Signaling       
BCL2L1 (bcl-x) BCL2-like 1 0.48 0.28 0.05 ns ↓ 
CASP3 Caspase 3 0.59 0.17 0.02 * ↓ 
TNFRSF1A Tumor necrosis factor receptor superfamily 0.54 0.31 0.06 ns ↓ 
TNFRSF6 (Fas) Fas (TNF receptor superfamily, member 6) 0.44 0.18 0.02 * ↓ 
TNFSF10 (TRAIL) Tumor necrosis factor (ligand) superfamily 0.58 0.13 0.03 * ↓ 
PPP1R13B Apoptosis -Stimulating Of P53 Protein 1 0.60 0.26 0.06 ns ↓ 
CASP6  CASPASE-6 Precursor  0.34 0.12 0.01 ** ↓ 
BID: (BID)  BH3 interacting domain death agonist BID 0.50 0.13 0.03 * ↓ 
       
Cell Cycle Arrest-Regulation of cell cycle      
CCNB1 cyclin B1    0.40 0.23 0.03 * ↓ 
CCNB2 cyclin B2 0.53 0.23 0.02 * ↓ 
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CDK4 cyclin-dependent kinase 4 0.52 0.28 0.07 ns ↓ 
PIG3 tumor protein p53 inducible protein 3 0.35 0.17 0.04 * ↓ 
TP53 Tumor protein p53 (Li-Fraumeni syndrome) 0.57 0.25 0.06 ns ↓ 
VEGF Vascular endothelial growth factor 0.54 0.22 0.12 ns ↓ 
       
Metal storage and utilization       
FTL Ferritin, light polypeptide  0.60 0.25 0.05 * ↓ 
SLC11A2 (DMT1) Solute carrier family 11  0.31 0.18 0.05 * ↓ 
       
Miscellaneous (several functions)      
GSS Glutathione synthetase  0.41 0.10 0.002 ** ↓ 
MCM7 
MCM7 minichromosome maintenance deficient 
7  0.23 0.12 0.01 ** ↓ 
MSH2 mutS homolog 2, colon cancer, nonpolyposis  0.49 0.15 0.23 ns ↓ 
NFKB1 
Nuclear factor of kappa light polypeptide gene 
enhancer  0.31 0.17 0.04 * ↓ 
PUMA  BCL2 binding component 3 0.54 0.30 0.12 ns ↓ 
TYMS Thymidylate synthetase  0.28 0.24 0.03 * ↓ 
 
Appendix E.7 Genes up-regulated by FB in LT 97 cells 
 
Gene name Descriptions Ratio SD Pvalue Sign  
Phase I       
CYBRD1 Cytochrome b reductase 1 1.66 1.11 0.51 ns ↑ 
CYP1A1 Cytochrome P450, family 1 2.02 1.23 0.16 ns ↑ 
CYP24A1 Cytochrome P450, family 1 1.71 1.26 0.48 ns ↑ 
CYP2A6 Cytochrome P450, family 2 2.86 2.79 0.33 ns ↑ 
CYP2B6 Cytochrome P450, family 2 2.60 2.29 0.34 ns ↑ 
CYP2D6 Cytochrome P450, family 2 2.20 1.39 0.39 ns ↑ 
CYP3A7 Cytochrome P450, family 3 4.34 2.07 0.26 ns ↑ 
CYP4B1 Cytochrome P450, family 4 1.78 1.11 0.45 ns ↑ 
CYP4F2 Cytochrome P450, subfamily 4  1.64 0.99 0.38 ns ↑ 
CYP7A1 Cytochrome P450, family 7 2.21 1.11 0.34 ns ↑ 
       
Phase II       
Acetyltransferases      
NAT1 N-acetyltransferase 1 1.65 1.40 0.54 ns ↑ 
       
Glutathione S-Transferases      
GSTA1 Glutathione S-transferase A1 1.55 1.08 0.51 ns ↑ 
GSTA4 Glutathione S-transferase A4 1.53 1.05 0.53 ns ↑ 
GSTM3 Glutathione S-transferase M3  7.25 5.21 0.29 ns ↑ 
GSTM5 Glutathione S-transferase M5 1.76 1.07 0.40 ns ↑ 
GSTP1 Glutathione S-transferase pi 1.59 1.63 0.71 ns ↑ 
GSTT2 Glutathione S-transferase theta 2 2.19 1.88 0.41 ns ↑ 
MGST3 Microsomal glutathione S-transferase  1.63 1.08 0.50 ns ↑ 
       
Methyltransferases      
HNMT Histamine Nmethyltransferase 1.64 0.75 0.43 ns ↑ 
TPMT Thiopurine Smethyltransferase 1.97 1.32 0.29 ns ↑ 
       
Sulfotransferases      
CHST3 Carbohydrate sulfotransferase 3 1.71 1.15 0.57 ns ↑ 
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CHST6 Carbohydrate sulfotransferase 6 2.06 1.68 0.45 ns ↑ 
CHST7 Carbohydrate sulfotransferase 7 2.62 1.47 0.33 ns ↑ 
CHST8 Carbohydrate sulfotransferase 8 2.58 1.33 0.30 ns ↑ 
SULT1B1 Thyroid hormone slfotransferase 3.01 1.31 0.26 ns ↑ 
SULT2B1  Sulfotransferase family,cytosolic, 2B 1.76 1.23 0.43 ns ↑ 
TPST1 Tyrosylprotein sulfotransferase 1 1.57 1.15 0.60 ns ↑ 
TPST2 Tyrosylprotein sulfotransferase 2 1.87 1.42 0.42 ns ↑ 
GAL3ST1 Galatosylceramide Sulfotransferase 1.53 0.79 0.68 ns ↑ 
       
UDP Glycosyltransferases       
UGT1A4 UDP glycosyltransferase 1 family 1.53 1.08 0.52 ns ↑ 
UGT1A6 UDP glycosyltransferase 1 family 1.80 1.48 0.60 ns ↑ 
       
Phase III drug transporters      
Metallothioneins:       
MT2A Metallothionein 2A  6.12 6.65 0.26 ns ↑ 
MT3 Metallothionein 3 1.60 1.18 0.54 ns ↑ 
       
P-glycoproteins      
ABCB1 ATP-binding cassette, sub-family B  2.67 2.32 0.36 ns ↑ 
ABCC1 ATP-binding cassette, sub-family C  1.88 1.10 0.47 ns ↑ 
ABCC2 ATP-binding cassette, sub-family C  5.52 4.89 0.16 ns ↑ 
ABCG2 ATP-binding cassette, sub-family G 1.81 1.36 0.43 ns ↑ 
       
Phase II gene regulation pathway      
CCAAT-enhancer-binding protein (C/EBP) mediated regulation   
PIK3CA 
Phosphoinositide-3-kinase, catalytic, 
alpha polypeptide  2.04 1.65 0.42 ns ↑ 
       
NF-E2 gene family NRF1 and 2 mediated regulations     
FOS_2 c-Fos proto-oncogene   3.52 3.30 0.25 ns ↑ 
FOSB FOSB PROTEIN 1.75 1.27 0.49 ns ↑ 
E2F2 E2F transcription factor 2 4.33 1.69 0.18 ns ↑ 
K-RAS 
V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog  1.50 1.13 0.88 ns ↑ 
JUND JUND Transcriütion Factor JUN-D. 2.05 1.74 0.50 ns ↑ 
       
Stress and Signal transduction      
Oxidative or Metabolic Stress      
DNAJA1  DNAJ (Hsp40) homolog, subfamily A 1.59 1.23 0.56 ns ↑ 
FMO1 Flavin containing monooxygenase 1 2.75 1.73 0.37 ns ↑ 
HMOX1 Heme oxygenase (decycling) 1 1.72 1.23 0.87 ns ↑ 
NOS2A nitric oxide synthase 2A  1.92 1.31 0.25 ns ↑ 
PRDX1 Peroxiredoxin 1 2.72 2.14 0.31 ns ↑ 
SOD2 Superoxide dismutase 2, mitochondrial 1.64 1.25 0.56 ns ↑ 
PGH2 Superoxide dismutase 2, mitochondrial 1.89 1.27 0.46 ns ↑ 
NMOR2 Prostaglandin Syththetase 2 precursor    1.80 1.38 0.48 ns ↑ 
HSP90AA1  NRH dehydrogenase 2 1.74 1.40 0.52 ns ↑ 
       
DNA Damage and Repair      
ATM  Ataxia telangiectasia mutated  2.99 1.99 0.12 ns ↑ 
ERCC4 Excision repair cross-complementing  1.51 1.18 0.62 ns ↑ 
RAD17 RAD17 homolog (S. pombe) 1.52 1.00 0.54 ns ↑ 
RAD9 RAD9 homolog A (S. pombe) 1.93 1.62 0.62 ns ↑ 
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XRCC3 
X-ray repair complementing defective 
repair  1.84 1.19 0.43 ns ↑ 
       
Growth Arrest and Senescence      
DDIT3  DNA-damage-inducible transcript 3 1.56 1.09 0.52 ns ↑ 
E2F1 E2F transcription factor 1 1.57 1.13 0.52 ns ↑ 
GADD45B Growth arrest and DNA-damage 1.64 0.94 0.45 ns ↑ 
       
Apoptosis Signaling      
APAF1 apoptotic protease activating factor 3.87 3.01 0.26 ns ↑ 
BAX  BCL2-associated X protein 4.32 2.38 0.18 ns ↑ 
TNFRSF10B tumor necrosis factor receptor  1.59 1.15 0.53 ns ↑ 
TNFRSF1A  Tumor necrosis factor receptor  1.51 1.23 0.84 ns ↑ 
TNFSF6 Tumor necrosis factor 2.15 1.76 0.38 ns ↑ 
CASP9 CASP9:  CASPASE 9 Precursor  1.75 1.45 0.62 ns ↑ 
BAK1  BCL-2 Homologus Antagonist killer  1.58 1.06 0.63 ns ↑ 
       
Wnt receptor signaling      
APC  Adenomatosis polyposis coli  2.00 1.63 0.41 ns ↑ 
CTNNB1 Catenin (cadherin-associated protein) 2.61 2.21 0.29 ns ↑ 
FRZB Frizzled-related protein 1.60 1.30 0.52 ns ↑ 
FZD5 Frizzled homolog 5 (Drosophila) 1.67 1.16 0.48 ns ↑ 
FZD9 Frizzled homolog 9 (Drosophila) 1.52 1.18 0.61 ns ↑ 
WNT3 Wingless-type MMTV integration 1.82 1.60 0.60 ns ↑ 
WNT5B Wingless-type MMTV integration  1.79 1.52 0.51 ns ↑ 
       
Protein-Tyrosin Phosphatase with potential role in tumorsupressor in colon 
PTPRJ Protein tyrosine phosphatase 1.56 1.08 0.49 ns ↑ 
PTPN6 Protein tyrosine phosphatase 1.75 1.55 0.71 ns ↑ 
PTPN14 Protein tyrosine phosphatase 3.32 2.24 0.62 ns ↑ 
       
Cell Cycle Arrest-Regulation of cell cycle        
CCNA1 cyclin A 4.68 2.77 0.22 ns ↑ 
CDK6 cyclin-dependent kinase 6 5.72 6.32 0.13 ns ↑ 
CDK8 cyclin-dependent kinase 8 1.69 1.15 0.46 ns ↑ 
CDKN2B Cyclin-dependent kinase inhibitor 2B  3.89 3.10 0.15 ns ↑ 
CDKN2D Cyclin-dependent kinase inhibitor 2D 4.69 4.94 0.21 ns ↑ 
CGRRF1 Cell growth regulator  1.54 1.28 0.76 ns ↑ 
MAD2L2 MAD2 mitotic arrest deficient-like 2 1.55 1.05 0.59 ns ↑ 
MAPK12 Mitogen-activated protein kinase 12 1.76 1.17 0.39 ns ↑ 
MYC V-myc myelocytomatosis  oncogene  1.63 1.12 0.58 ns ↑ 
PTEN Phosphatase and tensin homolog  2.12 1.57 0.30 ns ↑ 
TGFA Transforming growth factor, alpha 1.71 1.21 0.47 ns ↑ 
TP53 Tumor protein p53  1.52 1.01 0.58 ns ↑ 
PIK3R1  Phosphatidyl Inositol 3-Kinase  1.52 1.19 0.55 ns ↑ 
PIK3R3 Phosphytidyl inositol 3-Kinase 1.55 1.15 0.55 ns ↑ 
       
Metal storage and utilization      
EPO erythropoietin 5.39 3.31 0.19 ns ↑ 
FECH Ferrochelatase (protoporphyria)  2.83 2.22 0.23 ns ↑ 
FTH1 Ferritin, heavy polypeptide 1 1.80 1.39 0.50 ns ↑ 
HFE  Hemochromatosis  2.66 2.24 0.27 ns ↑ 
SLC11A2  Solute carrier family 11  member 2 2.79 2.43 0.29 ns ↑ 
TF Transferrin 1.61 1.26 0.58 ns ↑ 
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Miscellaneous (several functions)      
ACO1 Aconitase 1, soluble  1.77 1.09 0.51 ns ↑ 
AHR Arylhydrocarbon 1.87 1.25 0.43 ns ↑ 
ALAS1 Aminolevulinate, delta-, synthase 1 2.36 2.08 0.46 ns ↑ 
AR Androgen Receptor 1.72 1.31 0.46 ns ↑ 
ARNT aryl hydrocarbon receptor nuclear  3.74 3.57 0.19 ns ↑ 
ATF2 activating transcription factor 2 4.78 3.06 0.16 ns ↑ 
ESR1  estrogen receptor 1 (ER alpha) 2.61 1.63 0.40 ns ↑ 
ESR2  estrogen receptor 2 (ER beta) 2.24 1.54 0.29 ns ↑ 
HPX Hemopexin 2.25 1.53 0.30 ns ↑ 
TRAF1 TNF receptor-associated factor 1 4.17 3.18 0.21 ns ↑ 
UBE2D1 Ubiquitin-conjugating enzyme  2.01 1.69 0.45 ns ↑ 
IKBB Kappa Beta Thyroid Receptor Protein 1.85 1.66 0.97 ns ↑ 
IAP1 Baculoviral IAP Repeat  2.77 2.26 0.20 ns ↑ 
BIRC6 Baculoviral IAP Repeat  3.36 3.17 0.31 ns ↑ 
BIRC7 Baculoviral IAP Repeat  2.93 1.09 0.26 ns ↑ 
 
Appendix E.8 Genes down regulated by FB in LT 97 cells 
 
Gene name Descriptions Ratio SD Pvalue Sign  
Phase II       
Acetyltransferases       
ACAT2 Acetyl-Coenzyme A 0.39 0.20 0.01 * ↓ 
       
Epoxide Hydrolases      
EPHX2 Epoxide hydrolase 2 0.51 0.28 0.04 * ↓ 
       
Methyltransferases      
COMT  Catechol-Omethyltransferase  0.37 0.13 0.05 ns ↓ 
       
Stress and Signal transduction      
Oxidative or Metabolic Stress       
GPX1 Glutathione peroxidase 1 0.52 0.20 0.12 ns ↓ 
       
DNA Damage and Repair      
XRCC5 X-ray repair complementing 0.56 0.13 0.17 ns ↓ 
       
Growth Arrest and Senescence       
PCNA Proliferating cell nuclear antigen 0.45 0.30 0.06 ns ↓ 
       
Cell Cycle Arrest-Regulation of cell cycle      
CCNB1 cyclin B1    0.54 0.24 0.12 ns ↓ 
CDK4 cyclin-dependent kinase 4 0.50 0.19 0.07 ns ↓ 
CDK1   Cell Division Control Protein 2  0.59 0.17 0.11 ns ↓ 
       
Positive controls (Housekeeping )      
TUBB1 Tubulin, beta 1 and 5 0.42 0.18 0.13 ns ↓ 
       
Miscellaneous (several functions)      
MCM7 minichromosome maintenance deficient   0.28 0.14 0.02 * ↓ 
TYMS Thymidylate synthetase  0.35 0.08 0.00 *** ↓ 
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